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ABSTRACT 
Vascular endothelial growth factor (VEGF) is required for the 
development, growth and survival of blood vessels. Endothelial cell behavior is 
altered by cell substrate stiffness, suggesting that VEGF activity might also be 
influenced by cell-substrate mechanics. We studied VEGF binding, 
internalization, and signaling as a function of substrate stiffness using endothelial 
cells cultured on fibronectin (fn) linked polyacrylamide gels.  
Individual cell analysis of VEGF-induced calcium fluxes in endothelial cells 
on various stiffness extracellular matrices (ECM) revealed heterogeneity in our 
cell population that would have been lost using population based averaging. 
Cluster analysis of individual cells identified two key groups of reacting cells- a 
minor fraction of highly reactive cells and the bulk of the cells with minimal 
activation. At subsaturating VEGF doses, highly active cells were phenotypically 
	  	   x 
smaller and thinner than the bulk population. Overall, cells on our softest 
substrates (4 kPa) were most sensitive to VEGF. 
To better understand the mechanisms underlying the changes in VEGF 
signaling due to stiffness, we explored how matrix binding of VEGF and tethering 
of cells to the matrix modulates VEGF processing. VEGF-ECM binding was 
enhanced with heparin pre-treatment, which exposed a cryptic VEGF binding site 
in the fn ECM.  Cell produced ECM on the softest substrates were least 
responsive to heparin, but the cells internalized more VEGF and showed 
enhanced VEGF signaling compared to cells on all other substrates. Inhibiting 
VEGF-matrix binding with sucrose octasulfate decreased cell-internalization of 
VEGF in all conditions. β1 integrin, which connects cells to fn, modulated VEGF 
uptake in a stiffness dependent fashion. β1 protein levels were consistent with 
stiffness, yet cells on hard surfaces showed greater decreases in VEGF 
internalization than cells on softer matrices after β1 inhibition. Stiff matrices 
facilitate the unfolding of fn, which may reduce the binding capacity of β1 integrin. 
Thus a greater proportion of activated β1 integrin may be sensitive to inhibition in 
the stiff condition as compared to the soft.  
Ultimately, through analysis of individual and population-based VEGF-cell 
responses to stiffness, this study provides insight into how signaling dynamics, 
cell heterogeneity, and microenvironment influence tissue regeneration and 
response to injury and disease. 
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CHAPTER ONE: BACKGROUND AND SPECIFIC AIMS 
 Blood vessels provide nutrients, immune cells, and oxygen essential to the 
life of tissues within the body(1).  Dysfunction of blood vessels underlies many 
diseases including cardiovascular disease, pulmonary hypertension, cancers, 
and diabetes(1-5).  The dysfunction of blood vessels is often marked by an 
inability of the vessels to adjust to local changes in blood pressure, an altered 
immune response, altered lipoprotein balance, and excess cytokines and growth 
factors(6-8). In cancers, dysfunctional vessels can be leaky, contorted, and 
hyper-activated to accept immune cells(1, 9, 10). Atherosclerosis and diabetes 
are marked by flawed wound healing processes(1, 3, 10). The key players in 
angiogenesis and dysfunctional vessel development include stromal cells, 
haematopoietic cells, the extracellular matrix, and the endothelial cells that line all 
vessels(1). The activity of endothelial cells and how their behavior relates to the 
mechanical properties of the extracellular matrix and the availability of growth 
factors will be the focus of our studies.  
 
1.1 Endothelial Cells  
Endothelial cells provide essential functions to all organ systems within the 
body and loss of these functions can be catastrophic during any stage of life. 
Essential functions of endothelial cells include maintaining a selectively 
permeable barrier to nutrients and immune cells(11, 12), altering vessel 
compliance with NO release(8), and facilitating the wound healing process(1, 13). 
	  	  
2 
Endothelial cell dysfunction transcends all ages. During development, 
preeclampsia is linked to poorly functioning endothelial cells resulting in a 
disrupted blood supply to the placenta and a resulting medical emergency for 
both mother and baby(1, 14). Age itself leads to greater endothelial dysfunction 
and the more dysfunction present, the higher incidence of cardiovascular 
disease, the number one killer in the United States(15-17).  Cardiovascular 
disorders linked to endothelial cells include (but are not limited to) 
atherosclerosis, stroke, peripheral vascular disease, and myocardial infarction(5, 
17).  Endothelial cell dysfunction is also involved in macular degeneration of the 
eye (wet AMD)(18), diabetic retinopathy, diabetic ulcers, autoimmune diseases, 
and solid tumors within the body(1, 13, 19). There is a direct correlation between 
endothelial cell health and these conditions. For example, factors released by 
healthy endothelial cells implanted in the perivascular space adjacent to injured 
blood vessels reduce re-stenosis and thrombus in arteries(20-22). Conversely, 
implanted unhealthy, hyperactivated, pro-inflammatory endothelial cells induce 
endothelial cells to undergoing endothelial-mesenchymal transition, a poor 
prognostic indicator for cancer metastasis(6).  
 The location based and activation state variability of endothelial cells 
complicates the study of endothelial dysfunction. Receptor levels, receptor 
locations, and epigenetic changes imprint endothelial cells at specific areas 
within the body and can be identified with RNA and protein methods(23-25). 
Even within an individual vessel, endothelial cells can be quiescent, stalk cells, or 
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tip cells all taking on their own morphologies and individual functions as vessels 
are activated by injury or inflammation(26-28). Understanding the 
responsiveness and phenotype of the individual cells within an individual vessel 
or organ system, could help direct treatment modalities to target only hyper or 
hypo-activated cells depending on the condition.  
To further confound the story, the extracellular matrix (ECM) below the 
endothelial cells varies depending on vessel type and disease state. Cancers 
and vascular disease both present with stiffened stromal tissue(29-32).  
Inflammation products, such as lysol oxidase crosslink the matrix and 
mesenchymal cells increase production of collagen fibrils(33). In addition to 
alterations in ECM mechanics, the composition, organization, and signaling 
capacity of the matrix is also altered in disease(34). Many of the proteins 
involved in endothelial cell signaling have the capacity to bind to components of 
the ECM, and this binding is modulated by the composition and structure of the 
ECM(7, 35, 36).  
 A major ECM binding growth factor that plays critical roles in modulating 
endothelial cells is Vascular Endothelial Growth Factor (VEGF)(37, 38). There 
are several VEGF genes including VEGF-A, VEGF-B, VEGF-C, and VEGF-
D(38).  VEGF-A binds both VEGF receptor 1 (VEGFR1) and VEGF receptor 2 
(VEGFR2) which mediate much of the downstream angiogenic processes(13, 
38). VEGF-B is only able to bind VEGFR1, which is less capable of signaling 
than VEGFR2(38).  VEGF-C and VEGF-D can be processed to bind VEGFR2, 
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but they have high affinity for VEGFR3 found predominantly on lymphatic 
vessels(38). VEGF-A itself has several isoforms VEGF-165, VEGF-121, and 
VEGF-189, and VEGF-206(13, 19, 38).  VEGF-165, the most abundant form, 
works as both a soluble and matrix bound growth factor whereas VEGF-189 and 
VEGF-206 are less abundant, very basic, and found mostly bound to the 
matrix(13). VEGF-121 is unable to bind heparin or the extracellular matrix, except 
under acidic conditions(13, 39).  Our studies focus on VEGFA-165 (referred to as 
VEGF) and its matrix binding potential.   
 VEGF interacts with VEGFR1 and VEGFR2 on endothelial cells and 
VEGFR3 on lymphatic vessels(13, 38). VEGFR1 has traditionally been called the 
decoy receptor as it has high affinity for VEGF, but minimal tyrosine kinase 
activity and downstream signaling(38). It is involved in monocyte chemotaxis and 
MMP activation(13, 38). Mice deficient in VEGFR1 do not survive past E8.5 due 
to overgrowth of endothelial cells, which highlights a critical role for VEGFR1 in 
restricting VEGF activation of VEGFR2(38).  Conversely, knockout models of 
VEGFR2 are embryonically lethal at E8.5 due to lack of endothelial cells(38). 
VEGF binding to VEGFR2 causes receptor dimerization and downstream 
tyrosine kinase signaling triggering the major VEGF signaling pathways(38, 40).    
 Endothelial tyrosine kinase signaling has many downstream targets 
depending on the phosphorylation pattern and where the signaling is occurring.  
The three major pathways focused on within this paper include Mitogen-activated 
protein kinase (MAPK or ERK) activation driving proliferation and migration of 
	  	  
5 
endothelial cells, AKT phosphorylation providing a survival signal to the cells, and 
cytosolic calcium release which can both activate ERK and increase cell 
permeability(19, 38, 41).  Co-receptor binding including neuropillin and heparan 
sulfate proteoglycans alters the activation of these pathways(38). Furthermore, 
where the activation occurs, either on the cell surface or in an early endosome 
after internalization, may define signaling outcomes(41-43).     
 Despite the complex knowledge already known about endothelial cells, 
there is still much to learn.  It is likely that these gaps in understanding underlie 
the inability to fully treat or cure diseases linked to endothelial cell dysfunction. 
Systemic VEGF delivery and genetic up-regulation failed to induce angiogenesis 
and collateral formation around damaged vessels(44, 45). Likewise, blocking 
VEGF and its associated receptors has had limited success in the treatment of 
diseases linked to neovascularization(46, 47). It is likely our lack of 
understanding of all the intricacies affecting endothelial cell biology may limit the 
effectiveness of previously attempted treatments. We predict that one gap in our 
understanding relates to ties between biochemical signaling and the mechanical 
state of the cellular microenvironment.  We hypothesize that stiffness-induced 
changes in the extracellular matrix result in altered VEGF processing and 
signaling within endothelial cells.  The following summaries address major factors 
that contribute to this hypothesis.    
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1.2 Extracellular Matrix 
  The extracellular matrix (ECM) is extremely complex and varies 
depending on which tissue is being examined and the health of the cells 
associated with the tissue. The proteoglycan rich ECM resting below neuronal 
cells in the brain is vastly different than the collagen and elastin ECM associated 
with the lung(48-50).  Variability also exists within tissues of the same organ. 
Aortic vasculature has a greater elastin content than that of capillaries and 
veins(17). The ECM is involved in many cellular processes including providing 
mechanical support to cells, cell adhesion, hydration, and storing/signaling with 
biomolecules(48, 51, 52). 
  The two main proteins that form the structural support for ECM 
throughout the body are collagen and elastin.  Collagen provides tensile support 
whereas elastin provides compliance to mechanically active tissues(48, 50). 
Cells actively work to maintain ECM homeostasis. A trigger (environmental, 
genetic, or age) may cause alterations in matrix synthesis and degradation.  
These alterations lead to changes in the mechanics of the ECM, which in turn 
can trigger changes in the levels of matrix metalloproteinases and crosslinking 
molecules(17, 48, 53).  When these triggers are associated with disease, the 
resulting matrix is often dysfunctional, un-regulated, and exhibits poor 
organization. Lung extracellular matrix production provides two classic examples 
of this phenomenon. In lung fibrosis, fibroblasts become hyper-activated and 
produce excess collagen. The cells respond, but the normal feedback 
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mechanisms that return the ECM to a homeostatic point no longer function, 
which results in a stiff, un-organized, low volume lung(53). Similarly, in 
emphysema, the assembly of collagen and elastin is skewed resulting in 
destruction of alveolar structure and obstructive volume expansion(49, 50, 54). 
Similar alterations in ECM, such as the those described above, are also 
recapitulated in atherosclerosis and cancer(53).  
 Proteoglycans (PGs) provide the other main component to the ECM.  
They are comprised of a protein core with negatively charged glycosaminoglycan 
chains that act as docking sites for growth factor(s) and as a vehicle for water 
influx(55). Many growth factors including FGF, TGF- β, PDGF, and VEGF are 
able to bind and interact with the ECM through the proteoglycan matrix(39, 48, 
56-58). The binding to the ECM can modulate downstream signaling.  For 
instance, some members of the FGF family require heparan sulfate (HS) binding 
to interact with their receptor(52).  Regulation of cell signaling can also occur 
within the matrix. TGF-β binds the ECM in an inactive form that is activated upon 
MMP cleavage from the matrix(52).  
The endothelial cell matrix contains a rich mixture of heparan sulfate 
proteoglycans (HSPGs) including perlecan, agrin, and cell associated 
syndecans(48, 59, 60). HSPGs have a wide range of activities that can modulate 
endothelial cell function. Within the vessel wall, HS chains on perlecan inhibit 
smooth muscle cell proliferation blocking a major step of endothelial 
dysfunction(59). HSPG also can increase the number of VEGF-VEGFR2 
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interactions within endothelial cells highlighting its important role in endothelial 
cell biology(38). In tumor biology, cleaved HSPG fragments can up-regulate 
metastasis and growth factor signaling, but full length fragments can have anti-
proliferative effects(61). Many of these effects are through HSPG binding of 
growth factors or ECM proteins including fibronectin (fn), laminins, vitronectin, 
and thrombosopondin(60). 
Fn is a glycoprotein that is up-regulated in development and disease(57, 
62, 63).  The major HSPG binding site on fn is found in a type III module that is 
highly extendable(64).  Binding of HSPG or heparin to fn results in an extension 
of the fn molecule exposing a cryptic growth factor binding site(58, 65). VEGF is 
capable of binding to this site, which may alter VEGF presentation to endothelial 
cells. Data from our lab show that as VEGF-fn binding increases, VEGFR2 
chimera binding also increases whereas VEGFR1 binding remains constant 
indicating that binding of VEGF to fn may selectively present VEGF to VEGFR2 
and shield it from binding to VEGFR1. Others have shown matrix bound VEGF 
increases internalization of VEGFR2 prolonging downstream signaling(42, 57). 
Proliferation and migration of endothelial cells is enhanced by VEGF binding to fn 
matrices(57).   
 Overall, the ECM is a very active structure with ever changing mechanical 
properties, growth factor storage, and organization. The difference between cells 
that are predisposed to develop malignancies versus those that will not may well 
rest within the properties of the ECM(29). This connection highlights the 
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important tie between matrix health and cell function, which is not limited to 
cancers but instead transcends all organ systems and is essential for body 
system homeostasis. Thus, it is essential to fully understand how alterations in 
ECM composition and physical properties control cell and tissue function in order 
to fully understand the underlying biochemical mechanisms of disease 
processes.  
 
1.3 Mechanics 
 The microenvironment is critical to how cells develop, survive, and signal. 
The microenvironment for endothelial cells contains several mechanical stimuli.  
The blood flows over the cells creating shear stress that ultimately results in cell 
alignment. Areas with disrupted shear stress have an increased likelihood of 
unstable atherosclerotic plaques(66, 67). Wall stress increases with blood 
pressure, which can result in vessel wall hypertrophy(66, 68). The stiffness of the 
extracellular matrix is also translated into cell behavior.  Healthy endothelial cells 
rest on matrices ranging from 2.5-50 kPa whereas diseased or aged vessels can 
range from 10 to 240 kPa(30, 69, 70).  Tissue culture plastic is on the GPa scale, 
several orders of magnitude greater than even the most diseased vessel(71, 72). 
The variability in these measurements is attributable to the particular technique 
utilized and precisely where within the vessel the measurement is made.  
 To model stiffness, new substrates for cells had to be developed and 
measurement methods established to determine the stiffness of the 
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microenvironment. A variety of techniques can be utilized to measure the 
elasticity of vessels. Modern techniques to measure the stiffness on a micro/nano 
scale include atomic force microscopy (AFM) and shear rheology where 
displacement is measured with a micro-lever arm displacement or torsional 
stress/strain analysis respectively(53). Cell culture models of stiffness include 
thin, deformable silicon substrates(73), Matrigel matrices(74), 3D collagen 
matrices(21, 22, 75), PDMS substrates(76, 77), and polyacrylamide gels(78, 79). 
Each substrate has positive and negative qualities.  The most important variable 
to consider is the stiffness range. Matrigel formulations can be produced in the 
10-50 Pa range whereas PDMS sheets are non-porous and span from 0.1kPa-
1MPa(80), but they are subject to fouling and are difficult to handle at low 
stiffness values. Most models vary stiffness through enzymatic or non-enzymatic 
crosslinking, which can also alter pore size and ligand densities(53, 80-82). For 
our experiments we chose polyacrylamide gels.  These gels are relatively simple 
and reproducible and can be made between 4 kPa and 125 kPa, an ideal range 
for modeling blood vessel stiffness(79, 82). Additionally, the gels are now 
available in many formats commercially, which allows for the scale required in 
most biochemical experiments.  
Using these various models a number of alterations in cell phenotype and 
behavior have been observed with changes in substrate stiffness. In most studies 
(which largely use collagen or fn matrices), arterial endothelial cells increase their 
spreading, traction forces, proliferation rate, actin organization and permeability 
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without growth factor stimulus with increased substrate stiffness(78, 79, 83, 84). 
Endothelial cell sprouting, without the addition of VEGF (augmented with), 
decreases with stiffness(85). The matrix type (fn, collagen, laminin) and cell type 
can modulate the responses. For instance, smooth muscle cells plated on 
laminin decrease in size with stiffness, but the same cells plated on fn display 
increased cell size with stiffness, as has been reported in a number of other 
studies(78). Interestingly, in contrast to what is observed with arterial endothelial 
cells, venous endothelial cells do not spread or migrate as stiffness 
increases(86).  
A dynamic relationship exists between cells and their matrix. A positive 
feedback loop results in cells altering their actin and microtubule organization to 
stiffen themselves (1-7 kPa) in response to a non-compliant surface (up to about 
30kPa)(87).  At the same time, the cells continue to alter the ECM by depositing 
more fn, aligning matrix fibers, and further stiffening the matrix(88). Cell forces on 
the matrix increase with stiffness unfolding more fn fibers potentially modulating 
the availability of growth factor binding sites(89).  Stretching single fn molecules 
can decrease the binding of VEGF(90).  
Stiffness is a major variable effecting cell behavior. Much of the research 
to date considers how cell shape or response is altered by stiffness, but few 
researchers have looked at how stiffness modulates biochemical pathways.  We 
predict that stiffness-mediated changes in these pathways may account for the 
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discrepancies observed when treatments are brought from in vivo conditions to 
an in vitro environment. 
 
1.4 Cell Adhesion Proteins 
 Endothelial cells are adhesion dependent. They are not capable of 
surviving even when their RGD or integrin-binding domain is stimulated in 
suspension(83).  The adhesions in endothelial cells are dynamic changing with 
location, time, stiffness, and disease.  
Endothelial cell adhesions are made up of an assortment of proteins 
including talin, vinculin, and integrin proteins that all link together to modulate 
binding from the exterior of the cell to the actin cytoskeleton in the cytoplasm(55, 
91, 92). Focal adhesions go through several formation steps. During cell 
migration, the leading edge of the cell makes new adhesions while the trailing 
end removes its old adhesions(92).  The initial small adhesion occurs with talin 
protein recruitment.  After talin is recruited, the focal contact becomes a focal 
complex with the addition of vinculin, paxillin, and phosphorylated proteins(55, 
92).  The movement of the complex from the periphery of the cell and the further 
recruitment of proteins completes the focal adhesion process. Small, 1 um, initial 
adhesions take less than a minute to form whereas larger adhesions can take up 
to an hour to stabilize and recruit all the proteins(91).  
Integrin connections exert forces upon the cell matrix (traction forces).  
These forces can be upwards of 30 pN/integrin bond, which in most 
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circumstances decreases the time non-covalent bonds last 2-10 fold(92, 93). 
Many integrin proteins have adapted to take on force; instead of breaking or 
dissociating under an increased load, the catch bonds are strengthened. The 
connection of α5β1 to the fn matrix becomes a catch bond after engagement of 
both the RGD binding site and the synergy sites(92, 94, 95).  These connections 
are not limited to two protein integrin-matrix connections. A three-way catch-bond 
exists between α5β1, Thy-1 protein, and syndecan-4 a cell associated 
HSPG(95). It is possible that the ability of integrin proteins to engage in catch-
bonds may increase as compliance of a surface decreases, which may account 
for the less dynamic, larger, more mature adhesions found on stiffer 
substrates(83, 91). Focal adhesion number increases proportionally with cell size 
on stiffer substrates(79). Above 30 kPa, fibroblasts, epithelial cells, and smooth 
muscle cells show no discernible difference in adhesion size or shape compared 
to those found on glass(83, 87).  
The integrin heterodimer recruited to the focal adhesion depends on the 
ligand the cell is binding. For instance, fn binds α5β1 integrins whereas α2β1 and 
α1β1 are collagen-binding integrins and αvβ3 binds vitronectin and fn(7, 96, 97). 
Laminin engages α6β1 and α3β1 integrins(7).  
It is not surprising that as the balance of proteins within the ECM changes 
with disease or stiffness that the expression, activation, and binding of integrin 
proteins would also be modified. On stiff fn-coated surfaces, β1 integrin filaments 
appear to be longer and thinner with staining compared to their counterparts on 
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softer substrates(98). In normal breast cells, β1 binding to fn shows maximum 
traction force generation at the native breast tissue, but the addition of β6 
integrin, which is up-regulated with cancer, results in decreased recruitment of β1 
to the cell membrane and an increase traction forces above that of the native 
tissue(99). ECM organizational changes in vascular disease result in integrin 
switching that instigates smooth muscle cell proliferation(55). Fn preferentially 
binds α5β1 integrin on stiffer surfaces over αvβ3 due to an increased distance 
between binding locations with stiffness induced fn unfolding(98). The binding of 
α5β1 is also associated with greater bond stability whereas αvβ3 has a shorter 
bond time and more dynamic nature associated with migration(97).  
 Endothelial cell biology has several important integrin sets that have been 
tied to angiogenesis pathways. Sprouting of endothelial cells involves α2β1 and 
α1β1 integrins that bind collagen, and αvβ3 and α5β1 integrins that engage fn(7).  
VEGF itself can up-regulate αvβ3, α1β1, and α2β1, which are both pro and anti-
angiogenic integrins(35, 96). Collagen binding integrins (α1β1, and α2β1) can 
increase VEGFR1 expression leading to a decrease in angiogenesis(96, 100).  
The two most extensively studied integrins related to angiogenesis are the 
αvβ3 and α5β1 integrins. The fn/vinculin integrin αvβ3 exists in a delicate 
balance. Blocking its activity decreases angiogenesis, but complete knockout of 
αvβ3 results in early embryonic lethality due to up-regulation of angiogenesis(2, 
27, 38). Neuropillin-1, syndecans, and VEGFR2 have been shown to directly 
associate with αvβ3(60, 96, 100, 101). Treatment with matrix bound VEGF 
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promotes αvβ3 based adhesion, cell migration, and subsequent cell 
spreading(100, 102). Despite its prominent role in angiogenesis, clinical trials 
involving monoclonal antibodies against αvβ3 have only had modest gains(2, 
100). 
Integrin α5β1 is also up-regulated during angiogenesis(27) and its 
knockout or modulation of its RGD binding site promotes lethal embryonic 
mutations(103). β1 integrin has been found to co-precipitate with VEGFR2 only in 
states in which VEGF is present(57). The resulting connection brings about an 
increase in cell adhesion and migration(100). Neuropillin-1 increases α5β1 
directed formation of fn fibrils, which can then be modified to bind VEGF(58, 65, 
101). NRP-1 and α5β1 might further complex to initiate increased downstream 
ERK activation after VEGF binding(104). VEGF-fn is capable of increasing cell 
proliferation, but only when there is a direct cell connection between the single 
VEGF-fn complex(52). Matrix binding of VEGF, results in ERK signaling and 
receptor clustering(42).  These effects are lost with β1 suppression(42). 
β1 also enhances expression of focal adhesion kinase (FAK) protein(27, 
95, 101). FAK is an adhesion-associated protein recruited early in focal complex 
formation and up-regulated in many cancers (and the target of new 
treatments)(105). FAK results in SRC phosphorylation and further activation of 
key downstream proteins including MAPK(27, 105). FAK is involved in many 
other mechanosensing roles such as mediating migration of cells, directing cell 
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shape, and promoting cell survival(105, 106). VEGF binding leads to FAK 
activation(96).  
 Integrin engagement does not only up-regulate focal adhesion kinase 
signaling, but it stimulates the Rho/ROCK signaling cascade which has also been 
tied to angiogenic pathways(51, 107).  Increased stiffness leads to Rho 
activation, which is tied to other angiogenic processes including focal adhesion 
assembly and EGF associated ERK activation(53, 108). Blocking Rho decreased 
VEGF associated spikes in traction forces(77). Hypersensitivity of stiffness 
related signaling molecules (FAK/Rho/ROCK) may drive cell-induced alterations 
of the ECM further instigating growth factor binding and alterations in angiogenic 
signaling.  
 Cells also adhere to one another. As cells come in contact with each 
other, the contact can override matrix sensing of the integrin proteins(88). Cell 
contact, stiffness, and migration are tied to each other without the addition of 
growth factors.  Bovine endothelial cells remain in contact on soft surfaces, they 
explore and regroup on moderate stiffness surfaces, and they migrate away from 
each other on stiff surfaces(109). Imbalance of cell adhesion could modulate how 
cells are able to proliferate, migrate, and respond to injury or growth factors. For 
example, VE-cadherin, a cell-cell adhesion protein mediates VEGFR-2 
activity(110).  Confluent cultures or cultures with overexpressed VE-cadherin had 
decreased VEGFR-2 activity due to VE-cadherin blockade of R2 signaling 
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indicating that cells are primed to respond when they are not in constant cell-cell 
contact(110, 111).  
 It is clear that a multitude of adhesion proteins and associated signaling 
molecules are integrated together to affect the endothelial cell response to 
stiffness, disease, and aging. We predict that integrin-mediated alterations and 
clustering due to stiffness modulate VEGF presentation to endothelial cells.   
 
1.5 VEGF Internalization 
 VEGF signaling is a critical modulator of endothelial cell behavior both at 
rest and activated states. At rest, the VEGF signaling receptor VEGFR2 is stored 
in endocytic vesicles marked for recycling back to the plasma membrane(112, 
113).  A portion of the VEGFR2 is also on the cell surface and a portion of the 
receptor pool is found in late endosomes marked for degradation(112). Surface 
ligand binding to VEGFR2 and subsequent internalization into early endosomes 
is critical for complete VEGFR2 signaling. Without stimulation, every 15 minutes, 
40% of the VEGFR2 pool is recycled to the cell surface(113).  VEGF treatment 
facilitates a faster recycling rate with more VEGFR2 reaching the surface in a Src 
dependent manner(113).  Within 30 minutes after VEGF treatment, 40% of total 
VEGFR2 is degraded, but this level then remains at a steady state for at least 24 
hours post VEGF treatment(113).  
 The instantaneous distribution of VEGF can vary even within one 
subpopulation of cells.  It may be expected in the maturing retina that the 
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peripheral cells with the leading edge of angiogenesis may have high levels of 
VEGFR2 to facilitate rapid angiogenesis compared to the central mature region, 
yet VEGFR2 levels are identical(114). Despite this finding, the exterior cells have 
a much higher rate of VEGF internalization.  Blocking internalization, recycling 
and degradation for two hours brings VEGFR2 levels in the periphery up and 
above the cells in the central retina(114).  This finding indicates that VEGFR2 is 
rapidly produced where it is needed within a short time frame.  
Most VEGFR2 internalizes through clatherin-mediated vesicles to early 
endosomes marked by Rab5(41, 112).  While inside Rab5 vesicles, 
phosphorylation on Y1157 is decreased due to the activity of proteases. From 
Rab5 vesicles, VEGFR2 containing vesicles transition to either late endosomes 
Rab4 or Rab11 prior to either recycling to the plasma membrane or lysosome 
degradation in Rab7 designated endosomes(41). Rab4 is a faster recycling (5 
minutes) scheme than that of Rab11 (15-30 minutes)(113). Most un-ligated 
constitutively endocytosed VEGFR2 is found in Rab4 vessels(113). Certain 
proteins, including synectin and ephrin-B2 are required for internalization to 
proceed.  Ephrin-B2 is required for initial internalization events whereas synectin 
is necessary for receptor to progress from an early endosome containing 
proteases to a recycling endosome for in which signaling can continue(41). 
Understanding which proteins designate recycled VEGF to enter specific 
recycling vesicles could provide insight into alterations in VEGF-ECM bound 
signaling and biological responses.  
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The variety of receptors involved in internalization pull together several 
key concepts already discussed. NRP-1 bound VEGFR2 complexes move 
towards the slow Rab11 endosomes for recycling to the surface(112).  Without 
the co-receptor NRP-1, VEGFR2 associates with degradation Rab7 vessels(112, 
115).  A variety of adhesion proteins including β1 integrin facilitates NRP-1 
internalization, thus it can be inferred that β1 integrin has a role in VEGFR2 
internalization. Cells on fn showed β1 linked internalization whereas cells on 
collagen-coated surfaces had minimal VEGFR2 internalization(41). Syndecans 
are also involved in this process, which indicates that other HSPGs may also be 
involved in the internalization process.  Syndecans are capable of complexing 
with synectin, which is critical for trafficking material from a rab5 endosome to a 
rab4 or rab11 late endosome(41).  
VE-cadherin mediates its ability to block endocytosis by binding VEGFR2 
at the surface and increasing its de-phosphorylation at the surface.  Cells lacking 
VE-cadherin, regardless of matrix density are able to more rapidly recycle and 
degrade VEGFR2. The density dependency of VE-cadherin alterations is 
associated with alterations in cell signaling. Endothelial cells are capable of 
having full AKT activation from the cell surface, but internalized VEGFR2 is 
necessary for complete ERK signaling(41). Thus quiescent vessels will sequester 
their VEGFR2 at the surface and will still be able to undergo AKT signaling until 
the receptor is dephosphorylated. This activation is important for cell survival.  
Vessels undergoing active angiogenesis with decreased VE-cadherin will 
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sequester less receptor at the surface and the subsequent internalization of 
receptor will drive ERK activation and cell proliferation and migration.   
VEGF internalization into endothelial cells utilizes many of the proteins 
discussed previously with regards to the extracellular matrix, stiffness, and 
integrin activity.  It is likely that the function of these proteins does not stop at the 
exterior of endothelial cells, but that these co-receptors and binding partners may 
help differentiate between surface sequestered, recycled, and degraded 
VEGFR2, which can have marked impacts on the short and long term signaling 
capabilities of endothelial cells. 
 
1.6 Individual cell analysis 
 Cells throughout the body and even within specific organs have high rates 
of cell-to-cell variability(116). At any point there could be a 15-30% difference in 
protein levels when comparing one cell to another within a single tissue(116).  
These changes are pathway specific, ie if ribosomal proteins are up-regulated, 
the expression of their binding partners often rises as well(116).   Receptor 
levels, gene expression, and epigenetic alterations are common from one cell to 
the next.  In endothelial cells, each type of vasculature has its own imprinted 
phenotype/genotype to compensate for local parameters(28). Within a vessel, 
endothelial cells can be quiescent, tip cell, or a stalk cell(23, 26).  During 
development, endothelial cell signaling components essential for VEGF 
internalization have a heterogeneous distribution based on the developmental 
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age of the individual vessel(114). The phenotype of endothelial cells in disease 
may differ from cell-to-cell. A healthy endothelial cell may be positioned next to a 
lipid-laden cell in an atherosclerotic plaque(70). The matrix below the endothelial 
cells is also highly variable.  Bovine endothelial cells produce a heterogeneous fn 
matrix with some areas highly responsive to heparin treatment to modulate its 
conformation whereas other areas remained folded(90).  When endothelial cells 
are taken out of their endogenous environment and placed on tissue culture 
plastic many of the individual characteristics of each endothelial cell type are lost 
as the cells revert to a similar phenotype and within 48 hours(117). These 
findings indicate cells and their ECMs are variable, and many of the changes in 
cell-to-cell protein expression and biological activity can be attributed to 
alterations in the microenvironment surrounding the cells.  
 Measuring heterogeneous cells has become easier with the invention of 
new technologies. Individual cell transcriptome analysis can allow readout of cell-
to-cell variability in genetic expression(118). Mass spectrometry studies can 
show protein modifications within individual cells(119).  Finally, imaging 
techniques and processing tools have developed in such a way to allow 
individual cell analysis(120).   
 Imaging allows for quantitative, dynamic measurement of individual cell 
analysis.  Better image processing and the availability of cell dyes and tags 
facilitates the use of imaging to determine cell-signaling dynamics. Dynamics of 
individual cells can vary dramatically cell-to-cell and with the type of stimulus 
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applied to modulate the downstream response(120). Some stimuli result in 
consistent fold increases in protein activation over variable baseline values(121).  
Others result in multiple oscillations of response(122).  Transient or sustained 
responses are also common(123).  The type of cell input codes for a specific, 
individual output. The ability to analyze individual cells presents new avenues for 
exploring if all cells within a population respond similarly or if there are varied 
responses.  Important findings can be lost within a general sample average. A 
handful of very high responding cells could skew the entire average upwards. 
The variety of responses cells have can potentially be harnessed to develop 
therapies targeting only specific individual cells that will decrease disease states 
or instigate healing.  
 Endothelial responses to various angiogenic agents have been studied 
previously in a dynamic, individual cell manner.  It was shown that traction forces 
are activated equally for a variety of effectors including lipoprotein a (LPA), 
sphingosine-1-phosphate (S1P), histamine, and thrombin. The response to 
VEGF had two independent activations.  A subset of cells did not respond or had 
a muted sustained response, whereas the remaining responses showed a 
transient spike in traction force followed by a sustained activation(77).  
 We predict that we will find a similar distribution in our endothelial cell 
population as it has been well characterized that endothelial cells can respond 
differentially to VEGF. We hypothesize that differences may be partially mediated 
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by the variable extracellular matrix produced below which in turn was created by 
cells with slightly variable individual cell phenotypes.  
 
1.7 Calcium Signaling 
 VEGF signaling within endothelial cells has been studied extensively.  
ERK and AKT are two main effectors of response, with ERK activation leading to 
a migratory phenotype and AKT contributing to cell survival(38, 41). Cytosolic 
calcium release can occur in response to many stimuli including both mechanical 
activation and VEGF stimulation(124, 125).  Mechanical stimuli, including flow, 
instigate IP3-mediated calcium release within seconds(125) whereas VEGF 
activation of transient receptor potential cation channel (TRPC3 and TRPC6) 
channels results in a slower, more sustained calcium response beginning at 
about 4 minutes after VEGF treatment(126). Calcium influx mediates cell 
permeability and further activates ERK signaling for other downstream 
responses(19). The type of stimuli can modulate the dynamics of calcium flux, 
coding for varied downstream outputs(125, 127). For instance, transient spikes in 
calcium have been tied to activation of different transcription factors than those 
stimulated by sustained calcium release(128). The pattern of VEGF-endothelial 
cell calcium activation and how that activation relates back to cell biology has not 
been studied in depth.  
Calcium signaling is both quantifiable and occurs over a short activation 
window allowing for many sample replicates. With calcium imaging, it is not 
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necessary to transfect tagged proteins into the cells or use challenging 
techniques such as FRET to study individual cell dynamics. Calcium signaling 
involves pre-loading cells with a calcium sensitive dye, which can chelate calcium 
resulting in fluorescence that can be monitored with microscopy(129). Calcium 
flux monitoring provides an easy method to quantify a common downstream 
signaling target of many agonists.   
Calcium signaling responses can be clustered(129), found at the leading 
edge(130) of an injury, or random(125, 127).  Most prior studies have examined 
calcium signaling as a whole by taking the entire fluorescence of the image and 
normalizing it to its non-activated fluorescence(127, 130). Although this 
technique does allow for an average approximation, it does not account for 
background alterations in fluorescence or cells that may be pre-activated.  Other 
methods of analysis have involved region of interest selection, but a confluent 
culture, depending on cell type, can have well over 100-200 cells in a 20x field, 
thus there is an inherent bias in picking which cells to analyze and the result is 
less reliable(125, 131). The best method for analysis is one that is automated 
and individually corrects each cell for its own background and can produce 
individual cell data for further analysis.   
 Analyzing large data sets involves looking at statistical techniques.  In 
other large-scale bioinformatics questions, such as how to deal with microarray 
data, clustering schemes have been used.  These same techniques can be 
utilized in individual cell analysis to connect how cells are behaving frame to 
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frame with other cells acting similarly.  Two main types of clustering methods 
exist.  Some methods, such as k-means, pre-define how many clusters exist, and 
then relate the outputs together(132). Hierarchical agglomerative clustering 
methods utilize non-biased distance (intensity differences) measures to pair 
related cells, then related clusters are further grouped until distance measures 
are minimized(132).  Agglomerative techniques do not pre-define the number of 
clusters, thus the data itself drives the final relationships,(132) a characteristic we 
found useful in analysis of our data. The benefit of non-biased individual cell 
analysis is that hundreds of cells can be analyzed for individual or linked cell 
behavior in a short period of time.  New trends and dynamics can be identified 
outside of what is found in a mean.  Furthermore, any cells tied to the behavior 
can be re-examined to see if the dynamic behaviors documented connect back to 
cell phenotypes.  
 Calcium dynamics can code for downstream effects based on the type of 
stimulation. We predict intrinsically heterogeneous endothelial cells will have 
heterogeneous VEGF induced calcium flux.  
 
1.8 Specific Aims 
 The goal of the work described in this thesis is to examine how VEGF-
endothelial cell processing is modified by stiffness on a population based and 
individual cell level.  We hypothesized that endothelial cell responses to VEGF 
will be heterogeneous. We predicted matrix binding of VEGF, as a function of 
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stiffness, would be critical for VEGF internalization and signaling. We further 
hypothesized that co-receptors, such as integrin proteins, work in conjunction 
with the matrix bound VEGF to alter the internalization and recycling of 
VEGF/VEGFR2 (Illustration 1). To study this hypothesis we established the 
following aims.  
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Illustration 1.1 Hypothesis of stiffness-induced alterations in VEGF 
internalization and signaling. 
We predict matrix binding of VEGF is required for VEGF internalization and 
subsequent ERK signaling. We postulate that matrix binding of VEGF and 
engagement/activation of β1 integrin can be modified by ECM stiffness. 
Together, we hypothesize that β1 integrin complexed with VEGF-VEGFR2 
directs the internalization and recycling of VEGF-VEGFR2 complexes on soft 
ECMs.    
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Aim 1: Analyze individual VEGF-endothelial cell responses to stiffness to find 
unique cell populations. 
Develop a tool to individually analyze fluorescent cell responses to stimuli.  
Use cluster analysis to examine how populations of cells are responding 
and identify phenotypic characteristics of each cell population.   
Aim 2:  Identify critical changes in endothelial cell processing of VEGF due to 
stiffness and matrix modulation.  
Use traditional signaling techniques and radioactive binding assays to 
identify how and why VEGF is processed differently in cells as a function 
of substrate stiffness.  
 To accomplish these aims we utilized a tunable polyacrylamide system to 
model ECM stiffness.  We utilized calcium signaling to develop quantifiable 
individual cell analysis tools.  These tools allowed us to assess how population 
based cell dynamics and averages were drastically different from clustered and 
individual cell analysis.  The experiments showed both interesting stiffness 
dependent and concentration dependent findings.   
 Additional experiments explored how other downstream signaling 
pathways were modified by stiffness.  These findings along with internalization of 
VEGF, and the calcium signaling findings inversely correlated with matrix binding 
leading us to believe that matrix binding may be driving those findings. 
Enhancing VEGF matrix binding with heparin resulted in an increase in 
internalization, a contradiction in the result, but blocking VEGF matrix binding 
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with SOS decreased VEGF internalization. Together these findings suggest 
VEGF matrix binding, as a function of stiffness, is critical for VEGF 
internalization. Further studies indicate β1 integrin activation may be depressed 
with increased ECM stiffness reducing internalization of VEGF in conditions with 
enhanced VEGF matrix binding due to stiffness. Future studies are needed to 
parse out exactly how VEGF, VEGFR2, and β1 integrin work together to mediate 
these findings.   
 Together, we identified a new major modifier of VEGF signaling within 
endothelial cells – substrate stiffness.  We also documented changes in 
internalization with matrix binding and found specific changes in cell phenotype 
of high responding cells.  Ultimately, these findings could lead to advances in 
modeling blood vessels, developing therapeutic replacements, or creating new, 
targeted treatments to address individual cell populations.  
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 Materials  
Forty percent acrylamide and two percent bis-acrylamide solutions, ammonium 
persulfate, pre-cast stain free (7.5%) polyacrylamide gels, Clarity Detection 
Reagent, and low-fluorescence PVDF were purchased from BioRad (Hercules, 
CA).  Phosphate buffered saline (PBS) (10x) was purchased from Gibco (Grand 
Island, NY). Gluteraldhyde and Beta-tubulin antibody (T4026) was purchased 
from Sigma-Aldrich (Natick, MA).  Human fn was from Millipore (Billerica, MA). 
TEMED, nitrocellulose and coverslips were acquired from Fisher Scientific 
(Pittsburgh, PA). Total fn antibody 610077 was from BD Biosciences (San Jose, 
CA), and TMB Microwell Peroxidase was from KPL (Gathersburg, MD). Primary 
antibodies including ERK P44/P42 (9107/4695), Phospho-ERK (9101), Phospho-
VEGFR2 (3770), total VEGFR2 (9698), Phospho-AKT (4051/4060), AKT (9272), 
and GAPDH (2118) were all purchased from Cell Signaling Technologies 
(Danvers, MA).  Secondary HRP-linked antibodies to mouse and rabbit were 
purchased from Jackson Labs. Fluorescent secondary antibodies to mouse and 
rabbit (A488, A555, and A647) were purchased from Life Technologies (Grand 
Island, NY). We also purchased powdered DMEM without bicarbonate, Fluo-3 
AM, and TrypLE cell dissociation buffer from Life Technologies. Cell culture 
reagents, including fetal bovine serum (FBS), calf serum, trypsin EDTA, 
Dulbecco’s modified Eagle’s medium, penicillin streptomycin cocktail, and L-
glutamine, were purchased from Corning (Tewksbury, MA).  Fn-depleted fetal 
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bovine serum was made using gelatin-agarose (Sigma-Aldrich (Natick, MA)) as 
previously described(133). Human recombinant VEGF165 was obtained from R&D 
Systems via NCI Bulk Cytokine and Monoclonal Antibody Preclinical Repository 
(Frederick, MD). Bolton-Hunter I-125 kit (Perkin Elmer Waltham, MA) was used 
for radioactive VEGF-tagging as previously described(134).   FACS wash buffer 
was purchased from BD Biosciences (San Jose, CA) and cell fixation buffer from 
eBioscience (San Diego, Ca). Matlab (Mathworks, Natick, MA) segmentation 
scripts were written in version 2009b.  
 
2.2 Methods 
Polyacrylamide Gel Fabrication 
Polyacrylamide gels of defined stiffness (4, 25, and 125 kPa) were produced 
using a sandwich methodology developed previously(79, 82). Briefly, glass 
coverslips were cleaned with 0.1 N NaOH and washed with distilled water.  After 
drying, coverslips were coated with various concentrations of fn depending on 
the corresponding stiffness, in order to produce a uniform density of fn on the 
surface of all gels. See Table 2.1 for gel recipes. After drying the coverslips 
under vacuum at 4°C, they were washed and dried a second time.  A second set 
of coverslips was treated with 3-aminopropyltrimethoxysilane, allowed to dry, 
washed several times with distilled water and then treated with 0.5% 
glutaraldehyde for thirty minutes. Glutaraldehyde solution was removed, 
coverslips were washed several times with distilled water, and they were stored 
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in water until ready for use. Polyacryalamide gel mixture (0.1 ul/mm2) was added 
to each 3-Aminopropyltrimethoxysilanecoated coverslip(79, 82).  A 
corresponding fn coated coverslip was added to the top and gels were allowed to 
polymerize under vacuum at 4°C for 1 hr at which point the fn on the top 
coverslip was successfully transferred, without the aid of NHS-ester, to the 
covalently linked gel below.   Gels were washed in PBS, quenched in sterile 3% 
BSA-PBS for 1 hr and then washed again with PBS prior to cell seeding.  
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Stiffness 
(kPa) 
% 
Acrylamide 
% Bis-
Acrylamide 
µL 40% 
acrylamide 
solution 
µL 2% bis-
acrylamide 
solution 
µL 10x 
PBS 
µL di 
H2O 
4 10 0.07 250 35 100 588 
25 10 0.1 250 50 100 573 
125 12 0.6 300 300 100 273 
    
Stiffness 
(kPa) 
TEMED HCl* APS 
solution 
4 2 20 5 
25 2 20 5 
125 2 20 5 
 
 
* Amount of acid can depend on acid solution, ratio 
of bis/acrylamide, and age of solutions.  Verify with 
pH paper. Set pH to ~7.1 using pH paper 
 
 
 
Table 2.1 Composition of polyarylamide gel mixtures for in house PAAM 
gels.  
Composition tables were obtained from Sazonova et al(135) and were modified 
with an additional recipe (4 kPa) from Polio et al(82). Fn concentration values for 
the top coverslips used in sandwich assays were experimentally determined and 
verified periodically.   
Stiffness (kPa) Fibronectin 
(ug/ml) 
4 50 
25 35 
125 25 
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Matrigen Gel Functionalization 
Polyacrylamide (PAAM) gels in various sizes and stiffness values (4, 25, 125 
kPa) were purchased from Matrigen Corporation.  A sterile 10 ug/ml BD fn-PBS 
solution was added to each gel well.  After sufficient time for fn amine-
crosslinking to the gel to occur, excess fn was washed away with PBS and any 
remaining un-reacted amine binding sites were blocked with 3% bovine serum 
albumin phosphate buffered saline (BSA-PBS).  BSA-PBS was removed and the 
gels were washed with PBS in preparation for cell seeding.   
PAAM Protein Verification 
Fn-ELISAs were conducted to verify that the density of fn on the gel surfaces 
was consistent across the tested stiffness conditions.  Known concentrations of 
fn were adsorbed to polystyrene surfaces that were the same size of the gels in 
order to establish standard curves. Gels were fixed for 20 minutes at 4°C in 4% 
paraformaldehyde in PBS.  After fixation, samples were washed in Tris buffered 
saline (TBS) and then incubated in 3% bovine serum albumin (BSA) TBS for 1 hr 
to block non-specific sites.  After blocking, gels were incubated with BD total fn 
primary antibody for 1 hour at a 1:10000 dilution in 3% BSA-PBS, then washed 
with TBS prior to treatment with a Jackson Laboratories HRP linked secondary 
antibody to mouse at 1:5000 for 1 hour in 3% BSA-PBS.  Finally, samples were 
washed several times in 0.1% TBS-Tween (TTBS) and TBS prior to 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate reaction. The absorbances of multiple 
samples from each well were measured using a 96-well OptiMax plate reader 
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(Molecular Devices). Background A550 readings were subtracted from sample 
A450 readings.  Fn levels were calculated based on the standard curve.    
PAAM Gel Protein Adhesion 
To verify sustained crosslinking of fn protein to polyacrylamide gels, we 
measured remaining fn levels on gels after several days in culture (Figure 2.1). 
PAAM gels were fabricated in house and cross-linked with appropriate fn 
concentrations.  On given days, gels were fixed, as above in the protein 
verification.  Upon completion of all time points, protein verification was 
completed as outlined above.  
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Figure 2.1 Stability of fn coated PAAM gels. 
Fn on gels is stably attached to the surface. PAAM gels with adhered fn were 
incubated in PBS for up to 22 days.  At each day, samples were fixed, washed in 
PBS, and at the end of the time course the surface density of fn was measured 
using a fn ELISA with a standard curve of known quantities adsorbed to plastic. 
Data is the average of triplicates +/- SEM.  There are no significant differences in 
fn quantities as measured with an ANOVA.  
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Cell Culture 
Bovine Aortic Endothelial Cells (BAECs) (passage 6-16) or human Peripheral 
Blood Endothelial Colony Forming Cells (PB-ECFCs) (passage 3-8) were used 
for all experiments. BAEC Cells were maintained in DMEM supplemented with 
10% calf serum, 1% penicillin/streptomycin cocktail and 1% L-glutamine. PB-
ECFCs were maintained in endothelium growth media (EGM-2 MV Bullet Kit, 
Lonza) containing EBM-2, 5% fetal bovine serum, recombinant human (rh) EGF, 
rhVEGF, rhFGF-B, rhIGF-1, ascorbic acid, and heparin. Cells were prepared by 
washing several times with phosphate buffered saline (PBS) followed by 
trypsinization of cell sheets. Trypsin was inhibited with FBS supplemented media 
with fn-depleted serum. For calcium experiments, cells were seeded at 21,000 
cells/cm2 in the fn-depleted (10% for BAEC and 5% for PB-ECFCs) serum.  After 
24 hrs in culture, the cells were washed once with PBS and fresh 0.1% fn 
depleted serum was added for the remaining 24 hrs prior to experimentation.  We 
found variability in cell density with stiffness on the Matrigen gels. To adjust for 
these differences, we seeded BAEC plates at increasing density for decreased 
stiffness (9000/cm2 4kPa, 7000/cm2 25 kPa, 5000/cm2 125 kPa, and 4000/cm2 
plastic). PB-ECFC were seeded at half the above densities to account for rapid 
cell proliferation in these cells. Cell-cell contact through VE-cadherin decreases 
VEGF signaling.  To verify that our alterations in internalization were not due to 
density related changes we conducted an experiment where we seeded BAECs 
at one density (7000 cells/ cm2) and at a varied density as outlined above.  Our 
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findings indicate that density did not change stiffness dependent findings (Figure 
2.2).  In fact, decreasing the density of cells on the plastic wells, actually 
minimally decreased the rate of internalization. Experiments were conducted on 
cultures that were 50-70% confluent at 4 days post seeding.   
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Figure 2.2 Density of cell seeding does not impact internalization of VEGF 
Cells on various stiffness matrices were treated with 125I-VEGF for 3 hours at 
37oC. Samples were washed several times and then high salt was used to 
extract matrix bound portion.  Acid was used to remove membrane associated 
VEGF and NAOH was used to extract internalized VEGF.  A. MTT assays 
demonstrating the relative cell counts on the various stiffness substrates with 
either matched cell density or varied cell density. B. Matrix bound 125I-VEGF 
fraction for varied cell density or matched cell density. C. Internalization fraction 
of 125I-VEGF normalized to cell count MTT values.  All MTT/125I-VEGF values are 
the average of triplicates +/- SEM. 
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MTT Assay 
Relative cell counts were measured utilizing an MTT ((3-(4, 5-dimethylthiazolyl-
2)-2, 5-diphenyltetrazolium bromide) Proliferation Assay (kit from ATCC, 
Manassas, VA).  Manufacturer instructions were followed with MTT reagent 
added for 2 hours at 37oC followed by detergent addition for an additional 2 
hours in the dark at RT. After the incubations were complete, wells were 
individually mixed with a pipet to ensure even distribution of the precipitate.  
Samples were moved to a 96 well plate for plate reader adsorption measurement 
at A570. Wells with no cells in them were used for background correction.  
Western Blots 
After 4 days in culture, BAECs on 6 well PAAM plates of 4, 25, 125 kPa, and 
plastic were processed for protein analysis. Samples were serum starved for 24 
hours in 0.1% -fn DMEM. Conditioned media was collected from cells on plastic 
flasks.  This media was utilized as a buffer for heparin and VEGF additions.  
Heparin (10ug/ml) was added for one hour in a 37°C humidified incubator. 
Heparin was washed away and new conditioned media was added to each well.  
After a stabilization period, VEGF was added to the system. At pre-determined 
time-points, plates were placed on ice, media was removed and lysis buffer, 
supplemented with an anti-phosphatase and anti-protease cocktail was added. 
Cells were lightly scraped from the wells with soft rubber spatulas, collected, and 
solutions were briefly sonicated to dissociate any nuclear proteins.  
Centrifugation allowed for enrichment of a protein rich supernatant.  BCA assays 
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were utilized to quantify the amount of protein in each sample and normalize 
loading quantities.  Samples loaded into 7.5% SDS-PAGE stain free gels and 
transferred in a Tobins Transfer buffer bath to nitrocellulose or PVDF 
membranes.  Traditional blotting methods were followed starting with stain free 
gel imaging to verify even loading and protein transfer. Blocking and antibody 
additions (see table 2.2 for concentrations) were conducted in 5% milk TTBS. 
Fluorescent western protocol was modified so that no Tween was added until 
after milk blocking was completed. More antibody was needed due to decreased 
signal amplification as compared to chemiluminescence.  All imaging and 
densitometry quantification was completed with a BioRad ChemiDoc Imaging 
System. 
Antibody Company Product # Concentration 
β-tubulin Sigma T4026 1:10000 
GAPDH Cell Signaling 2118 1:10000 
P-ERK P44/P42  Cell Signaling 9101 1:1000 
ERK P44/P42 (rabbit) Cell Signaling 4695 1:2000 
ERK P44/P42 
(mouse) Cell Signaling 9107 1:1000 
P-AKT (mouse) Cell Signaling 4051 1:500 
P-AKT (rabbit) Cell Signaling 4060 1:1000 
AKT  Cell Signaling 9272 1:5000 
P-VEGFR2 Cell Signaling 3770 1:500 
VEGFR2 Cell Signaling 9698 1:1000 
Table 2.1 Concentrations of antibodies used for western blot experiments.   
Mouse P-AKT and Mouse ERK were used for dual antibody fluorescent western blots in 
lieu of their rabbit counterparts that were used for the remainder of the westerns. 
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VEGF Binding Assays 
After 4 days in culture, endothelial cells on 4, 25, 125 kPa and plastic matrices 
underwent 125I-VEGF binding assays.  First, half of the wells were treated with an 
ammonium hydroxide triton solution to remove the cells from the wells leaving 
behind an intact matrix. Wells were treated with and without 10 mg/ml heparin.  
After an hour, heparin was removed with washes and fresh binding buffer with or 
without sucrose octasulfate (SOS) was added to each sample and allowed to 
equilibrate(63).  125I-VEGF in binding buffer with or without SOS was added to 
each sample.  At set time-points, the plates were placed on ice and washed with 
binding buffer to remove any unbound VEGF.  A high salt (1 M NaCL 25 mM 
HEPES pH 7.4) solution was used to remove matrix associated VEGF as 
previously shown(65).  After high salt extraction, a 0.2 M acetic acid salt solution 
was utilized to remove membrane-associated 125I-VEGF.  To verify these 
methods, we adhered VEGFR2 and VEGFR1 chimera proteins to protein-A 
coated plates.  We verified salt was unable to dissociated bound radioactive 
VEGF, but acid was able to remove approximately 50-60% of VEGF bound 
directly to the receptor (Figure 2.3). Finally a 1 N NaOH wash extracted any 
remaining cell associated protein, which was considered the internalized fraction. 
Three-hour incubations were utilized for most experiments as steady state 
binding had been reached by that time on all stiffness matrices. The 
concentration of SOS utilized for experiments (1 mg/ml) was found by doing a 
titration experiment binding assay as outlined above (Figure 2.4). Radioactivity in 
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all samples was measured using a Cobra Auto-Gamma 5005 γ-counter (Packard 
Instruments, Meridian, CT). Readings from the ECM only samples were used to 
correct the internalized fractions for the amount of 125I-VEGF that was passively 
associated with the matrices.  Samples were further normalized to relative cell 
numbers as determined by MTT assay, outlined above.   
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Figure 2.3 Binding assay extraction verification. 
The effect of extraction methods on VEGF bound to 100 pM Fc chimera proteins 
of VEGFR1 and VEGFR2. VEGF was incubated with Protein-A bound chimera 
proteins for 1 hour at RT.  Excess was washed away prior to salt, acid, and 
NaOH extractions. A. High salt solution removes minimal VEGF form either 
VEGF receptor (2% R1 and 13% R2). B. Acid wash removes 50-60% of total 
bound VEGF from receptors. Data is the percent of the total extracted in each 
wash condition. It is shown as average of triplicates +/- SEM. 
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Figure 2.4 SOS blocks binding of VEGF to the ECM. 
A traditional binding assay on plastic was completed as outlined in the methods.  
During the 125I-VEGF addition, various concentrations of SOS were also added.  
Various fractions were extracted as previously discussed.  The ability of SOS to 
inhibit matrix binding is shown in the above figure.  Future experiments used 1 
mg/ml SOS to inhibit matrix binding (90% reduction in control conditions 80% in 
heparin conditions).   
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VEGF Release Assay 
To assess the release of VEGF from the system, we carried out a binding assay 
described above.  After removal of the membrane associated VEGF with acetic 
acid, the wells were washed with binding buffer to return the pH to normal.  Fresh 
excess binding buffer was added to each well and the cells maintained at 37°C 
for a range of times.  At each time point, binding buffer was removed, wells were 
washed with fresh binding buffer and then the remaining internalized VEGF was 
extracted with 1N NaOH and the radioactivity in each sample was measured with 
the γ-counter. 
Flow Cytometry Analysis 
Cells were grown on 150 mm Matrigen gel plates or non-TC plastic functionalized 
with fn as described above.  After 4 days in culture cells were washed briefly with 
FACS Buffer containing sodium azide to block further metabolic action.  Cells 
were collected after trypsinization of cell sheets with TrypLE.  Cell number was 
measured and the cells were spun down at 200xg for 5 minutes prior to 
resuspension in FACS buffer.  One million cells were placed in each individual 
tube and the tubes were centrifuged again to facilitate removal of the wash 
buffer.  Fixative containing permeabilization buffer was added to each tube for 30 
minutes at RT.  Solutions were spun down and cells were washed 2x in FACS 
buffer.  Cells were spun down, washed 2x with FACS buffer prior to addition of 
VEGFR2 antibody (1:100) for 1 hour at RT.  Samples were once again spun 
down and resuspended for two more washes prior to the addition of A488 anti-
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rabbit to each tube (10 ug/ml) for 30 minutes.  After incubation, samples were 
washed 2 more times in FACS buffer and resuspended for FACS analysis.  Cells 
were passed through cell strainers and were analyzed up to 30000 counts per 
condition. Background absorbance values at 488 nm were subtracted from the 
VEGFR2 readings.  
Calcium Imaging 
All calcium imaging was performed as previously described(129), with an Argon 
laser on a Zeiss Axiovert 100M LSM 510 (Thornwood, NY). Samples were 
washed 2x in HEPES buffer (10 mM HEPES, 137 mM sodium chloride, 5 mM 
potassium chloride, 4 mM magnesium chloride, 3 mM calcium chloride, and 25 
mM glucose) Fluo-3 AM was dissolved in DMSO supplemented with 0.02% 
pluronic acid. Samples were incubated in Fluo-3 AM (1% final concentration) in 
HEPES buffer for 20 minutes (stored in the dark at 37°C).  After incubation, 
samples were washed 1x with fresh HEPES prior to being moved to a flow-
mounting chamber (Warner Instruments) as previously described(130). Flow 
input was adjusted to approximately 40 µl/second so that flow did not stimulate 
cells.  For each experiment, images were acquired at 789 ms/frame using the 
argon laser (488 nm). Samples were equilibrated, under HEPES buffer, for 5 
minutes prior to exchanging the control flow buffer to HEPES buffer containing 
the indicated concentration of VEGF. Experiments lasted 10-15 minutes.    
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Calcium Image Analysis 
Segmentation:  MATLAB cell segmentation was conducted using a method 
modified from a Mathworks Engineering blog(136).  Briefly, to provide the best 
average cell representation, the first 50 frames of the treatment were added 
together.  Contrast was enhanced and cell areas were enhanced to optimize 
perimeter identification.  After identifying individual perimeters, the cell nuclei, or 
minima of each cell were identified. Marked areas containing both a nuclei and a 
cell perimeter were counted as individual cells(129). Figure 2.5 provides a step-
by-step description of this critical step in analysis.  
 
Data analysis:  The software script was written to address population based 
outputs and single cell analysis parameters.  For all analyses, the segmented cell 
outlines were utilized to break each image into individual cells that were 
quantified using a pre-defined MATLAB function, “regionprops”.  The regionprops 
function is able to assess cell area, pixel intensities, centroid location, and a 
variety of other parameters.  Utilizing this ability, we were able to calculate the 
individual cell intensity during treatment and correct it for its own individual 
background as averaged throughout the first 50 frames of control analysis. This 
correction minimizes the effect that cells that may be pre-activated or “primed” to 
respond prematurely prior to treatment would have on the overall analysis.  
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Normalized intensity: The normalized intensity is the average intensity in which 
each cell is further normalized (divided by) its own individual background. The 
values are represented as percentages. Our population based cell traces 
represent at least 7-11 gel runs from 2-3 independent experiment days. Any run 
where the average normalized maximums were two times greater or less than 
the maximum of the average normalized intensity for all other runs was pre-
excluded from the analysis.  
 
Percent activated: We considered any cells with intensity values over the 95th 
percentile of cell intensities in the background frames to be considered activated.  
These frames represent population-based averages of the number of cells 
activated in each frame.  
 
Number of maximums:  An open source peak detection script (PEAKDET, 
Billauer) was utilized to identify individual local maximum that occurred, 
separated by a pre-defined distance, in each cell over time.   
 
Hierarchical Clustering: Hierarchical clustering was completed on portions of 
the cell traces.  Cells were clustered and displayed as a clustergram heatmap.  
The cells from each cluster were averaged together to create visualizations of the 
cell traces.  Activation time was chosen as the time point, after the 50 control 
frames, in which the normalized intensity value for the trace was above 3%. The 
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deactivation point was chosen as the time in which the cell traces arrived at their 
maximum.  Activation and deactivation rates were calculated by creating a linear 
best-fit approximation of regions between activation and deactivation time 
(activation rate) and deactivation time and the end of the run (deactivation rate). 
Figure 2.6 provides a visual representation of these calculated values.  
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Figure 2.5 Progression of the MATLAB algorithm for cell segmentation and 
identification. 
A. Import the first control slide.  B. Add up the first 50 background slides, then 
adjust the contrast so that the cells are sufficiently bright. C. Utilize a function 
from the MATLAB library to identify cluster perimeters. D. Couple the previously 
identified perimeters with the local minima or nuclei. New segmentations are 
created between areas with two minima and one perimeter. Processed cells 
require both a minima and a perimeter. E. Number the cells and display for the 
user to critique the segmentation routine. F. Read in all un-processed slides.  
Use the segmented cells as a mask to identify areas of cell intensities and 
characteristics.  
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Figure 2.6 Definition of calcium response parameters. 
A model plot is shown to indicate the specific activities/parameters. A. At 50 
frames into the experiment, flow is switched to buffer containing VEGF. B. 
Activation time is the time at which the normalized intensity of the cell trace 
reaches 3% over background. C. Maximum time is when the overall maximum of 
the run occurs. D. Overall maximum is the intensity at the maximum of the run. E. 
Activation rate is the best-fit linear approximation from the activation time to the 
maximum time. F. Deactivation rate is the best-fit linear approximation from the 
maximum time to the end of the run. 
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CHAPTER THREE: EXTRACELLULAR MATRIX STIFFNESS MODULATES 
VEGF CALIUM SIGNALING IN ENDOTHELIAL CELLS: INDIVIDUAL CELL 
AND POPULATION ANALYSIS 
3.1 Introduction 
As humans and animals age, the vasculature of the body stiffens. The 
degree of stiffening correlates with cardiovascular morbidity, which can in turn 
lead to further stiffening pathologies such as atherosclerosis(5, 137).  The 
turnover of and alterations in the extracellular matrix (ECM) underlying the cells 
of the vasculature is largely responsible for this change.  Disruption of the matrix 
metalloproteinase (MMP) balance and increased advanced glycation end 
products (AGE) contributes to increased collagen deposition, cross-linking, and 
subsequent stiffening of the vasculature(7, 17, 33, 35). How much the stiffness is 
altered in aging and disease is highly variable and may also depend on where 
the measurement was made. While healthy vessels range from about 2.5-50 
kPa, diseased regions of vessels have stiffness ranges from about 10-200 
kPa(30, 69, 70, 72), and for comparison, tissue culture polystyrene stiffness is in 
the gigapascal range(71).    
 Various cell types respond to substrate stiffness differently.  The fate of 
stem cells has been shown to vary depending on the ECM stiffness(138).  
Confluent endothelial cells, without the aid of any growth factors, show increased 
permeability and proliferation as a function of the stiffness of the ECM on which 
they are cultured(79, 84).  Cells remodel and spread more extensively on stiffer 
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substrates and the actin cytoskeleton increases its organization. However, 
substrate stiffness is not an independent stimulus to the cell as we have recently 
shown that the response of vascular smooth muscle cells to substrate stiffness is 
dependent on the specific matrix proteins present(79) and others have shown 
dramatically different endothelial cell responses to stiffness depending on 
specific source of the cells(86).  Cells have also been shown to take on the size 
and shape of the matrix in which they reside(139).  An increase in protein ligand 
or stiffness results in a corollary increase in certain integrin proteins within 
mature focal adhesions(79, 80).  
 The ECM not only dictates cell adhesion properties, but also is a storage 
depot for growth factors. Fn, a protein up-regulated in pathological conditions 
such as at sites of endothelial cell dysfunction, is well characterized as having a 
heparin binding domain where numerous growth factors can bind and potentially 
interact with cells(58, 90, 140).  Vascular endothelial growth factor (VEGF), a 
major pro-angiogenic protein, binds to fn with a high affinity(39, 57, 58).  Prior 
studies have linked β1 integrin protein to matrix-bound VEGF and prolonged 
downstream signaling(42).  VEGF-receptor 2 activation, the functional pathway 
responsible for much of VEGF biology, has been shown to cross react with 
several downstream integrin pathways, further suggesting a connection between 
the two receptor systems(27).  
VEGF has been one of the most studied vasoactive agents as its potential 
to stimulate new vasculature and healing in areas damaged by age, wounds, or 
	  	  
55 
disease is widespread, yet attempts to use VEGF clinically have been 
unsuccessful likely due to a lack of complete understanding of its mechanism 
and effectors(1, 44, 45).  VEGF interacts with two main receptor types, VEGFR1 
and VEGFR2. VEGFR1, has a high affinity for VEGF, storing the growth factor, 
blocking its interaction with VEGFR2(38). VEGFR2 is responsible for 
downstream angiogenic properties such as vessel survival, migration, 
permeability, and proliferation. It signals through traditional tyrosine kinase 
receptor dimerization and activation of downstream effectors including ERK 
(proliferation), AKT (survival), and intracellular calcium release (permeability)(38). 
Endothelial cells have highly variable protein and epigenetic profiles based on 
the vascular bed of origin and even within an individual vessel. For instance, at 
any point an endothelial cell can be quiescent, or be involved in the angiogenesis 
process(23, 24). An angiogenically active population of endothelial cells will send 
out an individual tip cell that is highly responsive to VEGF to initiate the migration 
and growth of a new capillary as directed by a matrix-bound VEGF gradient.  
Stalk cells, resting behind the tip cell, are also responsive to VEGF, but they 
proliferate rapidly to form the new vessel lumen(26, 141).  A better understanding 
of how to switch quiescent cells to angiogenic cells and vice versa could provide 
a pathway towards new treatment paradigms.  
 To test our hypothesis that ECM stiffness selectively modulates VEGF-
endothelial cell activation, we developed a new analytical tool, which is able to 
uniquely access individual cell VEGF-calcium response and identify 
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heterogeneous trends within a seemingly homogenous cell population.  We 
found that response varied with stiffness in a complex manner.  A large 
proportion of VEGF-treated cells were non-responsive or showed a slow, steady 
increase in activity, whereas a smaller subpopulation of highly responsive cells 
spiked rapidly and returned to a lower activation level. Response magnitude and 
rate, independent of stiffness depended on VEGF concentration. The highly 
responsive cells maintained a distinct shape indicating that primed, highly VEGF 
responsive, cells may have a shape-dependent association. We present data 
that unmasks trends and populations previously hidden within a simple average.  
 
3.2 Results 
The mechanical environment in which cells grow must be considered in a 
biological context.  Growth factor availability and interactions vary with 
mechanical stiffening. To more fully appreciate how local mechanical properties 
impact growth factor activity, we devised an experimental system that allows 
cellular signaling kinetics to be monitored quantitatively using polyacrylamide 
gels of defined stiffness.  Moreover, we developed an analytical approach that 
distinguishes the averaged response of a population of cells from the response of 
individual cells and clusters of cells.  This approach will provide insight into the 
full range of growth factor activities within a biologically relevant context.  
Our stiffness model consists of tunable polyacrylamide gels that are 
covalently linked to glass coverslips.  The surfaces of the gels were exposed to a 
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coverslip coated with fn allowing passive transfer to occur during polymerization.  
Larger quantities of fn were needed to functionalize the softer gels to produce 
gels that contained the same concentration of fn on the surface (Figure 3.1A).  
To verify that the ECM environments remained comparable after several days of 
cell exposure, we imaged the fn matrix on the three stiffness substrates after four 
days in culture and found no visible differences in the fn fiber structure or density 
(Figure 3.1B). Thus, this system provides a similar distribution and pattern of 
ECM proteins such that the stiffness is the major variable being studied.   
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Figure 3.1 Characteristics of polyacrylamide gel experimental system. 
A. ELISA quantification of fn on the surface of the gels prior to cell seeding. B. 
Images of fn matrices 4 days after BAEC growth on the three different stiffness 
gels (4, 25, 125 kPa). 
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To study the cellular signaling response to VEGF and ECM stiffness, we 
measured the calcium response in endothelial cells cultured on gels of varying 
stiffness using live-cell imaging(129).  The individual cell analysis was conducted 
using a MATLAB script as that is described in the methods section (Figure 2.5).  
Analysis of 52 runs from various days, substrate stiffness, and treatment 
conditions indicate that the segmentation algorithm correctly identified cells 87% 
of the time.   
The built-in functionality of MATLAB provided a way to quantify the 
average pixel intensities of every cell identified by the algorithm.  Additionally, the 
major axis, minor axis, and area of each cell were quantified.  There statistically 
significant differences in the size and shape of the cells analyzed on the various 
stiffness ECMs (Table 3.1). 
Stiffness Average # of Cells/Run Area  (µm
2) Major Axis Length (µm ) 
Minor Axis  
Length (µm ) 
4 kPa 79 +/- 30 556.64 +/- 6.43 34.84 +/- 0.22 18.67 +/- 0.12 
25 kPa 70 +/- 12 625.47 +/- 9.10 37.22 +/- 0.28 19.66 +/- 0.15 
125 kPa 87 +/- 18 528.87 +/- 5.39 33.90 +/- 0.19 18.39 +/- 0.11 
Table 3.1 Cell Characteristics by Stiffness.   
Descriptive information regarding the geometry and size of cells analyzed.  Area 
is the quantitative area of the region segmented, it is a true value, not an 
approximation based on a relative diameter. For each region, an artificial ellipse 
with the same second moments of the cell is created over the segmented cell.  
The major axis length and minor axis length are reflective of this ellipse. The 
number of cells per run is represented with +/- standard deviation.  The 
remaining characteristics are given as +/- standard error of the mean.  All areas 
and relative cell lengths were significant when compared to each other, except 
for no significant difference between the minor axis length of the 4kPa and 125 
kPa samples. 
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Numerous studies have investigated the various responses of endothelial 
cells to VEGF treatment. Many of these studies compile average readouts from 
experiments including western blots, ELISAS, and tube formation assays. While 
these studies have defined important VEGF activities, it is likely that averaging 
the response over large populations of cells results in loss of pertinent 
information. To address these possibilities, while also exploring how substrate 
stiffness influences VEGF activity, we compared population base and individual 
cell analysis of the endothelial cell calcium response to VEGF to determine if 
ECM stiffness modulates VEGF responsiveness. We found minimal calcium 
mobilization in response to low doses of VEGF and attenuation of the response 
at high doses of VEGF treatment (Figure 3.2A).  Maximal responses were 
observed with 5 ng/ml on 4 kPa ECM (1.5 and 1.7 fold over the 25 and 125 kPa 
samples, respectively) and 10 ng/ml on the 25 kPa ECM (1.6 and 1.8 fold over 
the 4 kPa samples and 125 kPa samples, respectively).  The cellular response to 
VEGF on the 125 kPa ECM was insensitive to VEGF concentration, with the 
response showing little variation across the dose range analyzed.   
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Figure 3.2 VEGF activation of calcium signaling in BAECs. 
Population based outputs from MATLAB quantification of BAECs stimulated with 
the indicated concentration of VEGF are shown. Each measurement represents 
a composite of 7-11 runs from at least 2-3 independent experiments.  All 
measurements were conducted on three stiffness gels, 4 kPa (blue), 25 kPa 
(red), and 125 kPa (green), with four different concentrations of VEGF (1, 5, 10, 
and 25 ng/ml). A. Normalized intensity output represents an average of individual 
cell intensities that have been normalized to the average of their individual initial 
control background. B. Percent of cells that are activated over the 95th percentile 
of background intensity values as a function of time.  C. Average number of local 
maxima throughout the observation period. 
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To examine the dynamics of the average calcium response in greater 
detail, we computed a variety of outputs including maximal calcium response, 
rate of activation, and deactivation rate (parameters defined in methods Figure 
2.6) for each of the conditions (VEGF dose and ECM stiffness) tested (Table 
3.2).  Table 3.2 also highlights the percent of cells that were activated for each 
treatment type for comparison to the normalized intensity values.  The percent of 
cells activated was not dependent on concentration or stiffness and all alterations 
were minor compared to the magnitude of change in the normalized intensities. 
For example, although only 11% more cells responded in the 10 ng/ml treatment 
on the 25 kPa gels compared to the 4 kPa condition, there was a 43% increase 
in normalized intensity (Figure 3.2).  There were no changes in the number of 
local maximums that each cell displayed across any stiffness. Together, these 
data indicate that the cells that responded in the 25 kPa condition responded with 
greater fortitude. Activation rates in the cells on 4 and 25 kPa matrices maintain a 
bell curve response with the maximum rate correlating with the maximal 
response, but on 125 kPa substrates, there was a concentration-dependent 
activation.  This finding may indicate that a VEGF concentration leading to 
maximal activation in our 125 kPa condition was not met within our experiments.  
Simply, increasing doses of VEGF are necessary to maximally activate 
endothelial cells on stiffer substrates.   
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Table 3.2 Dynamics of cell traces, population based analysis.   
Descriptive information on the cell traces provided in Figure 3.2.  Information on 
overall trace maximum, activation time, deactivation time, and the rate of 
activation and deactivation is provided for each normalized intensity trace. These 
values are demonstrated on Figure 3.2B.  Activation rate is the slope of the best-
fit linear approximation from the activation time (the first point over 3% 
normalized intensity) through to the overall maximum. Deactivation rate occurs 
from the overall maximum time to the end of each run. The percentage maximum 
number of cells activated for each run is also included. 
  
Stiffness VEGF Dose 
Activation 
Time (min) 
Max 
Time 
(min) 
Activation 
Rate 
Deactivation 
Rate Max 
% 
Activated 
Maximum 
4 kPa 
1 ng/ml 3.00 10.00 7.16 -2.46 51.2 60.68 
5 ng/ml 2.07 5.96 25.8 -5.3 96.88 68.58 
10 ng/ml 0.68 5.60 18.95 -5.23 74.47 60.79 
25 ng/ml 1.93 4.68 28.06 -6.89 77.41 63.02 
25 kPa 
1 ng/ml 3.56 10.27 9.78 -1.54 63.10 63.21 
5 ng/ml 2.39 7.49 13.33 -2.33 69.80 63.07 
10 ng/ml 1.76 5.60 31.63 -4.48 116.93 72.01 
25 ng/ml 1.04 5.37 24.42 -4.98 90.37 63.88 
125 kPa 
1 ng/ml 3.84 9.98 7.26 -1.95 47.93 54.36 
5 ng/ml 2.64 8.36 9.11 -0.67 56.51 59.94 
10 ng/ml 2.16 7.02 12.15 -3.43 64.57 59.76 
25 ng/ml 2.06 5.62 14.18 -4.03 52.07 51.53 
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While population-based analysis can provide considerable insight into how 
cellular response varies with conditions, the fact that a large fraction (30-50%; 
Table 3.2) of the cells within the population did not become activated suggest 
that there might be considerably cell-to-cell variation that could impact the 
interpretation of the overall response.  To compare and contrast the population-
based average response to individual cell responses we utilized hierarchical 
clustering techniques to assess various portions of the clustering curves.  In the 
hierarchical clustering scheme, we tested all the permutations of 8 distance 
measurements, 3 linkage measurements, and 5 different portions of the cell 
traces. The best clustering was completed with Seuclidean distances and 
average linkage analysis over only the peak activation time point (150 - 450 
frames). Clustering accuracy was determined with a cophenetic correlation 
coefficient.  The closer the coefficient is to 1, the more accurate the clustering 
scheme. All runs had coefficients of greater than 0.9.  
The clustering scheme was utilized to organize cell traces of the peak 
frames (frames 150 - 450) into heatmaps (Figure 3.3).  Dark maroon plots 
represent the highest activation and green represents no activation (positive or 
negative) as indicated by the heatmap scale.  Each cluster that contained more 
than three cells (with a cutoff value of 10 in the hierarchical tree) was plotted on a 
line graph presented under each corresponding heatmap.  The average values 
were highlighted (bold blue line) and the largest individual cluster was also 
highlighted (bold gold lines).  In every case the bulk of the cells (64-81%) had a 
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response that was 1.7 to 8 fold less than that of the average response. The 
remaining cells, which were referred to as high responders, accounted for only 
19-36% of the cells.  The high responders had a magnitude of activation that was 
as much as 550% of the initial intensity in the highest response condition (25 
kPa, 10 ng/ml VEGF).  
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Figure 3.3 Hierarchal clustering analysis of normalized intensity of the VEGF 
response. 
BAECs on 4, 25, and 125 kPa gels were treated with VEGF and normalized 
intensity measured.  Heatmaps range from -400 (blue) to 400 (dark red).  Line 
plots show the average of all clusters, containing more than three cells. The 
average of all cells is represented by the bold blue line.  The cluster containing 
the bulk of all cells analyzed is shown highlighted by a bold gold line.  The 
percent of cells in each cluster is listed in each inset legend.  Data for VEGF 
treatments: A. 1 ng/ml, B. 5 ng/ml, C. 10 ng/ml, D. 25 ng/ml. 
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To better examine how VEGF responses change with stiffness, we plotted 
the averages of all the normalized intensities for the overall average (thinnest 
lines within the middle), the bulk hierarchical cluster (thicker lines near the 
bottom) and the high responders not included in the bulk cluster (thick spiked 
lines on top) (Figure 3.4).  The average intensity of the high responders was 
73%-177% greater than the average normalized intensity value and 98-255% 
greater than the bulk cell response. The rate of activation of these clusters and 
the magnitude of response varied dramatically between the three different 
clusters of cells.  Most of the cells (>50%) are activated in all conditions (Figure 
3.2B), but showed a response of only 11-35% greater that the untreated values. 
Thus, the overall average response observed for all conditions was heavily 
weighted by the small fraction of cells that responded strongly to VEGF.    
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Figure 3.4 Average cell traces by cluster. 
Line plots showing the normalized intensity average (thin line), the average 
normalized intensity of the bulk cluster (medium size line), and the average of the 
cells not included in the bulk cluster (large line).  Experiments are shown for 
4kPa (blue), 25 kPa (red), and 125 kPa (green) over four VEGF concentrations: 
A. 1 ng/ml, B. 5 ng/ml, C. 10 ng/ml, D. 25 ng/ml. 
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Figure 3.5 Bulk cluster average cell traces. 
Line plots showing only the largest (bulk) cluster of cells on each stiffness (4 kPa 
(blue), 25 kPa (red), and 125 kPa (green)) and VEGF concentration: A. 1 ng/ml, 
B. 5 ng/ml, C. 10 ng/ml, D. 25 ng/ml. 
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Table 3.3 Dynamics of cell traces, cluster based analysis.     
Descriptive information on the cell traces provided in Figures 5 and 6.  Information on 
maximum, activation time, deactivation time, and the rate of activation and deactivation 
is provided for each normalized intensity race.  The information is separated by both 
concentration and the average of all traces, the bulk cluster, and the cells not included in 
the bulk cluster (ie the high responders). 
Stiffness VEGF Dose Cluster 
Activation 
Time (min) 
Max 
Time 
(min) 
Activation 
Rate 
Deactivation 
Rate Max 
4 kPa 
1 ng/ml 
Average 
3.00 10.0 7.16 -2.46 51.2 
5 ng/ml 2.07 5.96 25.8 -5.3 96.88 
10 ng/ml 0.68 5.60 18.95 -5.23 74.47 
25 ng/ml 1.93 4.68 28.06 -6.89 77.41 
1 ng/ml 
Bulk 
Cluster 
5.77 10.39 4.70 -2.01 23.49 
5 ng/ml 3.27 8.32 5.49 -2.54 30.23 
10 ng/ml 3.49 7.92 4.19 -2.09 20.72 
25 ng/ml 2.65 5.02 3.21 -1.66 11.13 
1 ng/ml 
High 
Respond 
1.63 8.12 35.91 -12.82 189.80 
5 ng/ml 1.10 5.59 78.40 -18.71 274.07 
10 ng/ml 1.59 5.09 62.42 -14.19 198.59 
25 ng/ml 1.75 4.68 77.06 -18.30 214.09 
25 kPa 
1 ng/ml 
Average 
3.56 10.27 9.78 -1.54 63.10 
5 ng/ml 2.39 7.49 13.33 -2.33 69.80 
10 ng/ml 1.76 5.60 31.63 -4.48 116.93 
25 ng/ml 1.04 5.37 24.42 -4.98 90.37 
1 ng/ml 
Bulk 
Cluster 
5.68 10.27 6.69 0.49 35.08 
5 ng/ml 4.73 10.50 2.66 0.00 20.02 
10 ng/ml 3.03 9.91 3.82 -7.69 31.51 
25 ng/ml 1.04 6.69 3.99 -1.18 19.23 
1 ng/ml 
High 
Respond 
2.87 7.77 33.34 -4.20 151.29 
5 ng/ml 1.89 5.39 69.15 -10.43 211.03 
10 ng/ml 1.63 5.12 88.13 -14.49 286.28 
25 ng/ml 0.66 5.40 64.37 -13.90 231.68 
125 kPa 
1 ng/ml 
Average 
3.84 9.98 7.26 -1.95 47.93 
5 ng/ml 2.64 8.36 9.11 -0.67 56.51 
10 ng/ml 2.16 7.02 12.15 -3.43 64.57 
25 ng/ml 2.06 5.62 14.18 -4.03 52.07 
1 ng/ml 
Bulk 
Cluster 
6.02 10.14 4.98 0.31 23.08 
5 ng/ml 5.37 10.50 3.03 0 18.77 
10 ng/ml 4.53 9.56 2.80 -2.65 18.20 
25 ng/ml 3.83 6.51 2.93 -1.15 11.43 
1 ng/ml 
High 
Respond 
3.23 7.05 32.77 -4.77 121.14 
5 ng/ml 2.02 6.09 51.29 -8.33 188.50 
10 ng/ml 1.73 5.46 60.40 -14.41 212.21 
25 ng/ml 1.52 5.22 59.04 -15.36 193.47 
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The kinetics and maximal responses of the three clusters are compiled in 
Table 3.3. The response of the bulk cluster was much more sustained than that 
of the high responders and the average response as indicated by the lower 
activation and deactivation rates and increased maximum time.  For 
concentrations of VEGF below 25 ng/ml, cells on the 25 kPa and 125 kPa ECMs 
within the largest (bulk) cluster reached maximal response at the end of the 
treatment period (Figure 3.5). Activation and deactivation times, regardless of 
cluster, were almost always inversely correlated with concentration of VEGF. 
Activation time varied with VEGF dose suggesting that the rate of activation is 
likely a reflection of the time it takes for a threshold level of activated VEGF-
VEGF receptor complexes to be reached, instead of being based on the intrinsic 
time required for signal processing.  Faster activation rates also correlated with 
higher maximum intensity values in almost all samples (except the average 
cluster on the 125 kPa ECM).  The deactivation rate did not correlate with VEGF 
dose or ECM stiffness.   
After segregating the cells into clusters based on normalized cell intensity, 
we wanted to explore how much variation remained in these after their extraction.  
We computed the coefficient of variation (COV; standard deviation/mean), for a 
variety of different parameters (Figure 3.6).  We did not find any statistically 
significant differences among stiffness or VEGF concentration, but we did find 
that certain variables were much more predictable than others.  We found that 
the maximum time and the overall area of the cells were the least variable (lower 
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COV) as compared to the highly variable activation time and maximum values.  
When the high responders and bulk responders were analyzed separately we 
found significant differences in activation time, maximum time, and maximum 
values between these clusters.  The differences were most notable for the high 
responder category, which has significantly reduced variability as compared to 
the bulk responders or to all the cells together.  This suggests that cells in the 
high responder cluster are behaving in a more unified manner than the rest of the 
cell population, indicating that they may posses a characteristic that is predictive 
of VEGF responsiveness.   
To determine if there are specific phenotypic characteristics among cells 
within a larger population that might indicate VEGF responsiveness, we 
compared specific cell shape parameters of the high responders to those of the 
bulk responders. Specifically, we compared the average cell area, and the major 
and minor axis lengths of the cells within the bulk responder cluster to those in 
the high responder cluster (Figure 3.7).  At low concentrations of VEGF (1 ng and 
5 ng/ml) we detected a significant decrease in overall cell area of the high 
responders. We also found a reduction in the minor and major axis lengths of the 
high responders in the 1 ng/ml VEGF treatment groups  (Figure 3.7 A-C).  The 
differences were no longer statistically significant in the groups that were treated 
with higher VEGF concentrations (10 and 25 ng/ml), and, as such, we observed 
that the differences in cell size between the two clusters were significantly 
reduced with increased VEGF concentration (Figure 3.7 D-F). 
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Figure 3.6 Statistic analysis of clustering. 
A. Coefficient of variation (mean/standard deviation) averaged for all cell 
treatments and conditions. Parameters are those defined in Figure 4. There is no 
significant difference between the variation in cell areas, but there is significant 
differences between most of the subtypes of the remaining categories. 
Significance (α < 0.5) in reference to the all cells category, is marked with bars. 
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Figure 3.7 Cell size is different between clusters. 
A-C: Average values for cell sizes of bulk responders and high responders +/- 
SEM. Significance (always α < 0.5) is defined as a difference between the high 
and bulk responder categories in a pairwise one-tailed T-test. D-F: The average 
differences between bulk and high responders for each cell size parameter.  
Significance is defined for differences between concentrations using an unequal 
variance, two-tailed T-test.  A and D: Area, B and E: Major Axis, C and F: Minor 
Axis 
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3.3 Discussion 
 
Phenotypic changes in endothelial cells in response to stiffness have been 
well documented(86, 87, 109, 142), but little is known about how these changes 
impact intracellular signaling in response to external stimuli. In the present study 
we show that VEGF-induced calcium signaling within endothelial cells is 
modulated by stiffness. These changes in signaling were largely reflected by 
alterations in the magnitude of the cell response. The cells maintained the same 
number of local maxima, and the percentage of cells being activated was similar 
across the stiffness range evaluated.  Interestingly, responses were attenuated in 
the cells on the stiffest substrates. Previous studies have shown specific integrin 
heterodimer expression increases with matrix stiffness(79, 143), suggesting a 
molecular mechanism by which cell-ECM engagement may be modulated by 
substrate stiffness. The mechanism of action of VEGF has been linked to the 
state of the extracellular matrix in a number of studies. VEGF has been shown to 
directly interact with matrix proteins such as fn(58, 104, 140). VEGFR2 signaling 
has been shown to coordinate with integrin signaling, and physical association of 
VEGFR2 with integrins has been suggested to modulate VEGF internalization 
and signaling kinetics(37, 38, 41, 42, 100, 144-146). Thus, the intimate 
connection between the VEGF system and the process by which the cell 
interacts with the ECM may provide the basis for how VEGF signaling is 
modulated by ECM stiffness.  
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The attenuation of VEGF signaling that we observed in cells on the stiffest 
matrices may relate to the inability of the body to repair severely stiffened 
atherosclerotic blood vessels as well as the ability of newly developing soft 
tissues and tumors to actively recruit the development and growth of new 
vasculature. The stiffness of diseased vessels can vary up to an order of 
magnitude, which can lead to dramatically altered cell phenotypes(30, 69, 70).  
Primary cell cultures lose up to 40% of their microenvironment specific 
phenotypes when they are cultured on plastic(24, 117). Thus, the use of cell 
culture substrates at more physiologically relevant stiffness may provide 
important insight into how cell response is controlled in vivo.  
While our study revealed interesting distinctions in the response of 
endothelial cells to VEGF as a function of stiffness when averaged over the 
entire population, the power of our study was largely in the individual cell 
analysis.  Prior studies have looked at endothelial cell heterogeneity(23-25, 117). 
In particular, studies have explored how phenotypes, genetic, and epigenetic 
alterations occur in different vascular beds throughout the body. The size of cells, 
orientation of the cells, receptor densities, and immune system properties vary as 
a function of the specific vascular bed. Even within a single population of cells in 
one vascular bed, cells are known to dynamically change their behavior from 
quiescent to tip cell to stalk cell(23-25, 117). In the present analysis we found 
that individual cell responses differ dramatically within a single population of cells 
in a well-controlled culture system. Thus, cell-to-cell variability may be an intrinsic 
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property of endothelial cells that reflects a natural ability to exist in distinct 
phenotypic states. It is not clear from our analysis if the property of being highly 
sensitive to VEGF-induced signaling is a stable characteristic of a select group of 
cells within the population or a transient property that all cells posses under some 
conditions. Nevertheless, the ability to identify the relative proportion of sensitive 
cells as a means to accurately predict VEGF responsiveness in endothelial cells 
within specific environments in vivo could lead to new directed treatment 
avenues or cell models.  
The kinetics of cellular response to external stimuli such as growth factors 
have been evaluated by measuring binding and signaling kinetics averaged over 
a large population of cells using biochemical methods, or analyzed in a select 
number of cells generally using microscopic techniques.  Until recently, high 
order, individual cell dynamics and patterns were not explored. With the 
availability of new computational methods it is now possible to individually 
analyze fields of cells compiling thousands of individual data points to answer a 
question.   These techniques will be invaluable in deciphering how distinct growth 
factors can have such diverse endpoint responses while sharing many of the 
same signaling components. It is likely that cellular response is ultimately 
dictated by the sequence, timing, duration, and frequency of signal activation. 
Thus, it will be critical to develop tools to quantitatively track the dynamics of 
individual cell response in order to eventually decode cell behavior.  For 
example, P53 protein levels oscillate with set frequency and amplitude after cell 
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exposure to γ-radiation, but there is a concentration dependent persistent 
response after UV radiation(147). In PC12 cells, epidermal growth factor induces 
transient ERK activation while nerve growth factor leads to a sustained ERK 
response, a response that may be essential for cell differentiation(148-150). In 
other instances, the amplitude from baseline, not the timing, dictates the specific 
ERK activation(121). Uncovering the role of signal dynamics in endothelial cells 
could provide further insight into activation and targets for inducing/eliminating 
angiogenesis.  
The dynamics of calcium signaling have been shown to control individual 
cell fates.  For example, transient spikes in calcium have been shown to activate 
different transcription factors than a sustained response(120, 128). It is well 
known that VEGF activates phospholipase C and results in IP3-mediated release 
of intracellular calcium stores, but individual cell calcium response to VEGF has 
not been explored previously. We used a non-biased hierarchical clustering 
scheme to identify several distinct clusters.  Analyzing these responses together 
as the bulk response and comparing it to remaining cells, or high responders, 
yielded some interesting findings. We found that temporal speed is a sensor for 
concentration.  In general, as the concentration of VEGF increased, regardless of 
stiffness, we found a shortening of the time until activation and time until the 
overall maximum point was reached. This finding indicates that activation time is 
not fully dependent on the reaction time, but instead likely reflects a threshold 
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reaction whereby signaling is activated when a specified concentration of ligand-
receptor complexes is reached.  
While parsing out the individual cell response we were able to determine 
that endothelial cells on the softest substrates (4 kPa) were most sensitive to 
VEGF treatment. The percentage of high responders was altered by stiffness, but 
not in any discernable pattern. For example, in the 1 ng/ml VEGF condition, 19% 
of cells on the 4 kPa substrates, 29% of cells on the 25 kPa substrates and 35 % 
of the cells on the 125 kPa substrates were high responders.  Despite those 
differences, the average of maximums of the high responders from each run in 
the 4 kPa condition was greater than that of either remaining stiffness indicating 
the active cells that were responding were stimulated to a greater extend than in 
the other stiffness conditions. High responders for the 4 kPa condition also had a 
greater difference between their high responders average maximum and bulk 
responders average maximum than in the other conditions. These trends were 
clear when looking at individual cell responses, but were not detectable within the 
average of the population-based responses.  
Cells on our 25 kPa constructs (our model for a moderately aged vessel) 
had the greatest overall maximum and activation rate compared to any other 
condition, but this occurred at a moderate VEGF dose.  It is possible that the 
integrin connection, or another biological pathway, is limiting the ability of the 
cells to respond to VEGF as stiffness increases. At the maximal VEGF dose 
tested, the difference in average maximum values of the high responders and 
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bulk responders with substrate stiffness was lost. This indicates that the stiffness 
limitations to VEGF dose are overcome.     
Our clustering analysis revealed some interesting conclusions regarding 
variability within the overall cell population. We found that ~40% of the cells did 
not respond at all regardless of stiffness and VEGF dose.  In addition to the non-
responders there were an additional 15-35% of cells that showed a slow muted 
response. The high responder group had a rapid, large, and transient increase in 
calcium release. Two distinct patterns of VEGF responsiveness that we detected 
have been reported previously. The Chen group reported two main clusters of 
traction force strain curves after VEGF treatment of endothelial cells(151). They 
treated endothelial cells with a range of VEGF doses and found that most cells 
exhibited no response or a gradual increase in strain energy when treated with 
lower concentrations (10 ng/ml) of VEGF, but as VEGF dose increased (up to 
100 ng/ml), the number of cells displaying an initial spike of strain energy after 
VEGF treatment increased(151). The high responders in our data set as an 
average have a peak response at 10 ng/ml, but closer examination of the 
heatmaps (Figure 5) shows that even though the average responses decreased 
at 25 ng/ml, there are more of the high responders exhibiting spikes as indicated 
by the increase in yellow lines. The similarities in dynamics and quantity of cells 
responding between our study and the Chen study may indicate that our high 
responders represent cells that have a migratory phenotype.  
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Only a fraction of the cells within the population responded strongly to 
VEGF suggesting that there may be a phenotypic characteristic that defines 
these “VEGF-sensitive” cells. We explored the size and shape of the cells within 
the various clusters to determine if these characteristics were linked to 
responsiveness. Previous studies indicated that cell shape itself can feedback 
and influence the stiffness of the actual cells on the matrix(87).  Others have 
noted that alterations in endothelial cell shape are linked to the cellular release of 
chemotactic factors and the consequent recruitment of monocytes in in vivo 
models(152). Indeed, classic studies using mouse retina models identified 
distinct morphological phenotypes of tip cells with long thin lamellipodia 
compared to more bulky stalk cells(26). In the present study we observed that 
the high responders are statistically smaller than the bulk responders at low 
doses of VEGF. The alteration in size was largely due to decreased length of the 
minor axis indicating a narrowing of the cells.  At higher doses of VEGF, there 
was no significant difference in size between high responders and low 
responders. Together, these findings indicate that at low doses of VEGF high 
responders were morphologically different from bulk responders, but at high 
doses of VEGF, cells of any shape or size could overcome a threshold allowing 
them to become a high responder. Two distinct phenotypes of endothelial cells 
have been reported in vivo with respect to VEGF responsiveness – tip cells and 
stalk cells. Both tip and stalk cells are known to respond to VEGF via VEGFR2 
leading to distinct endpoints with tip cells being induced to migrate forward 
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leading to outward sprouting and growth while stalk cells are stimulated to 
proliferate developing the lumen behind. We previously demonstrated cells on 
the leading edge of a stimulus are capable of the greatest magnitude of calcium 
mobilization(130). Thus it is possible that our distinct subgroups are reflective of 
these two sub-types of endothelial cells(26). In this paradigm, the high 
responders take on the tip cell, leading edge, migratory role and the bulk 
responders act as stalk cells with a slow steady VEGF activation.  
We found that endothelial cell responsiveness to VEGF could be tuned to 
the stiffness of the ECM resting below the cells. A new analytical tool was 
developed that allows for individual cell analysis, which identified an interesting 
concentration sensor and two distinct groups of responding cells within each 
treatment condition. Our high responding group of endothelial cells was highly 
sensitive to VEGF at all concentrations and presented with an altered, more 
compact cell shape, which may correlate with migratory, highly active tip cells. 
Ultimately our study provides insight into how signaling dynamics, cell 
heterogeneity, and microenvironment influence tissue regeneration, which may 
have applications in engineering replacement tissues and the development of 
therapies to direct tissue repair in response to injury and disease. 
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CHAPTER FOUR: ENDOTHELIAL CELL PROCESSING OF VEGF IS 
MODIFIED BY STIFFNESS 
4.1 Introduction 
Endothelial cell dysfunction affects most organ systems. It is classically 
noted to contribute to cardiovascular disease, the number one killer in the United 
States(15).  Endothelial dysfunction results in hyper-activated endothelial cells.  
Breaks in cadherin junctions that link endothelial cells to one another are 
detected and it is thought that they lead to increased permeability(84). Activated 
endothelial cells also express more immune adhesion proteins, and are primed to 
migrate and move to where they are needed(1, 10, 12).  Endothelial cell 
dysfunction also correlates with an increase in abnormal fibroblasts better known 
as myofibroblasts and smooth muscle cell excretion of extracellular matrix 
(ECM)(7, 17, 35).  The altered extracellular environment results has increased 
structural ECM proteins, and modified matrix metalloproteinase activity, and 
enhanced lysyl oxidase crosslinking. During disease, advanced glycation end 
products (AGE) activity further modifies the ECM(7, 17). Collectively the ECM 
alterations observed in cancer or cardiovascular disease result in a stiffening of 
the local extracellular environment of the endothelial cells(32, 33).  
 The ECM stiffening can further modify endothelial cell behavior.  Cells on 
stiffened fn or collagen surfaces traditionally increase their cell-cell permeability, 
decrease sprouting, and produce more focal adhesions in proportion to an 
increased cell area(79, 83-85, 143). The composition and engagement of the 
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focal adhesions is also modified by stiffness.  For instance, the cell’s ability to 
engage fn, which is a glycoprotein up-regulated in both healthy wounds and 
endothelial dysfunction in atherosclerosis or cancers, is modified by stiffening(7, 
153). In stiffness environments associated with healthy tissue, endothelial cells 
engage fn through mostly through α5β1 integrin, but stiffening unfolds type III 
modules in fn protein increasing the distance between the Arg-Gly-Asp (RGD) 
binding site on fn and the synergy site, which is predicted to lead to an increase 
in αvβ3 integrin binding and a decrease in the α5β1 engagement(89, 98, 154). 
These switches could alter growth factor binding or associated integrin signaling 
mediating transitions between healthy and pathological phenotypes.  
 Both αvβ3 and α5β1 have distinct roles in angiogenesis in both normal 
and pathologic conditions. Integrin αvβ3 is up-regulated in many cancers(155). 
Blocking its behavior results in a decrease in angiogenesis, but completely 
knocking out αvβ3 results in an abundance of endothelial cell sheets and early 
embryonic lethality(27, 38). Similarly, β1 integrin function has been tied to 
pathological angiogenesis and endothelial dysfunction(57, 104). Both integrin 
heterodimers can complex with VEGFR2, but β1 integrin only does so in the 
presence of VEGF(57, 62). They are capable of complexing with neuropilin-1 
(NRP-1) and syndecans (cell associated heparan sulfate proteoglycans 
(HSPGs)), leading to alterations in matrix binding and migration(38, 60, 100, 
104). As stiffness changes, it is likely integrin behavior and activation will also be 
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altered which could influence the ability of endothelial cells to undergo 
angiogenesis.  
VEGF is a critical growth factor involved in angiogenesis. There are 
several distinct VEGF genes with variable binding to the VEGF receptors(38). 
The individual VEGF genes also each produce multiple isoforms that have varied 
ability to bind to the ECM(13, 38). Within the present studies we exclusively used 
VEGF-A 165 (referred to as VEGF). VEGF is capable of acting in soluble form 
and also binds to heparan sulfate as well as to fn within the extracellular matrix 
after it undergoes conformational remodeling in the presence of heparin or 
heparan sulfate proteoglycans(57, 58, 65). The binding of VEGF to the 
extracellular matrix has been noted to enhance its ability to stimulate endothelial 
cell proliferation, likely through an increase in MAPK activity(42, 52).  
VEGF activity is mediated through VEGFR2 and VEGFR1 tyrosine kinase 
receptors(38). VEGFR1 has minimal kinase activity, but a high affinity for VEGF 
suggesting that it serves as a VEGF sink, preventing binding to the active 
VEGFR2 receptor(38). VEGFR2 binding on the surface leads to activation of 
AKT and calcium release, whereas internalization of the activated receptor 
results in ERK signaling in the early endosome compartments(41, 156). The 
internalization and trafficking of VEGFR2 can be influenced by many factors 
including neuropilin-1 (a co-receptor for VEGFR2), syndecans (cell bound 
HSPG), and possibly b1 integrin(41, 156). The activation of VEGFR2 and its 
downstream targets leads to increased permeability, proliferation, migration, and 
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survival of endothelial cells(38). The coordination between VEGF co-receptors, 
heparan sulfate proteoglycans, and integrin switching is likely altered by ECM 
stiffness, which could lead to altered downstream VEGFR2 signaling.  
We hypothesized the ability of VEGF to bind to the ECM would be 
modulated by stiffness, which would impact the ability of the cells to engage with 
VEGF, internalize the protein and fully transduce intracellular signals. To test this 
hypothesis, we tracked VEGF signaling and intracellular trafficking under a 
variety of conditions in endothelial cells on various stiffness fn polyacrylamide 
substrates. Our findings indicate that matrix binding and in particular binding of 
β1 integrin is critical or VEGF processing.  
4.2 Results 
Microenvironment induced changes in endothelial cell behavior can have 
profound effects on the health of blood vessels throughout the body(7, 17, 29). A 
simple change in the extracellular matrix (ECM) structure can mean the 
difference between normal functioning cells and cancer development(29).  
Stiffness of the ECM can vary up to an order of magnitude with various 
pathologies(30, 83). Understanding how a change in the ECM stiffness mediates 
cell alterations could be critical to developing new treatments and strategies to 
normalize endothelial cell function. We sought to understand how the stiffness of 
the ECM alters endothelial cell processing of VEGF. 
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Model creation: 
 Many prior researchers, our lab included, have utilized a tunable 
polyacrylamide (PAAM) ECM system to study how cell behavior is modified by 
stiffness(78, 79). PAAM gels are highly reproducible and can be produced in a 
relevant stiffness range to model blood vessel stiffening. For this series of 
studies, we used commercially available polyacrylamide gels from Matrigen Life 
Technologies. Our prior studies on PAAM gels that we fabricated ourselves using 
traditional methods demonstrated that increasing doses of fn were necessary to 
match final surface protein densities as stiffness decreased(79).  We found the 
proprietary chemistry that Matrigen utilizes to form amine connections between 
the polyacrylamide and fn does not follow this same concentration dependency.  
On all five stiffness levels tested, encompassing our entire range of stiffness 
values used for the remaining experiments, we saturated binding of fn at 1 ug/ml 
(Figure 4.1A) and we found no significant differences between conditions at 10 
ug/ml, the concentration of fn utilized for future experiments. Cells require a 
threshold quantity of matrix in order for adequate connections and cell adhesion 
to occur(80). To verify we were over that threshold, we seeded BAECs on PAAM 
gels with various input doses of fn and monitored relative cell number with an 
MTT assay. Relative cell numbers remained consistent regardless of fn input 
concentration (Figure 4.11B). Even at concentrations of fn below binding 
saturation (100 ng/well), we found we still were above the minimum threshold for 
adhesion and thus there were no differences in cell number with fn dose.   
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Figure 4.1: Matrigen polyacrylamide gel fn normalization.  
A. Various concentrations of fn-PBS solution were incorporated onto easy coat 
Matrigen PAAM gels. A BD fn antibody ELISA was completed both on gels and 
plastic. A standard curve was created with plastic samples to compute fn-binding 
capabilities for each stiffness and concentration fn. No significant differences in 
the levels of fn on gels with fn input above 10 ug/ml (1000 ug/well) were noted 
between gels of different stiffness.  All polyacrylamide gels were coated with a 
saturating concentration of fn (10 ug/ml) for future experiments. B. Various 
densities of fn were coated onto Matrigen plates.  BAECs were plated on the gels 
and cell number measured after 24 hours in triplicate (±SEM). Cell number did 
not vary with stiffness or fn concentration across the range tested.  
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Stiffness and matrix binding modulate VEGF induced ERK signaling 
 Other groups, ours included, have found alterations in VEGF-endothelial 
binding, signaling, and biology with changes in ECM mechanics and matrix 
binding of the growth factor(42, 100, 157, 158). ERK activation is a commonly 
studied event in the VEGFR2 signaling pathway(38). We found increased ERK 
P44/P42 activation in response to VEGF in endothelial cells on soft substrates 
compared to stiffer substrates (Figure 4.2). We observed a high level of 
phosphorylation of ERK proteins at the earlier time points (2-10 minutes) that 
was significantly attenuated by 20 minutes. The cells on the 25 kPa substrates 
exhibited the most dramatic activation of ERK (14-fold and 28-fold increase over 
control respectively at 2 min). Additionally, cells on the stiffer conditions, 125 kPa 
gels and tissue culture plastic, showed limited ERK excitation regardless of time 
point studied. Heparin pre-treatment, known to induce matrix binding of VEGF,  
(Figure 4.2 C/D) increased ERK phosphorylation, 4-fold and 2-fold respectively 
for the softer conditions (4 and 25 kPa) compared to 0.5 and 1.5 fold for the stiff 
substrates (125 kPa and plastic).  
 To validate our data with a more robust normalization method, we 
repeated the 5 minute time-point with a dual antibody western blot method with 
normalization to six bands on a on a stain free gel (Figure 4.3).  We found similar 
trends as before, at 5 minutes we observed significant activation in cells on the 4 
kPa gels (1.9+/-0.26 and 2.3+/-0.1 fold activation with VEGF for control and 
heparin treated) compared to plastic.  Heparin minimized the differences 
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between the different stiffness conditions, yet cells on the softest matrices 
maintained a significantly increased signaling ratio compared to plastic.
	  	  
92 
 
Figure 4.2:  ERK activation time course with stiffness.  
A/C. BAECs were grown on PAAM gels for four days. Samples were pre-treated 
with and without 10 ug/ml heparin for one hour. Heparin was removed, samples 
were washed 3-times, and samples were allowed to equilibrate for one hour in 
fresh binding buffer after which 10 ng/ml VEGF was added in a reverse time 
course fashion for all time points. Cells were lysed and subjected to SDS-PAGE 
and Western blot analysis for p-ERK. Western blots showing vehicle or VEGF 
activation of ERK P44/P42 at various time points A. Control Cell Blots B. Heparin 
Pre-treated Cell Blots C. Densitometry quantification of Phospho ERK P44 
normalized to GAPDH in control cells. D. Densitometry quantification of Phospho 
ERK P44 normalized to GAPDH in heparin pre-treated cells. E. Heparin/Control 
quantification. 
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Figure 4.3: ERK signaling is stiffness dependent.  
Western blots showing vehicle or VEGF activation of ERK P44/P42 at 5 minutes.  
BAECs on 4, 25 kPa, 125 kPa PAAM gels and plastic were pre-treated with or 
without 10 ug/ml heparin for 1 hour in conditioned media, the buffer was removed 
and the cells were washed two times with PBS, and the washed cells were 
allowed to stabilize for 4 hours in conditioned media prior to the addition of 10 
ng/ml VEGF or vehicle treatment for 5 minutes prior to cell lysis. Samples were 
resolved on stain free gels prior to Western blotting for p-ERK. A. (control) and C. 
(heparin) are fluorescent Western blots completed on stain free gels allowing 
multiple bands for total protein normalization (6 bands/sample).  B. (control) and 
D. (heparin) are densitometry ratios of normalized P44 and P42 protein activation 
in VEGF treated cells normalized to vehicle treated cells. These results represent 
the averages ±SEM of four samples from two independent experiments. B. 
Significance was found for the 4 and 25 kPa samples as compared to plastic. C. 
Significance was found only for the 4 kPa endothelial signaling as compared to 
the other samples. E. Blots were completed as previously discussed, but prior to 
VEGF addition, samples were treated +/- VEGFR2 Kinase Inhibitor III for 90 
minutes.  VEGF ERK and AKT activation (VEGF with inhibitor/VEGF control) was 
reduced 75+/-4.3% and 87% +/- 4.3 respectively.  
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VEGF Receptor 2 phosphorylation mediates stiffness-induced changes in 
endothelial cell signaling 
To ensure that the VEGF-mediated signaling that we were measuring is 
attributed to VEGFR2 activation, we pre-treated samples with a VEGFR2 
tyrosine kinase inhibitor (VEGFR2 kinase inhibitor III) and observed reduced 
activation of phospho-ERK 75+/-4.3% (VEGF with inhibitor/VEGF control) at 10 
minutes and phospho-AKT, another indicator of downstream VEGF activation, 
was reduced by 87% +/- 4.3 (Figure 4.3E).  
VEGF activity is magnified in cells on soft substrates, which could be the 
result of altered receptor density on the higher responding cells. To measure cell 
surface VEGFR2 levels we conducted a flow cytometry evaluation of total 
VEGFR2 antibody binding to permeablized BAEC. We found similar distribution 
curves of VEGFR2 on two separate experiment days with only 3-16% 
Kolmogorov-Smirnov (K-S) values indicating a low probability of difference 
between sets and we found similar median fluorescent intensity across all PAAM 
stiffness conditions (118 +/- 4.3) (Figure 4.4A). Cells seeded on plastic matrices 
had lower mean intensity or VEGFR2 in both experiments (71% of the other 
stiffness conditions) compared to cells on PAAM gels. Phosphorylation of 
VEGFR2 at Tyr1175 was significantly increased in cells on our softest gels as 
compared to all other conditions. Pre-treatment of the cells with heparin, which is 
known to increase matrix binding of VEGF, increased VEGFR2 phosphorylation 
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significantly and in a stiffness dependent manner (Figure 4.4 C/D).  Heparin-
pretreatment caused a 2.5 fold increase in cells on the 4 kPa gels and a 8.4 fold 
increase on cells on the plastic surfaces.   
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Figure 4.4: VEGF receptor 2 levels and activation with stiffness.  
A. BAEC cells on 4, 25, 125 kPa and plastic were analyzed after 4 days in 
culture.  Samples were incubated in binding buffer for 3 hours prior to TrypLE 
removal from gels. Samples were counted and 1 million cells were fixed and 
permeabilized for 30 minutes, the fixative was removed by centrifugation and 
samples were washed/centrifuged 3 more times prior to the addition of total 
VEGFR2 antibody for one hour.  Primary antibody was removed, samples were 
washed/centrifuged 3 more times prior to Alexa A488 anti-rabbit IgG addition for 
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30 minutes at RT in the dark. Secondary antibody was removed by 
centrifugation, samples were washed 3 times and resuspended in FACS Buffer 
for analysis. At least 30,000 cells were analyzed for each sample. A. A 
representative run from three separate experiments is shown. B. BAECs were 
grown on 4, 25, 125 kPa and plastic for 4 days.  Samples were treated with 10 
ug/ml heparin for 1 hour. Heparin was removed, samples washed 2x with binding 
buffer and fresh binding buffer was added.  After an hour for stabilization, 
samples were treated with 10ng/ml VEGF for 5 minutes. Cells were lysed, 
resolved through SDS-Page. Western blots were completed for total and 
VEGFR2 phosphorylation (site Try1175). Each stiffness ECM is represented in 
triplicate. C. Densitometry quantification of western blot results. The levels of 
phospho and total VEGFR2 were quantified and normalized to actin on two 
independent blots using the same cell extracts, and the average ratio of phospho 
VEGFR2 to total VEGFR2 is shown for triplicate samples ±SEM.  All heparin 
conditions were significantly increased compared to the non-heparin treated 
controls.  The 4 kPa condition showed significantly higher activation with or 
without heparin treatment as compared to the remaining stiffness treatments.  
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Matrix binding is essential for internalization 
 It is possible that the alterations in VEGFR2 phosphorylation and signaling 
in cells on different stiffness substrates reflect alterations in VEGF-matrix binding.  
One possibility in particular is that binding of VEGF to the ECM may sequester it 
in an inactive form such that it is not available to activate cell surface receptor 
signaling. However, the fact that we observed increased VEGFR2 
phosphorylation and intracellular signaling in heparin pretreated cells, which 
would be predicted to have increased VEGF matrix binding, suggest that matrix 
bound VEGF might lead to increased VEGFR2 signaling. To address these 
possibilities, we used 125I-VEGF to measure matrix binding and internalization of 
VEGF. Steady-state levels of VEGF bound to the matrix and associated with the 
cell were reached at 1-3 hours of incubation (Figure 4.5).  
We found that as stiffness increased, VEGF binding to the matrix, and the 
potential for heparin to enhance matrix binding increased. In multiple 
experiments with BAECs, we found an average of 7.7 fold increase in 
heparin/control binding on plastic as compared to an average 2.0 fold increase in 
the 4 kPa condition (Figure 4.6A). To determine how general this response is, 
and if it is applicable to human cells, we also measured VEGF binding to human 
endothelial colony forming cells and observed a similar increase in matrix binding 
with stiffness (Figure 4.6C). The opposite was observed for VEGF internalization 
as a function of stiffness (Figure 4.6B/D) where levels were highest in cells on 
the softest substrates for both cell types. Similar to the signaling data, heparin 
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pre-treatment of BAEC resulted in a 2.4 increase in VEGF internalization in cells 
on 4 kPa gels on average compared to a 1.4 fold increase in cells on plastic. The 
amount of internalized VEGF was 2.3 fold (control) and 4.5 fold (heparin) greater 
in the cells on 4 kPa matrices as compared to cells on the plastic surfaces.  
 Noting the inverse correlation between the levels of VEGF bound to the 
matrix compared to internalized fractions, we predicted that blocking matrix 
binding would increase internalization of VEGF in our stiffest condition.  We were 
able to significantly decrease matrix binding on the 25, 125, and plastic matrices 
with sucrose octasulfate treatment (SOS) (Figure 4.7A), which has previously 
been shown to compete for VEGF binding to fn within the ECM. Internalization of 
VEGF was also reduced (30-49%) by SOS treatment in control and heparin 
pretreated cells on PAAM gels across the entire range of stiffness (Figure 4.7B). 
In contrast, SOS had no significant effect on the amount of internalized VEGF in 
cells on plastic surfaces. 
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Figure 4.5: VEGF-endothelial steady-state binding time. 
Three hour reverse time course VEGF binding assay on BAEC four days in culture on three 
different stiffness gels (4, 25, 125 kPa). 125I-VEGF 10ng/ml was added in DMEM binding buffer 
(DMEM with 25 mM HEPES, 1 mg/ml BSA, pH 6.5) for three hours at 37°C CO2, and then the 
125I-VEGF containing buffer was removed and cells were washed with binding buffer. A. High salt 
buffer was used to extract the matrix bound fraction of VEGF followed by a PBS wash to remove 
any residually released VEGF. Radioactivity was counted in a gamma counter and the average 
values of triplicates samples ± SEM normalized for differences in cell number are presented. 
Membrane-associated VEGF was removed with an acid wash followed by a PBS wash to 
removal residual. B. NaOH removed the internalization fraction of VEGF in endothelial cells and 
the radioactivity counted in triplicate samples. Averages +/- SEM are presented. Samples 
approached steady-state binding as early as 60 minutes into experimentation.   
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Figure 4.6:  VEGF matrix binding increases and internalization decreases 
with stiffness.  
Cells (BAECs (A and B); PB-ECFCs (C and D)) on 4, 25, 125 kPa and plastic were pre-treated for 
one hour with and without 10 ug/ml heparin.  Heparin was removed with two binding buffer 
washes and 10ng/ml 125I-VEGF was added in DMEM at 37oC for three hours at pH 6.5.  At three 
hours (BAEC and PB-ECFCs internal, 1 hr PB-ECFCs matrix bound), non cell/matrix associated 
VEGF was removed with neutral washes and the matrix bound fraction was released with a high 
salt solution and a PBS wash, and samples were counted in a gamma counter. The membrane 
bound fraction was removed with a low pH acid wash followed by PBS, and finally extractions 
using 1 N NaOH were utilized to collect remaining VEGF (internalized fraction). The internalized 
fractions were normalized to relative cell number, determined using an MTT assays. Individual 
representative experiments are shown (PB-ECFCs experiments were repeated 2x and BAEC 
experiments were repeated at least 6x in various contexts). Bars represent the averages of 
triplicate samples +/- SEM. A. BAEC matrix binding of 125I-VEGF. All binding values (stiffness to 
stiffness and heparin to control) are significant from one another except 25 kPa compared to 125 
kPa. B. BAEC internalization of 125I-VEGF. All findings across stiffness values and heparin 
treatment were significantly different except for heparin 4 kPa compared to 25 kPa and heparin 
125 kPa compared to plastic. C. PB-ECFCs matrix binding of 125I-VEGF. Heparin significantly 
increased binding in all cases except the 4 kPa condition. D. PB-ECFCs internalization of 125I-
VEGF. The 4 kPa heparin treated sample was significantly increased over the heparin treated 
plastic condition.  
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Figure 4.7:  Blocking matrix binding alters stiffness dependent internalization of 
VEGF.  
BAEC binding assays were conducted as outlined previously on all experimental stiffness 
conditions with and without 10 ug/ml heparin pretreatment.  The only variation involved adding 1 
mg/ml SOS solution to the cell media 30 minutes prior to 125I-VEGF 10 ng/ml addition. Figures are 
representative experiments and all values are the average of three points +/- SEM. A. Matrix 
bound fractions. Matrix binding with SOS treatment was decreased significantly in all cases 
except 4 kPa. B. Internalized fraction. The internal fraction was decreased significantly in all 
cases except plastic with heparin treatment.  
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VEGF cell removal remains constant regardless of stiffness  
The variation in internalized VEGF quantities in cells under various 
conditions could reflect differences in the rates of VEGF uptake or removal from 
the cell. To address this issue, we measured the rate of VEGF removal from cells 
using a pulse-chase experiment. 125I-VEGF was allowed to accumulate within the 
cells for 3 h and then the rate of decay of intracellular VEGF was measured over 
8 h after removing unbound VEGF from the media and replacing it with fresh 
DMEM containing no VEGF. At each time-point we removed VEGF and VEGF 
degradation products released into the media and then quantified the remaining 
cell associated VEGF by solubilizing the cells in NaOH. We found that the 
percent of VEGF remaining within the cell at 8 hours was not dramatically 
different and trended slightly upwards with stiffness (Figure 4.8). There were no 
significant differences in the rates of VEGF removal in control and heparin 
pretreated cells. Thus, VEGF is not removed from the cells at different rates, 
indicating that the alterations in internal VEGF observed in cells on different 
substrates are the result of altered internalization. Specifically, the increased 
levels of internal VEGF in cells on the softest gels suggest that VEGF-VEGFR 
endocytosis is facilitated by soft conditions.  
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Figure 4.8: 125I-VEGF is released/degraded from cells in a stiffness-
independent manner. 
 125I-VEGF binding assays on BAECs on various stiffness ECM were carried out as 
previously described (1 hour pre-treatment with 10 ug/ml heparin prior to 3 hours 
incubation with 10 ng/ml 125I-VEGF ).  At three hours, samples were washed three times, 
to remove excess VEGF.  A high salt solution removed the matrix bound VEGF, followed 
by PBS and an acid solution to removed any membrane associated VEGF followed by 
two washes with fresh DMEM.  Fresh DMEM was added to each sample and the cells 
allowed to incubate at 37 °C for the indicated time. At each time point, the cells were 
extracted twice with 1 N NaOH to collect the 125I-VEGF remaining in the cells.  Open 
triangles (Δ) represent control samples and black squares (n) are heparin treated.  
Values are the average of three points +/- SEM and represent how much VEGF is 
remaining in the cells at the indicated time point. No significance was found between 
heparin and control samples.  A. 4 kPa B 25 kPa C. 125 kPa D. Plastic 
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β1 integrin mediates differential uptake of VEGF with stiffness 
 There are many possible mechanisms by which cell-ECM interactions 
could influence VEGF binding and internalization. Cell binding to the matrix could 
alter the mobility and proximity of the VEGF receptor and other cell surface 
proteins that are required for VEGF endocytosis, which might further be 
modulated by the stiffness of the matrix. VEGF binding to VEGFR2 has been 
found to be modulated by a variety of co-receptor proteins including heparan 
sulfate proteoglycans (syndecans), neuropilin-1 (NRP-1), and β1 integrin(104, 
112, 156). Any one of these proteins, or others, might alter the affinity of the 
VEGFR2 receptor for VEGF or modulate its ability to be targeted for recycling or 
degradation. Beta 1 integrin is an obvious candidate as it is a critical mediator of 
cell interactions with a fn-rich matrix.  Thus, we measured the levels of β1 
integrin in cells on various stiffness substrates and noted no differences in 
expression (Figure 4.9A/B). However, when we blocked β1 integrin with antibody 
9EG7, we observed a decrease in the levels of internalized VEGF in cells on 25 
kPa and plastic substrates, with the effect being much more dramatic in cells on 
plastic (Figure 4.9C-E). Interestingly inhibition of β1 integrin resulted in no 
significant changes in matrix binding of VEGF on either substrate. The 
internalization blockade was attenuated in the soft condition and was enhanced 
by pre-treatment with heparin and increased stiffness, both conditions that 
exhibited increased matrix binding.  
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Beta 1 integrin has been linked to the internalization of HSPGs, and NRP-
1 both of which are known to modulate trafficking and recycling of associated 
proteins including VEGFR2(104, 112, 159). To begin assessing if alterations in 
recycling patterns may be contributing to stiffness induced alterations, we 
monitored total VEGFR2 levels in BAEC after three hours of VEGF treatment.  
Decreases in total VEGF receptor-2 quantity could indicate enhanced 
degradation over cell surface recycling of the receptor. Indeed, we found in our 
stiffest conditions a greater percentage of the total VEGFR2 pool was down 
regulated in our BAECs after VEGF treatment as compared to cells on moderate 
stiffness surfaces (Figure 4.10).   
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Figure 4.9: β1 integrin mediates stiffness-induced internalization.  
A. BAEC were grown on 4, 25, 125 kPa PAAM gels and fn-coated non-TC 
polystyrene. After 4 days in culture the samples were pre-treated with 10 ug/ml 
heparin for 1 hour. Heparin was removed and the cells were washed twice PBS. 
Conditioned media was added back for 4 hours prior to VEGF addition. VEGF 
(10 ng/ml) was added for and the cells allowed to incubate for 5 minutes before 
lysis buffer extraction and cell scraping.  A. Samples were resolved on stain-free 
TRIS-HCL gels followed by blotting with BD G6E7 β1 integrin antibody at 1:5000. 
B. Integrin levels were normalized to 6 easily identified bands on stain free gels 
C/D. BAEC were grown on our various stiffness gels and plastic for four days.  
125I-VEGF binding assays were completed as previously described, but prior to 
VEGF addition, samples were pre-incubated with 5 ug/ml G6E7 β1 integrin 
inhibitor for 30 minutes prior to VEGF addition.  Cells were treated with VEGF (10 
ng/ml) for three hours prior to extraction. All bars are the average of three 
samples +/- SEM C. VEGF-Matrix binding is not modified by β1 inhibitor G6E7.  
D. BAEC VEGF internalization is significantly reduced by G6E7 in all conditions 
except 25 kPa heparin. E. Percentage of total VEGF internalization maintained 
with β1 inhibition (internalized faction with β1 inhibition X 100)/(total internalized 
fraction).  
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Figure 4.10: Stiffness results in increased down regulation of total VEGFR2 
levels. 
 BAEC on 4, 25, 125 kPa PAAM gels and non-TC polystyrene were grown for 
four days in culture. Samples were treated with and without 10ng/ml VEGF in 
binding buffer for three hours. Cells were suspended with TrypLE, fixed, 
permeabilized and incubated with anti-VEGFR2 antibody as previously 
described. At least 30,000 cells were analyzed for each sample. A. Histograms 
show the total levels of VEGFR2 present in control and VEGF treated samples 
with median fluorescent intensities for 25 kPa and plastic indicated by the 
numbers. B. Average ratios of total VEGFR2 in VEGF/Control samples on two 
independent days +/- SEM.   
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4.3 Discussion 
Endothelial cells are heterogeneous varying by location within the body 
and even within individual blood vessels(23, 25, 26).  The extracellular matrix 
(ECM) underlying the endothelium is also highly variable both in composition, 
compliance, and function with health and disease(51, 83, 90). As stiffness 
changes, cells increase their traction forces on the ECM, thus increasing strain 
on individual ECM fibers resulting in structural rearrangement and un-folding of 
specific ECM proteins leading to exposure of cryptic binding sites for proteins 
such as vascular endothelial growth factor (VEGF)(58, 65, 89, 98). We 
hypothesize that the binding of VEGF to the ECM is modulated by stiffness, 
which alters the ability of VEGF to activate VEGFR2 to induce downstream 
signaling. Understanding how the interaction and activity of VEGF with 
endothelial cells is controlled by ECM stiffness could provide critical insight for 
the development of next generation pro- and anti-angiogenic therapies.  
 We found that VEGF-induced phosphorylation of VEGFR2 and 
downstream ERK activation were modified by stiffness. The changes in VEGF-
induced signaling were not the result of variable VEGFR2 expression as we 
observed no significant alteration on VEGFR2 levels on cells across the range of 
stiffness tested (Fig 4). Increased VEGF-mediated signaling correlated with 
increased internalization of VEGF and decreased binding of VEGF to the matrix 
(Fig 5). If matrix binding inhibits internalization, blocking matrix binding with an 
inhibitor such as SOS should enhance internalization, particularly in the stiffer 
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conditions. Blocking matrix binding of VEGF with SOS, actually inhibited 
internalization within a specific range regardless of stiffness. Heparin, which has 
been previously shown to enhance matrix binding, both increased matrix binding 
and the internalization of VEGF in all of our conditions. VEGF internalization and 
signaling due to heparin was still attenuated in our stiffest conditions, which 
exhibited the highest levels of matrix binding.  Together these two findings 
suggest that a delicate balance exists between matrix binding and internalization 
of VEGF. Both the quantity and quality of VEGF matrix binding could be 
contributing to VEGF interactions with the receptor and the subsequent 
internalization of a VEGF-Receptor complex. 
The observation that there are different levels of internalized VEGF in cells 
as a function of ECM stiffness indicates that the rates of VEGF endocytosis or 
degradation are altered.  VEGF degradation, as indicated by the rate of internal 
VEGF loss, does not appear to be altered across the range of stiffness tested 
irrespective of the mass of VEGF retained. Indeed, there was even a slight 
downward trend in the rate of release of VEGF in cells as stiffness increased 
whereas the level of internal VEGF was decreased suggesting the overall 
process of VEGF exocytosis may be attenuated in cells as a function of stiffness.  
The VEGF degradation findings suggest that endocytosis of VEGF must 
be increased since degradation does not appear to be changed.  Several 
scenarios could increase endocytosis of VEGF. Greater affinity of VEGF for the 
receptor, the availability of the receptor for active binding, or alterations in the 
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engagement of various internalization-enhancing co-receptors could be 
modulated by stiffness. After endocytosis of VEGF-VEGFR2 complexes, a 
fraction of VEGFR2 is targeted for degradation and the remaining receptor is 
recycled back to the cell surface(113). β1 integrin, an fn binding integrin, is up-
regulated during angiogenesis and plays important roles in controlling cell 
migration and proliferation(27). In prior studies, blocking β1 integrin prevented 
VEGFR2 internalization and blocked extended MAPK signaling in response to 
matrix bound VEGF(42, 102). β1 integrin and Neuropilin-1 (NRP-1) work in 
tandem to increase signaling(101, 104).  Blocking β1 activity or NRP-1 by altering 
fn conformation decreases the percentage of VEGF bound to VEGFR2 and 
reduces subsequent downstream signaling(104). β1 integrin is involved in the 
internalization of NRP-1, which can mediate recycling of VEGFR2 receptor(104).  
VEGFR2 bound to NRP-1 is trafficked to Rab11 containing endosomes whereas 
VEGFR2 internalized without NRP-1 is driven towards Rab7 containing 
lysosomes(43, 156).  Rab11 vesicles are slow recycling vesicles whereas Rab7 
vesicles are designated for destruction in lysosomes(43, 113). The ability of 
these co-receptors to engage VEGFR2 might be modulated by stiffness, which 
could in turn modify the total quantity of receptor that is recycled to the surface. 
We found that the proportion of VEGFR2 remaining after VEGF treatment 
was reduced on the stiffest substrates as compared to a moderate stiffness 
condition.  This result suggests that VEGFR2 recycling may be reduced on the 
stiffest substrate possibly because β1 integrin is less able to be activated and 
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fully participate in VEGFR2 internalization and recycling when associated with 
the stiffer, more extended matrix.  Indeed, when β1 integrin was blocked we 
observed decreased levels of internalized VEGF particularly in conditions with 
increased VEGF matrix binding (high stiffness or pre-treatment with heparin). 
The quantity of β1 integrin was not altered by stiffness suggesting that its ability 
to be activated and engaged, not its net quantity, is driving the stiffness-induced 
alterations. 
It is possible that stiffness can cause integrin type switching which could 
modify VEGF signaling and processing even if the concentration of integrin 
proteins is not changing. Computer modeling predicts that as stiffness increases, 
the distance between the synergy site and the RGD binding site on fn increases 
leading to decreased relative β1 integrin binding and increased engagement of 
other integrins such as αvβ3(154). As matrix stiffness increases, the number of 
β1 integrin bonds does not change, but the tensional state and synergy site 
engagement of the bonds does increase(160).  Thus, as stiffness increases, the 
proportion of β1 integrin binding and its ability to be engaged and internalized 
may decrease until β1 integrin is no longer able to engage the matrix and 
effectively participate in VEGFR2 internalization. Modifying the conformation of fn 
protein can also decrease the quantity of active β1 integrin and subsequent 
internalization of VEGF(104).  
Although we have no direct evidence yet, we hypothesize that the amount 
of β1 integrin that is available for internalization may be decreased in the stiffest 
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condition and thus the effect of blocking β1 integrin, which is involved in 
internalization, may lead to a more pronounced reduction of internalized VEGF. 
Furthermore, internalized β1 integrin may be involved in directed recycling of 
VEGFR2 protein.  
Biological systems are much more complex than just a single cell 
interacting with a single type of ECM protein through integrin bonds. Exploring 
the role of matrix binding led us to modify the ECM with heparin, which is a highly 
sulfated version of heparan sulfate, which is capable of exposing a VEGF binding 
site on fn(58, 60, 62, 65). Heparin enhanced VEGF matrix binding, 
phosphorylation of the VEGFR2 receptor, internalization of VEGF and 
subsequent signaling in response to VEGF. Endothelial cells on our softest 
substrates (4 kPa) were most responsive to heparin induced internalization and 
signaling as compared to all other stiffness surfaces indicating the effect of 
heparin is not uniform as stiffness changes.  
 One possibility is that heparin is influencing both matrix binding of VEGF 
as well as interactions between VEGF and VEGFR2 on the cell surface. The 
quality of matrix binding in heparin treated samples may be different than the 
type of matrix binding produced by cell traction forces on the matrix.  As 
previously alluded to, the proximity of the synergy site for α5β1 can alter the ratio 
of α5β1 to αvβ3 and the tensional engagement of the protein(154, 160). The 
unfolding of fn in response to heparin may be less severe than the unfolding in 
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response to cell traction forces and thus the ability to engage and internalize 
α5β1 may be retained. 
Another possibility is that the ability of heparin to mimic the role of cell 
surface HSPGs in enhancing VEGF-VEGFR2 binding, internalization and 
signaling(38, 56, 161) may allow it to promote VEGF signaling in spite of its 
ability to lead to increased sequestration of VEGF in the matrix.  HSPGs are 
directly involved in the internalization of VEGF. Syndecans, cell associated 
HSPGs, have been found to bind synectin and syntenin important proteins for 
VEGF-VEGFR2 complex internalization and recycling (41, 159, 162, 163).  
HSPG complexes with β1 integrin can also make very strong bonds (catch 
bonds), which are enhanced instead of weakened with increased force(95, 160). 
Thus adding heparin may further induce catch bond formation allowing for 
increased the β1 integrin engagement and subsequently enhanced 
internalization of VEGF even at high stiffness. Prior studies from our lab have 
indicated that heparin is effectively removed after treatment of cells and matrices 
with standard buffer washes, but these studies were done with plastic 
substrates(65).  It is possible that enhanced cell-complex formation, prior to 
washes, may protect heparin from removal during wash steps on our gel 
substrates.  The creation of this super complex may enhance internalization of 
VEGF in cells independent of VEGF matrix binding.   
 We present the novel finding that VEGF processing is modified by 
substrate stiffness. The context and quality of VEGF-matrix binding ultimately 
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dictates the ability of cells to internalize VEGF. The ability of factors such as β1 
integrin, and heparin to engage VEGF, likely forming a complex with the 
receptor, is critical for internalization. Future studies should explore if β1 integrin, 
HSPGs, and VEGFR2 are indeed creating a super complex in our soft 
conditions. Additional studies could create specific conformational modifications 
in fn matrix to better understand how the proximity of these factors modifies 
internalization in various stiffness conditions. Selectively targeting cells that are 
undergoing enhanced VEGFR2 turnover or VEGF signaling due to ECM changes 
could provide new treatment avenues for either enhancing or attenuating VEGF 
signaling.  
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CHAPTER FIVE: GENERAL DISCUSSION AND FUTURE DIRECTIONS 
5.1 Introduction 
Endothelial cell behavior is extraordinarily complex.  Endothelial cells can 
respond to a variety of factors including lipids, growth factors, and many other 
chemical components and physical properties of the extracellular environment(7, 
35, 164).  Often, these factors are studied independently. Mechanically inclined 
biologists have long documented changes in cell behavior in response to 
stiffness including endothelial cell spreading, increased permeability, and the 
availability and quantity of focal adhesion complexes(83, 84, 109, 143).  Matrix 
biologists have shown that VEGF signaling is enhanced and prolonged by 
binding of VEGF to the ECM, but the mechanisms underlying the altered 
signaling have not been determined(57, 58, 62, 65).  Growth factor biology is 
dependent on the extracellular matrix, which is highly dynamic and based on cell 
type and local pathology(29, 35, 85, 145). No studies to date have explored how 
stiffness and matrix binding of VEGF act together to modulate downstream 
signaling. Attempting to bridge the gap between matrix biology and 
mechanobiology presents a number of challenges, yet also provides a means to 
develop a deeper understanding that would not be revealed by either approach 
alone. Ultimately a more comprehensive understanding of how matrix mechanics 
and biochemical composition combine to control VEGF may eventually lead to 
the development of new approaches to treat disease by targeting VEGF-ECM 
interactions.   
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 The research presented in this dissertation brings growth factor biology 
together with the study of extracellular matrix stiffening.  We completed a series 
of VEGF-endothelial studies across an entire range of physiological and non-
physiological (yet often studied) stiffness conditions(30, 69, 70). We found 
endothelial cell behavior is responsive to VEGF dose, ECM stiffness, and heparin 
treatment in a complex manner.  It has been recently shown that decreased 
matrix density or stiffness mediates VEGF-induced sprout formation and 
mesenchymal progenitor cell differentiation in response to VEGF(85, 165).  Our 
findings largely fit with these data and add to them, ultimately connecting matrix 
stiffness, individual cell analysis, VEGF responsiveness, and VEGF processing 
together.   
 
5.2 VEGF-Endothelial cell processing is altered by stiffness 
 We found that endothelial cells on soft extracellular matrices are most 
sensitive to VEGF stimulation compared to those on stiffer matrices.  Matrix 
binding of VEGF and critical endothelial integrin proteins mediate changes in 
VEGF internalization.  Fn makes up at least 15% of most endothelial cell 
basement membranes(65).  The fn hep 2 domain, which contains the major 
matrix-binding site for VEGF, can be exposed by both heparan sulfate 
proteoglycans (HSPGs) or cell induced traction forces(39, 57, 65, 89).  
Endothelial cell traction forces increase with stiffness(143, 166), thus it is likely 
that these forces mediate unfolding of fn and exposure of the cryptic VEGF 
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binding site. On average we found around a 2-fold increase in VEGF-matrix 
binding with stiffness comparing our softest to stiffest conditions, but we also 
found that this increased matrix binding was inversely correlated to internalization 
of VEGF.  However, experiments with SOS indicate that matrix binding of VEGF 
is critical to internalization, since inhibition of VEGF binding to fn with SOS led to 
reduced VEGF internalization (Fig 4.7).  The ability for co-receptors to interact 
with the matrix bound VEGF may direct the stiffness induced alterations in 
internalization.  
Endothelial cells can be tethered to the ECM through a myriad of different 
integrin proteins. The stiffness, type of matrix protein, and cell pathology dictate 
integrin type(7). Our matrices should be diverse as all experiments were 
completed after 3-4 days in culture, allowing sufficient time for the endothelial 
cells to produce their own native matrix by the time the VEGF-stimulation 
experiments were conducted. Both αvβ3 and β1 integrin have been associated 
with angiogenesis(96, 97, 100-102, 160, 167-170).  Many studies suggest that β1 
activity is more critical to angiogenic processes as certain αvβ3 binding situations 
also require the activity of β1 integrin in order initiate events(100, 103).  β1 
integrin can be found in cells under relaxed or tension-induced states(160).  The 
activation of β1 integrin, as monitored with antibody staining, has been linked to 
its ability to play an active role in VEGF induced internalization and 
signaling(104).   
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Blocking β1 integrin in BAECs resulted in decreased VEGF internalization 
in both control and heparin treated conditions, but the blockade was enhanced 
both in very stiff and heparin pre-treatment conditions even as β1 integrin levels 
remained constant.  This finding indicates that the active state of the β1 integrin 
or its ability to engage the matrix or other co-receptors may be proportionately 
altered depending on stiffness directly impacting the quantity of internalized 
VEGF protein.  In addition, we observed reduced VEGFR2 quantities after VEGF 
treatment within cells on soft substrates, thus the β1 mediated internalization, or 
its action in conjunction with another co-receptor such as neuropilin-1 (NRP-1) 
may be directing a greater proportion of VEGFR2 to a recycling pathway 
compared to VEGFR2 in endothelial cells on our stiff substrates.  
Although we found connections to matrix binding and β1 integrin, there are 
still many studies that must be explored to completely understand our findings 
mechanistically. Others have shown that blocking fn assembly with a mimetic 
peptide results in decreased levels of active β1 integrin connections to 
endothelial cells interrupting VEGF signaling(104).  We predict that stiffness may 
be modulating the conformation of fn, decreasing the ability of β1 integrin to be 
activated and interact with matrix bound VEGF. Thus future experiments should 
examine the state of β1 integrin in control and heparin treated cells as well as the 
composition of VEGFR2 containing vesicles within these cells.  It will also be 
critical to confirm our VEGF internalization results with other cell types that have 
a broader range of species-specific β1 integrin inhibitors available.  While the 
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inhibitor used in our experiments 9EG7 has been documented to have both 
enhancing and blocking properties(171, 172), a number of peer-reviewed 
published data that use other β1 integrin antibodies or genetic knock out models 
that block activation or binding of β1 integrin also show decreased VEGF 
internalization(42, 104). Hence, our results with 9EG7 are consistent with it 
functioning in an inhibitory manner.     
 The reduction in VEGF internalization that we observed with 9EG7 
treatment suggest that β1 integrin is involved in the process of VEGF 
internalization in BAECs, but these data clearly do not rule out the possibility that 
other integrin types may also be involved in controlling this complex process. A 
protein array to examine a variety of integrin proteins and their respective levels 
due to stiffness-induced changes could help identify useful targets to explore. 
This search will not be exhaustive though as we have also seen that it is not just 
protein quantity, but also orientation and activation levels that are critical to 
internalization and signaling.  
There are other co-receptors that have been demonstrated to influence 
VEGFR2 signaling such as the neuropilins and HSPGs. The possibility that the 
levels or function of these co-receptors are modulated by stiffness should also be 
explored. Neuroplin-1 (NRP-1) is a common co-receptor for VEGFR2 signaling 
and has been linked to increased signaling events in the presence of VEGF(38, 
101, 104, 112).  NRP-1 is also internalized through β1 integrin-dependent 
mechanisms, and its internalization mediates directed recycling of VEGFR2(41, 
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101, 112).  VEGFR2 internalized in the absence of NRP-1 is tagged for lysosome 
destruction(112).  
Consequently, VEGF treatment of endothelial cells in the presence of both 
inhibitors for β1 integrin and NRP-1 should reveal additional mechanistic insight.  
Additional inhibitors can also be utilized to block specific components of the 
recycling and trafficking pathways to mechanistically identify where each of the 
respective co-receptors is influencing internalization, trafficking, and subsequent 
signaling. Further flow cytometry experiments can explore how the total VEGFR2 
levels are proportionally modulated by β1 integrin and NRP-1 blockade in the 
presence of VEGF. 
We have begun to identify parameters involved in stiffness-induced 
changes in VEGF signaling.  We predict that the orientation and proximity of 
matrix bound VEGF is critical to its ability to engage VEGFR2 and its co-
receptors including β1 integrin, which modifies stiffness induced internalization of 
VEGF. Illustration 5.1 visually brings together our findings into one model, which 
addresses how stiffness may modify endothelial cell VEGF internalization and 
signaling.    
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Illustration 5.1: Model of stiffness induced changes in cell internalization of 
VEGF.  
Matrix binding of VEGF is enhanced with stiffness. Beta-1 integrin levels remain 
constant regardless of stiffness and its inactivation decreases internalization of 
VEGF regardless of stiffness. Cells on the stiffest ECMs showed the greatest 
proportional drop in VEGF internalization with β1 integrin inhibition. Together, this 
suggests that β1 integrin is necessary for internalization of VEGF and that there 
may be less engaged or activated β1 integrin in stiffer conditions.  
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5.3 Heparin enhances stiffness induced VEGF signaling 
 Heparan Sulfate Proteoglycans (HSPGs) have multiple effects on VEGF 
mediated signaling(38, 62, 161).  The HS chains within HSPGs themselves have 
a weak affinity for VEGF, which may mediate some of the alterations in signaling 
that are found(38, 56).  However, HSPGs can bind to both VEGFR2 and NRP-1 
and dramatically enhance the binding of VEGF to VEGFR2(173). Ultimately, 
there are several ways in which heparin may be enhancing VEGF internalization 
and signaling.  
 Within the context of our current studies, we found that heparin pre-
treatment, which has traditionally been used in fn studies to enhance matrix 
binding of VEGF, likely has multiple roles in modulating VEGF biology. Matrix 
binding increases as stiffness increases and it also seems to be necessary for 
internalization, yet cells on softer substrates have less matrix binding and greater 
internalization. We also found markedly increased internalization in all conditions 
after treatment with heparin, which enhanced matrix binding. We predict that 
these changes are due to the quality or type of matrix binding. Fn is the most 
stretchable protein studied to date(64). Overstraining of fn fibers actually results 
in dissociation of VEGF from fn(174). This indicates that the quality of matrix 
binding may be shifting as cell traction forces on the matrix are enhanced with 
increasing stiffness(89, 98). The VEGF binding region likely remains the same 
regardless of heparin pre-treatment or cell induced unfolding of fn, but in the stiff 
cell induced model the entire protein may be over extended blocking the 
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availability and stability of critical co-receptors for VEGF and VEGFR2 
internalization(154, 175). The positioning and orientation of co-receptors has 
been demonstrated to have a role in internalization previously(159, 160). Beta 1 
integrin, the major integrin protein for fn, switches from a relaxed state to a state 
of tension with stiffness(160). Thus all together, heparin enhanced matrix binding 
in our soft condition, where cell traction forces remain minimal and β1 integrin 
protein remains relaxed may lead to maximal internalization of VEGF.  We 
predict that these ideal conditions position matrix bound VEGF, VEGFR2, and 
co-receptors in close proximity to one another facilitating increased uptake of 
these complexes into vesicles where signaling and recycling are facilitated.  
Future studies should utilize other VEGF isoforms such as VEGF-121, 
which is incapable of binding to the ECM. If VEGF-121 uptake is still enhanced in 
soft conditions, the ability of VEGF to bind the matrix may be less relevant than 
the orientation and proximity of VEGFR2 in relationship to other co-receptors 
including β1 integrin. Genetic modifications of fn protein could artificially extend 
the distances between critical sites, such as the synergy site and RGD binding 
site. The modified fn could be tested with cells on soft matrices and compared to 
those with native matrix on stiff matrices to see if binding and internalization 
patterns are modified. Ultimately, these studies aim to determine what fn 
conformation or VEGF binding conditions must be met for enhanced 
internalization of VEGF to occur.  
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When we started these experiments we worked under the assumption that 
heparin was completely removed after pre-treatment of the cells prior to 
conducting the VEGF binding and signaling assays. This assumption was based 
on extensive prior experiments with ECM and fn on polystyrene surfaces(65).  
However, our assumption may not be valid within our cell-gel system if high 
affinity complexes are being created on the cell surface or if heparin is being 
trapped within the pores of the PAAM gels. Future studies should resolve this 
possibility by using aggressive measures to digest and remove residual heparin 
and cell associated HSPGs to determine if the ability of heparin to promote 
VEGF internalization is directly related to its influence on the ECM or other 
functions. Staining for HSPGs and the use of fluorescently labeled heparin could 
also reveal whether there are any differences in endogenous HSPG expression, 
or heparin binding and gel uptake due to stiffness.  
Native cell produced HSPGs and any residual heparin that remains after 
its removal prior to VEGF addition could have a direct impact on VEGF biology 
and internalization. Direct analysis of the various complexes that might form 
could reveal potential mechanisms.  For example, surface plasma resonance 
(SPR) studies could be done to measure the ability of HSPGs, β1 integrin, and 
VEGFR2 to engage fn protein together or sequentially with or without VEGF, and 
then each protein of the VEGFR2 super complex could be manipulated within 
cells (i.e., knocked down, overexpressed, mutated) to test their roles in 
modulating VEGF binding, internalization and signaling. Imaging studies will 
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allow for co-localization and identification of specific trafficking pathway 
contributions. The proposed studies would quantify native cell produced HSPGs 
and study the effect of residual heparin within our PAAM gels as a step toward 
parsing out how these contributing factors individually influence VEGF 
internalization.  We predict there is a combined effect of HSPGs on facilitating 
matrix binding and impacting VEGF-receptor internalization.  
 HSPGs have an active role in internalization of many receptors(159). An 
increase in intracellular HSPGs has been linked to more aggressive cancer 
phenotypes, which often also have increased VEGF activity(159). Similarly, the 
ability of fibroblast growth factor 2 (FGF-2) to activate the MAPK pathway 
through intracellular signaling has already been shown to be enhanced by 
syndecan binding of FGF-2. Syndecan-4 can bind two proteins involved in 
internalization, synectin and syntenin(159). Syntenin drives recycling of syndecan 
back to the cell surface, whereas synectin is an essential protein required for 
internalization of VEGF (41, 159, 163).  It is unknown at this time if the binding of 
HSPGs to synectin is enhancing, inhibiting, or essential in modulating 
internalization or trafficking of internalized VEGFR2.  HSPGs also act in a feed 
forward manner, facilitating the internalization and recycling of α5β1 integrin, 
which has been linked to VEGF internalization(159). Future studies could 
examine this mechanism by tracking these various proteins in the presence or 
absence of HSPGs. Genetic modifications in the proteins resulting in blockade of 
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HSPG binding sites would also allow for specific identification of the contribution 
of HSPGs in VEGF internalization.    
 HSPGs have many roles in cell biology.  They are involved in cell-matrix 
biology, receptor binding, and internalization reactions.  Parsing out the individual 
roles and how those functions translate into biological outputs is difficult.  We 
hypothesize that heparin is selectively modifying the matrix on our soft gels 
allowing for enhanced relaxed state binding of VEGF, VEGFR2, and co-receptors 
leading to increased uptake of VEGF in these cells. Modifying VEGF matrix 
binding with heparin/SOS unveiled a key role of matrix binding in facilitating 
VEGF internalization and signaling (Illustration 5.2).  
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Illustration 5.2: Matrix binding dictates VEGF-internalization.  
Heparin pre-treatment of fn matrices exposes a cryptic VEGF binding site which 
enhances matrix binding and subsequent internalization of VEGF. Blocking 
matrix binding with SOS decreases the internalized quantity of VEGF. Thus, 
matrix binding of VEGF is essential for VEGF internalization and signaling.   
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5.4 Endothelial Cells are Heterogeneous 
 Endothelial cells are heterogeneous, varying receptors type and quantity 
based on the vessel location and type of vessel the cells are lining(23, 24, 116, 
121).  The extracellular matrices differ in elastin and collagen content depending 
on the vessel location and any presenting pathologies(17). Endothelial cells 
within an actively healing wound or in an angiogenic sprout appear to exist in one 
of three phenotypic states(26).  There are those that are quiescent and 
selectively non-responsive to angiogenic signals(28) and there are others, 
namely tip cells, that are hypersensitive to the environment and in particular to 
VEGF signaling(26).  Finally, there are stalk cells, which proliferate behind the tip 
cells to allow the new vessel to expand(28).  
 It was not surprising that we would observe so much heterogeneity in the 
VEGF responsiveness within our endothelial cell cultures.  While looking for a 
way to quantify individual cell-stiffness dependent responses to VEGF, we found 
that the average calcium response is a very poor indicator of VEGF activity within 
a population of cells.  It grossly underestimates the contribution of responding 
cells and it overestimates the bulk response of the cells to VEGF. Although our 
calcium-signaling studies largely correlated with findings we had with ERK (cells 
on our softest gels were most sensitive to VEGF), we were able to gain more 
specific information on VEGF signaling dynamics and cell phenotypes. 
 We found that a concentration threshold exists for calcium signaling.  
More VEGF led to faster responses, thus the responses themselves were not 
	  	  
130 
limited by the time it takes for one signaling event to occur, but instead were 
limited by the availability of VEGF protein at the doses we tested.  The 
magnitude of VEGF responsiveness could be predicted by the rate of activation.  
Finally, we correlated our individual cell analysis back to the phenotypic 
characteristics of the individual cells and found that at low doses of VEGF 
smaller, thinner cells were more responsive to VEGF.  As dose increased, this 
effect was lost likely due to the threshold of activation being reached in a myriad 
of different cells (Illustration 5.3).  
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Illustration 5.3: Endothelial cells are heterogeneous.  
Phenotypically, cell shape and size characteristics correlate with changes in 
VEGF-endothelial cell calcium signaling. Endothelial cells on soft matrices were 
most sensitive to VEGF. Regardless of stiffness, at low VEGF doses thin small 
cells showed enhanced VEGF-endothelial calcium flux.  High doses of VEGF 
obliterated the effect as a threshold for VEGF activity was met in more cells 
regardless of cell size/shape. The total quantity of VEGFR2 did not vary on the 
cells as stiffness changed and did not correlate with cell size suggesting the 
mechanistic alterations are more complex than just proportional alterations in 
VEGFR2 density.  
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Individual cell analysis provides a unique and data driven method to study 
cell signaling processes.  Signals produced by cells can be oscillatory, transient, 
driven by fold increases, or prolonged(120, 121). The difference in signal type 
often translates into downstream signaling and ultimately cell output and 
behavior(120).  Our studies identified two unique individual cell outputs of VEGF 
treated cells – a small fraction of highly responsive cells with a small cell 
phenotype and the bulk responding cells, which were wider and had larger cell 
areas. Future work should examine how each of those individual responses and 
phenotypes translates into downstream signaling and furthermore results in a 
specific biological function.  
Future work should include individual cell analysis in a variety of 
conditions utilizing blocking antibodies and multiple fluorescent labeling 
parameters. The additional factors could be fluorescently labeled so that 
VEGFR2 and signaling proteins such as ERK can be localized and monitored in 
individual cells. Additional outputs, including the biological responses can also be 
examined this way to determine how specific parameters correlate with particular 
biological responses to VEGF. 
Understanding how signaling dynamics and magnitude relate to cell 
phenotype could provide valuable insight into developing new drugs or therapies. 
For instance, VEGF stimulatory therapies could be attempted with low dose 
cytoskeletal inhibitory drugs to mildly decrease cell surface area and potentially 
enhance VEGF responses. Drug doses could be titrated within our calcium 
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imaging analysis model to decrease the percentage of high responding cells 
while not inducing apoptosis or cell death in the remaining cells. Drug therapies 
could be screened for those that selectively slow VEGF internalization as slower 
responses were met with lower maximum activation in our experiments and we 
can predict they would have decreased VEGF activities such as cell migration. 
An increasing percentage of smaller, thinner cells, or fatter wider cells after a 
drug treatment may ultimately prove to be an inexpensive and easy indicator of 
VEGF responsiveness. Cells with specific disease pathologies could be modeled 
with our calcium system to assess the number of high responding and low 
responding cells and their individual cluster dynamics potentially revealing new 
information and targets for further treatment developments. Our calcium-flux 
analysis tool provides a quantitative, robust method to screen for new drugs and 
develop new cell models of disease.  
 
5.5 Translational Approach  
 The goal of all biomedical research is to be able to apply what is learned 
to the human body.  Our studies provide new insight into how stiffening of aged 
or diseased vessels might contribute to deficiencies in wound healing(51). 
Current blood vessel replacements for bypass and aneurysm are mostly made of 
polymers that do not match the compliance of healthy tissue. These synthetic 
replacements generally have high rates of failure(176), which might reflect, in 
part, this mechanical mismatch.  The ability to distinguish endothelial cells that 
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are highly VEGF responsive (small, thin cells) from the bulk responders, can help 
guide the development of new therapies. Cell sorting might be used to select for 
high or low responding cells for various cell-based therapies to provide a rational 
means to achieve directed angiogenesis where and when it is desired.  These 
cells could be seeded on physiologically relevant ECMs with particular attention 
to the stiffness.  From a drug treatment perspective, inhibitors can be designed 
with specific properties to only target the high responding or low responding cells 
within a population or specific cells engaged with a local ECM phenotype. Using 
this type of approach, we might imagine a situation whereby off target effects 
could be minimized and the side effect profiles reduced.  
To move towards an approach that better replicates intact healthy 
vasculature, future experiments could add a variety of vessel-associated 
variables. Within the context of our experimental paradigm, we only examined 
how stiffness modulates the function of endothelial cells. Vessels vary, as 
previously mentioned, due to cellular location, local microenvironment 
mechanics, and the presence of local vessel pathologies(23, 25). The 
endothelium in capillaries and veins will have different ECM architectures and 
mechanical loading than the endothelium of the aorta. Several studies have 
documented that a balance exists between ECM structure and the function of the 
endothelium(152, 177). The structure of a three-dimensional  (3D) artificial 
endothelium can create an anti-inflammatory environment as compared to a 2D 
endothelium(152). Stiffening itself creates a dynamic environment in which cells 
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themselves try to equilibrate, thus cells regulate matrix production, which in turn 
regulates cells. Collagen and fn deposition and fibril formation are tied to one 
another and can change with dimensionality and stiffened tumor 
microenvironments(177, 178). Thus within our studies, a limitation may be the 
fact that cells are continually altering ECM structure and composition over the 
several day culture period, and this could vary with stiffness. Un-coupling ECM 
structure/content from stiffness and determining the true underlying mediators of 
cell change is a difficult and potentially impossible challenge since any change in 
one aspect of the system will undoubtedly lead to changes in another that is 
critical for cell function. Additional information may be gathered by examining cell 
responses at shorter time points, and by using genetic models where matrix 
production is modified, or through the use of proteases that selectively degrade 
specific matrix proteins.  
Further complexity can be introduced with 3D models and the addition of 
flow. Studies on 3D collagen gels with lower elasticity than our PAAM gels have 
demonstrated increased endothelium stability under flow(179). The addition of 
flow, 3D architecture (thus the modification of focal adhesion behavior), and 
increased compliance could contribute to the enhanced stability or decreased 
active angiogenic processes. These findings do not contradict our current 
studies. Our lab has previously shown that matrix stiffening leads to decreased 
cell mobility and a resulting increased number of cells in stiffened areas, a finding 
that may be considered as increased cell stability or quiescence(174). In our 
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current studies, it can be inferred, that the attenuated ERK and VEGF flow 
calcium signaling in our stiffened conditions would likely lead to decreased cell 
migration, permeability, and proliferation. These findings are once again more 
consistent with quiescent cells in a stable vessel phenotype. Even if further 
biological studies ultimately match our cells on stiffened matrices with an 
enhanced angiogenic phenotype, the changes in behavior could be attributed to 
a shift in cell connections due to the 3D architecture. In 3D environments, focal 
adhesions become more punctate, dynamic structures, which are more similar to 
the focal adhesions classically, found in cells on 2D soft substrates(83, 180). 
Thus it is also possible that endothelial cells in our elastic 2D condition are more 
similar to the stiffened 3D environment. We predict that a combination of factors 
– flow, ECM structure/dimension, stiffness, and innate cell programing 
collaborate to create a niche for endothelial cell driven angiogenesis and survival 
and likely all interact in a complex manner to activate the VEGF signaling axis.   
To ascertain how pathological cells respond to both VEGF and stiffness, 
primary cells from old mice or atherosclerotic mice could be harvested and 
seeded onto pre-established matrices of various stiffness values and compared 
to young or healthy mouse cells plated on the same stiffness matrices. After 
several hours to allow cell attachment, VEGF binding assays could be completed 
to gauge the responsiveness of actual diseased cells. These experiments would 
highlight differences in the contribution of VEGF internalization to inherent cell 
characteristics versus features of the matrix. Additional follow up experiments 
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could monitor the health and viability of the primary cells from aged arteries after 
treatments to block or engage VEGF signaling.  These studies could be extended 
using our approach to discriminate the response on an individual cell basis or as 
a population.  
 The actual vessels of the young and old mice could be examined with our 
individual cell calcium imaging methods.  In vitro calcium imaging on vessels has 
been demonstrated previously(181), thus it seems plausible that we could create 
a heterogeneous map of VEGF vessel responses in a variety of different 
pathologies. Drug treatments could be titrated and changes in signaling 
characteristics could be correlated with biological outputs.      
 Integrin inhibitors are already in clinical trials and beginning to show some 
effectiveness. Volociximab is a α5β1 monoclonal antibody that has shown early 
success in trials for non-small cell lung cancer and possibly wet macular 
degeneration(182, 183), yet no benefit was found for advanced ovarian 
cancer(184). It is possible that the effects of integrin inhibitors such as 
Volociximab could be potentiated further by combining this therapy with agents 
that would stiffen the matrices possibly through the use of crosslinking agents or 
the local applications of radiotherapy. Conversely, inducing integrin activation by 
softening the matrix with proteases might provide a means to enhance 
angiogenesis in order to facilitate tissue regeneration. It seems likely from our 
studies that it is not just the balance of integrins, but also the ability of the 
integrins to engage and be activated by the matrix below.  
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 Heparin has a long and complex history as a drug in the clinic.  It has 
been used for years as an anti-coagulant drug and interestingly, cancer patients 
who are on heparin, depending on the study context, show a small survival 
benefit from factors independent of the anti-thrombic activity of heparin(185). 
Heparanase, which is typically up regulated in cancers, can be inactivated by 
endogenous heparin. Typically, heparanase cleaves cell bound HSPGs initiating 
down stream effects(61). Cleaved HSPGs could lead to modification of the fn 
matrix, VEGF binding and subsequent internalization of VEGF as we described 
in our model. Heparin treatment for cancer is not currently efficacious, likely 
because of its ability to enhance and inhibit many key mediators of cancer 
progression (i.e., growth factors, matrixmetalloproteinases, and cytokines, 
chemokines and other inflammatory mediators). The heparin-mediated 
alterations in matrix binding could be directly targeted with factors such as SOS 
to decrease matrix binding.  Additionally, heparan associated 
internalization/recycling factors could become drug targets. While our current 
work has focused on obtaining basic information regarding the ability of matrix 
stiffness to modulate VEGF activity, a better understanding of the underlying 
science is necessary to project new outlets and avenues for the clinic.  
 
5.6 Conclusion 
 We have attempted to bring together the fields of matrix biology, 
mechanotransduction, and growth factor signaling creating one cohesive model 
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(Illustration 5.4).  Our findings on the sensitivity of endothelial cells to VEGF on 
substrates of physiologically stiffness could contribute important components to 
the design parameters for tissue engineering for the treatment of complex 
vascular pathologies.  Ultimately, cell biology is not an average, each individual 
cell can respond uniquely to the particular matrix and soluble cues in which they 
are exposed, collectively creating a biological system.  
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Illustration 5.4: Hypothesis of stiffness-induced alterations in VEGF 
internalization and signaling.  
We predict matrix binding of VEGF is required for VEGF internalization and 
subsequent ERK signaling. We postulate that matrix binding of VEGF and 
engagement/activation of β1 integrin can be modified by ECM stiffness. 
Together, we hypothesize that β1 integrin complexed with VEGF-VEGFR2 
directs the internalization and recycling of VEGF-VEGFR2 complexes on soft 
ECMs.   
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APPENDIX 
A.1 Code to segment cells on calcium images and create various 
outputs 
Main script for cell segmentation/quantification 
%% This is the main program for segmenting portions of code.  It individuall identifies cells, 
% collects data on each of the cells and analyzes them for various outputs 
% including normalized intensity, number of maximus, percent activated, and 
% locational cluster analysis. 
  
%This program can run multiple folders containing Tiff images.  
%There are many functions included verify they are all in the pathway  
%before running.   
  
% clear background 
clearvars -global 
clc; 
close all; 
clearvars; 
clear workspace; 
tic 
carmca 
% load colormap for use - the created color map has a large array of colors 
% with spacing so that cluster analysis can be seen    
scriptpath = mfilename('fullpath'); 
[spath, ~, ~] = fileparts(scriptpath); 
fullnamecolor = fullfile(spath, ['mycmap.mat']); 
p = load(fullnamecolor); 
p = p.cm; 
% The user selects the folders with runs for analysis 
[dname, numfiles, cyclenum, threshpercent, tocluster] = selectfolders; 
numfig = 1;  
% For loop to run through the various runs 
for numruns = 1:numfiles 
    namefile = dname{numruns};   
    %gathers specific file information for the run 
    [name, dirlistc, fileNamesc, numFramesc] = fileinfo(namefile); 
    %segments the cells in the run 
    [rgbpic, L, s, numObj, backslide] = segment(dirlistc, cyclenum, numfig); 
    numfig = numfig + 1;  
    % inputs the information for each cell throughout each frame 
    [tarray] = inputframes(numFramesc, numObj, fileNamesc, L, rgbpic); 
    % subtracts background and computs percent change value 
    [F1F0, percentchange, avgperchange, adjcarray, activatedcutoff] = 
Percentchange(name,threshpercent, numFramesc, numObj, tarray, backslide, cyclenum); 
    % reads in and computes cluster analysis if requested 
    if (tocluster == 'Y') || (tocluster == 'y') 
        [clustercat] = clusterinput(F1F0, numFramesc, s, fileNamesc, rgbpic, activatedcutoff, 
backslide, L, p, numObj); 
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    end 
    %% Create Time array 
    for frames6 = 1:numFramesc 
        time(frames6,1) = 0.7872*frames6/60; 
    end 
    %% generate outputs including percent change, intensity vs time, percent activated,  
    % maximum intensities of each cell, number of maximums per cell, and 
    % the number of maximums throughout time 
    percentchangefig(name, time, avgperchange, numfig) 
    numfig = numfig + 1;  
    intensityfig(name, time, F1F0, numfig) 
    numfig = numfig + 1;  
    activatedfig(name, numFramesc, numObj, activatedcutoff, F1F0, time, numfig) 
    numfig = numfig + 1;  
    maxintenhisto(name, percentchange, numfig) 
    numfig = numfig + 1;  
    [maxcoord] = maxnumhisto(name, numObj, numFramesc, F1F0, numfig); 
    numfig = numfig + 1;  
    maxtimefig(name, numFramesc, numObj, maxcoord, numfig) 
    numfig = numfig + 1;  
    %% cluster outputs 
    % commputes ths number of clusters throughout time and the number and 
    % percent of cells within each of those clusters 
    if (tocluster == 'Y') || (tocluster == 'y') 
    clusternumfig(name, clustercat, time, numfig) 
    numfig = numfig + 1;  
    [meancluscellavg] = avgcluscellfig(name, time, clustercat, numfig); 
    numfig = numfig + 1;  
    percellclusterfig(meancluscellavg, numObj, time, name, numfig) 
    numfig = numfig + 1;  
    end     
  
    %% Save all variables 
    save(name);  
    clearvars -except p dname numfiles cyclenum threshpercent tocluster numfig 
end  
toc 
 
Select folders for calcium analysis 
%% This function allows the user to input how many 
% calcium runs they want to analyze and select the various folders  
% containing TIFF images for analysis an unlimited number of different  
% folders can be selected and the program will run indefinitely until  
% they have all been analyzed 
  
function [dname, numfiles, cyclenum, threshpercent, tocluster] = selectfolders 
numfiles = input('How many files do you want to analyze?: '); 
for numindex = 1:numfiles; 
    display('Please select the folders with your run TIFF images'); 
    dname{numindex} = uigetdir; 
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end 
% The code prompts the user for specific data on all runs being analyzed 
cyclenum = input('Please enter the cycle number where you started treatment: '); 
threshpercent = input('Please provide a percentile over background you would consider activated: 
'); 
tocluster = input('Please select Y/N if you would like cluster analysis: ', 's'); 
  
end 
 
Break apart each folder into its individual parts 
%% Get all the different file parts and save them into individual variables 
  
function [name, dirlistc, fileNamesc, numFramesc] = fileinfo(filename) 
  
% prompt user for directory that contains images, save various portions of 
% the file for further use 
  
[~, name, ~] = fileparts(filename); 
cd(filename); 
  
%delete any prior excel sheets in the same directory with the same name 
deletesheets(name, filename); 
%Save the information on the run in the current directory 
dirlistc = dir('*tif') ; 
fileNamesc = {dirlistc.name}'; 
numFramesc = length(fileNamesc); 
  
end 
 
Segment cells 
%% Use methods outlined in Mathworks (Steve's) blog to segement a  
%field of cells 
  
function [rgbpic, L, s, numObj, backslide] = segment(dirlistc, cyclenum, numfig) 
  
%set colormap, load colormap for clustering 
cmap = repmat(linspace(0,1,256)',1,3) ; 
y = uint16(zeros(512)) ; 
% add all frames together up until treatment started (about 50 frames) 
for ii = cyclenum:-1:1  
    x = imread(dirlistc(ii).name,'tif') ; 
    y = y + uint16(x); 
    %set(uih,'cdata',y) 
    clc, disp(ii) 
end 
%% make BW and adjust thresholds to increase contrast for segmentation only 
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I_eqp = imadjust(y); 
I_eq = adapthisteq(I_eqp);  
bw = im2bw(I_eq,graythresh(I_eq)); 
I_eq8 = im2uint8(I_eq); 
imshow(I_eq8) 
imwrite(I_eq8,'contrastimage.jpeg'); 
  
%% Outline perimeters - fill in holes in outlines, 
%delete small non cells 
%reset and outline perimeters 
bw = imfill(bw,'holes'); 
bw = imopen(bw, ones(4,4)); 
bw4 = bwareaopen(bw, 4); 
bw4_perim = bwperim(bw4); 
overlay1 = imoverlay(I_eq, bw4_perim, [1 .3 .3]); 
imwrite(overlay1,'overlay1.jpeg'); 
  
%% Find maximums (whitest area), extend outward and overlay on image 
mask_em = imextendedmax(I_eq, 15000); 
mask_em = imerode(mask_em, ones(6,6)); 
mask_em = imfill(mask_em, 'holes'); 
mask_em = bwareaopen(mask_em, 20); 
overlay2 = imoverlay(I_eq, bw4_perim | mask_em, [1 .3 .3]); 
imwrite(overlay2,'overlay2.jpeg'); 
%% Combine perimeters with maximums to segment image 
I_mod = imcomplement(I_eq); 
I_mod = imimposemin(I_mod, ~bw4 | mask_em); 
L = watershed(I_mod); 
  
%% Convert to White outlines of cells 
% first label RGB, then convert to greyscale and then black and white 
% complete statistics on remaining areas and display image w/ cell count to 
% verify segemntation - also computes the largest area - which is 
% background 
rgbpic = label2rgb(L); 
rgbpic = rgb2gray(rgbpic); 
%imshow(rgbpic) 
figure(numfig); 
title('Outlines for segmentation');  
rgbpic = im2bw(rgbpic, .99); 
imshow(rgbpic); 
s = regionprops(L, 'Centroid', 'Area', 'PixelList'); 
numObj = size(s); 
numObj = numObj(:,1); 
x = max([s.Area]); 
backslide = find([s.Area] == x); 
s(backslide) = []; 
hold on 
labelregionprops(s, numObj-1); 
hold off 
  
end 
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Function to read individual cell frames 
%% This function reads in each frame and creates a video of the input.  It 
% also calculates regional data for each cell.   
  
function [tarray] = inputframes(numFramesc, numObj, fileNamesc, L, rgbpic) 
%% Read in Test frames - create move of frames w/ outlines of areas 
% being measured 
normalmovie = VideoWriter('nocluster.avi'); 
normalmovie.FrameRate = 60; 
open(normalmovie); 
sta2struct = struct(); 
for frames2 = 1:numFramesc 
    % Read in each frame of the calcium study 
    seq = imread(fileNamesc{frames2}); 
    % overlay the segmentation over the image 
    overlay4 = imoverlay(seq, rgbpic, [1 0 0]); 
    writeVideo(normalmovie, overlay4);  
    %complete statistics on each region - average the pixelValues inside 
    %each segemented image to put into an array - tarray 
    sta2 = regionprops(L, seq, 'PixelValues'); 
    for regions2 = 1:numObj 
        pv2(regions2) = mean(sta2(regions2).PixelValues); 
        tarray(frames2,regions2) = pv2(regions2); 
    end  
end 
close(normalmovie);  
overlay4 = im2uint8(overlay4); 
% segmented image to file 
imwrite(overlay4,'segementedtreated.jpeg'); 
end 
 
%% Calculates the normalized intensity for each cell 
  
function [F1F0, percentchange, avgperchange, adjcarray, activatedcutoff] = 
Percentchange(name,threshpercent, numFramesc, numObj, tarray, backslide, cyclenum) 
%% Normalize data to percent change - subtract out background, subtract (F1-F0)/F0 
% Substract out the background for each slide - ie the larest area as found 
% previously (backslide).  The intensity for this area could change 
% depending on conditions and is subtracted from each test array 
for frames2 = 1:numFramesc 
    for regions2 = 1:numObj 
        backsubarray(frames2, regions2) = tarray(frames2,regions2) - tarray(frames2, backslide); 
    end  
end 
% Then remove the background array from the set so only cells are being 
% analyzed 
backsubarray(:, backslide) = []; 
% Make a separate array for the background frames and take the average of 
% the individual cells over those 50 frames.  Subtract that value from the 
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% test values to get F1F0 
% Percent change is then the F1F0/the average value 
% All calculations are done for individual cells 
first50 = backsubarray(1:cyclenum-1, 1:numObj-1); 
avgfirst50 = mean(first50); 
for frames2 = 1:numFramesc 
    for regions2 = 1:numObj-1 
        F1F0(frames2, regions2) = backsubarray(frames2,regions2) - avgfirst50(1, regions2); 
        percentchange(frames2, regions2) = F1F0(frames2, regions2)/avgfirst50(1, regions2);  
    end  
end 
  
avgperchange = mean(percentchange,2); 
%Calculates activated cells by being above the 95th percentile of  
%cells in the first 50 frames.  This value - ie anything over it is 
%activated is the "activatedcutoff" 
adjcarray = F1F0(1:cyclenum-1, 1:numObj-1); 
toppercent = prctile(adjcarray, [threshpercent], 2); 
activatedcutoff = max(toppercent); 
  
%write to excel doc 
xlswrite(name, F1F0, 'adjustedintensity'); 
xlswrite(name,tarray,'testarraybackfirst'); 
xlswrite(name,percentchange,'percentchange'); 
 
 
Geographic cluster analysis 
%% Does cluster analysis if the user decides to complete it 
function [clustercat] = clusterinput(F1F0, numFramesc, s, fileNamesc, rgbpic, activatedcutoff, 
backslide, L, p, numObj) 
%Creates a cluster movie.  Reads in each image.  Overlay cluster 
clustermovie = VideoWriter('cluster.avi'); 
clustermovie.FrameRate = 60; 
open(clustermovie); 
  
%for frames2 = 1:numFramesc 
for frames2 = 180:181    
    seq = imread(fileNamesc{frames2}); 
    %figure(11) 
    overlay4 = imoverlay(seq, rgbpic, [1 0 0]); 
    imshow(overlay4); 
    title('Read in treated cells, colored areas indicated clusters'); 
    active = 1;    
    activeregions = 0; 
    %Find the regions that are activated with treatment by selecting all points that are 
    %above the selected percentile of the control frames 
    for regions3 = 1:numObj-1    
            if F1F0(frames2, regions3) > activatedcutoff; 
                activeregions(active,1) = regions3; 
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                active = active + 1; 
            end 
    end 
%     findbackslide = find(activeregions == backslide); 
%     activeregions(findbackslide) = [];   
    [clusterout, totalpic] = clusteranalysis4(p, seq,L,rgbpic, overlay4, s,backslide, activeregions);  
    clustercat(frames2,1) = struct('cluster', clusterout);  
    writeVideo(clustermovie, totalpic); 
    clc,  
    disp(frames2); 
end  
  
close(clustermovie); 
 
function [totalcluster2, totalpic] = clusteranalysis4(p, seq, L,rgbpic, overlay4, sta2, backslide, 
activeregions) 
%% Function to determine clusters - defined as 3 cells w/in 1 cell length of each other which are 
also active 
% active cell # passed to the code along with background slide, current 
% picture 
% Read in active cells, compare to L the regions selected in signaling script 
% overlay the active cells with the regions 
% compute the average area of each cell, from area calculate the radius and 
% the average radius.  Use this value to expand out (bwdist) each cell the 
% one cell size.  Label these new regions that 
% may have joined together into clusters.  Separate out back to individual 
% cells and labelw tih color to display. For coding purposes, 
% commented out code is included with code to label each identified region.  
  
seqim = seq;  
%figure(1) 
%imshow(seqim); 
for adjust = 1:size(activeregions,1) 
    if activeregions(adjust) < backslide; 
        newactiveregions(adjust) = activeregions(adjust); 
    else   
        newactiveregions(adjust) = activeregions(adjust) + 1;  
    end 
end  
         
activecells = ismember(L, newactiveregions); 
activecells = im2bw(activecells, 1); 
overlay20 = imoverlay(activecells, rgbpic, [0 0 0]); 
overlay20 = im2bw (overlay20); 
%imshow(overlay20); 
cellsize = 1;  
for cell = 1:size(sta2,1) 
    area(cell,1) = (sta2(cell).Area); 
end  
radius = sqrt(area/pi); 
avgradius = mean(radius);  
bw2 = bwdist(overlay20) <= avgradius; 
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%figure(7); imshow(bw2); 
L2 = labelmatrix(bwconncomp(bw2)); 
rgb2 = label2rgb(L2, p, [.7 .7 .7]); 
figure(8); imshow(rgb2) 
L2(~overlay20) = 0; 
%figure(9);  
indvcolors = label2rgb(L2, p, [0 0 0]); 
%imshow(indvcolors); 
s = regionprops(L2, 'Area','PixelList','Centroid');  
numclus = size(s,1); 
%  hold on 
%  labelregionprops(s, numclus); 
%  hold off 
%% This cell calculates the "rows" or coordinates that are similar between the clustered  
% regions and the individual cell regions. It creates the output totalcluster which is a 
% structure in which each element has a listing of the cells numbers which 
% coorelate with that region 
common = 0; 
  
totalcluster = struct('centroid', {}); 
    for region = 1:size(s,1) 
        clustercount = 1;  
           for centroid = 1:size(sta2,1) 
           common = ismember(round(sta2(centroid).Centroid), s(region).PixelList, 'rows'); 
                if common == 1;  
                    cluster(clustercount,1) = centroid;  
                    cluster(clustercount,2) = region;  
                    clustercount = clustercount + 1;  
                    totalcluster(region, 1).centroid = cluster; 
                end   
            end 
       clear cluster;   
       clear clustercount; 
    end  
     
  
%% Create a variable totalcluster2 which only contains cells/regions with 
% more than 3 cells involved 
  
region2 = 1;   
totalcluster2 = struct('centroid', {}); 
    for region = 1:size(totalcluster,1) 
        if size(totalcluster(region).centroid,1) >= 3; 
         totalcluster2(region2,1).centroid = totalcluster(region).centroid; 
            region2 = region2 + 1;  
        end 
    end  
%% Find unique values in totalcluster to index and compare 
% Find the various regions associated with the cells. Find the regions that 
% are not clusters by using setdiff and the number of total regions.  Mask 
% out the areas that are not clusters and overlay onto the segemented 
% cells. Save the overlayed image for movie creation.   
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regionnum = 1; 
uniqueregions = 0;  
indexunique = 0;  
for region = 1:size((totalcluster2),1) 
%for region = 1:2 
    uniqueregions = unique(totalcluster2(region).centroid(:,2)); 
    for region2 = 1:size(uniqueregions) 
        indexunique(regionnum,1) = uniqueregions(region2); 
        regionnum = regionnum +1;   
    end 
end  
B = 1:size(s,1); 
B = B'; 
badindex = setdiff(B,indexunique); 
badcells = ismember(L2, badindex); 
Mask = imoverlay(indvcolors, badcells, [0 0 0]); 
figure(3); 
totalpic = (overlay4 + 0.35*Mask); 
imshow(totalpic) 
title('Read in treated cells, colored areas indicated clusters'); 
  
%  
% hold on 
% h = imshow(Mask); 
% alpha(h,.3) 
% hold off 
% print('-djpeg', 'r150'); 
% totalpic = imread('figure3.jpg'); 
 
Create normalized intensity figure 
function [] = percentchangefig(name, time, avgperchange, numfig) 
%% Average Percent Change/Time - F1-F0/F0 
%Use prior avgperchange and turn to a percent. Graph 
figure (numfig) 
plot(time, avgperchange*100);  
title('Average percent change vs time'); 
xlabel('Time (min)'); 
ylabel ('Average Normalized Change'); 
Inttime = [time avgperchange*100]; 
header1 = {'Time', 'Normalized Change'}; 
xlswrite(name,header1,'NormVSTime','A1'); 
xlswrite(name,Inttime,'NormVSTime','A2'); 
end 
 
Create raw intensity figure 
function [] = intensityfig(name, time, F1F0, numfig) 
%% Average Intensity/Time - average the cells by frame - F1-F0 and plot vs time 
avgI = mean(F1F0,2); 
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figure(numfig) 
plot(time, avgI); 
title('Average intensity vs Time'); 
xlabel('Time (min)'); 
ylabel('Average Intensity') 
Inttime = [time avgI]; 
header1 = {'Time', 'Average Intensity'}; 
xlswrite(name,header1,'IntensityVSTime','A1'); 
xlswrite(name,Inttime,'IntensityVSTime','A2'); 
end 
 
 
 
Percent activated figure 
function [] = activatedfig(name, numFramesc, numObj, activatedcutoff, F1F0, time, numfig) 
%% # Activated/Time 
count = zeros([numFramesc 1]); 
% Compare each cell to the average of the control frames, count any cell 
% that is greater than that value as activated.  Compute this value for 
% each frame so that an average can be computed by dividing by the total 
% number of cells 
for frames3 = 1:numFramesc 
    for regions3 = 1:numObj-1 
        if F1F0(frames3, regions3) > activatedcutoff; 
            count(frames3, 1) = count(frames3,1) + 1;  
        end 
    end 
end 
figure(numfig) 
plot(time, (count/(numObj-1))*100); 
title('Percent of cells activated vs Time'); 
xlabel('Time (min)'); 
ylabel('Percent cells activated'); 
axis([0,9,0,100]) 
set(gca,'XTick',[0 2 4 6 8 10 12 14]) 
Acttime = [time (count/numObj)*100]; 
header2 = {'Time', 'Percent of cells Activated'}; 
xlswrite(name,header2,'ActivatedVSTime','A1'); 
xlswrite(name,Acttime,'ActivatedVSTime', 'A2'); 
end 
 
Intensities of maximums figure 
function [] = maxintenhisto(name, percentchange, numfig) 
%%  Cell Maximums/Intensity  
% calculate the maximum normalized intensity of each cell and bin by intensity level 
maxnum = max(percentchange*100); 
maxaxis = round(max(maxnum)+5); 
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amax = 0:.5:maxaxis; 
[n,xout]=hist(maxnum,amax); 
maxcellnum = round(max(n) +5); 
figure(numfig) 
clear figure(3); 
bar(xout,n); 
title('Number of cells with specific Intensities');  
xlabel('Intensity values'); 
ylabel('Number of cells'); 
axis([0,maxaxis,0,maxcellnum]) 
xlist = transpose(xout); 
nlist = transpose(n); 
MaxINT = maxnum'; 
header3 = {'Intensity levels of all cells'}; 
xlswrite(name,header3,'MaxVSINT','A1'); 
xlswrite(name,MaxINT,'MaxVSINT','A2'); 
  
end 
Number of maximums figure 
function [maxcoord] = maxnumhisto(name, numObj, numFramesc, F1F0, numfig) 
%%  Number of maximums/cell 
% plot single cell intensity plot vs frames, use peakdet open source program 
%to find maximums after minimal smoothing. Filter out values less than 40% of the 
% maximum. Collect coordinates of maximums and count total number for 
% binning 
for frames4 =1:numObj-1 
 %for frames4 = 1:10 
   % figure(frames4) 
    x = 1:numFramesc; 
    y = F1F0(:,frames4); 
    %plot(x,y); 
    y2 = smooth(y,  5); 
    %plot(x, y2); 
    [maxtab, mintab] = peakdet(y2,.9); 
    count = 1; 
    if size(maxtab) > 0 ; 
        for maxnum = 1:size(maxtab,1) 
         if abs(maxtab(maxnum, 2)) > (0.4*(max(maxtab(:,2)))); 
                y3(count,1) = maxtab(maxnum,2); 
                x3(count,1) = maxtab(maxnum,1); 
                total = count;  
                count = count + 1; 
                maxcoord(frames4, 1) = struct('x', x3, 'y', y3); 
         end        
        end 
    end 
    if size(maxtab) == 0; 
        x3 = 0; 
        y3 = 0; 
        total = 0; 
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        maxcoord(frames4, 1) = struct('x', x3, 'y', y3); 
    end  
     % hold on 
      %plot(x3, y3, 'r*'); 
      %hold off 
    maxcount(frames4, 1) = total; 
    clear total; 
    clear y3; 
    clear x3; 
    clear x4; 
    clear y4; 
end 
mmaxcount = roundn(max(maxcount),1); 
mmaxcountbins = 0:1:mmaxcount; 
[n1,xout1]=hist(maxcount, mmaxcountbins); 
maxn = roundn((max(n1)+10),1); 
figure(numfig) 
clear figure(50); 
bar(xout1, n1); 
title('Number of peaks for each cell');  
xlabel('Number of Peaks'); 
ylabel('Number of cells');  
axis([0,mmaxcount,0,maxn]) 
xlist2 = transpose(xout1); 
n1list2 = transpose(n1); 
Peaks = maxcount; 
header4 = {'Number of Maximums each cell has'}; 
xlswrite(name,header4,'Maxpercell','A1'); 
xlswrite(name,Peaks,'Maxpercell', 'A2'); 
save(name, 'maxcoord'); 
 
Number of local maximums throughout time 
function [] = maxtimefig(name, numFramesc, numObj, maxcoord, numfig) 
%% Number of maximums throughout time  
% Count maximums in descrete time intervals (15 frames), find out where 
% each maximum is located and count.  Plot data as time w/in each time.  
count2 = 1;  
for stages = 15:15:numFramesc+ 15 
    count = 0; 
    for regions = 1:numObj - 1 
        for coord = 1:size((maxcoord(regions).x),1) 
            if ((maxcoord(regions).x(coord) > (stages -25))); 
                if (maxcoord(regions).x(coord) < stages); 
                    count = count+1;   
                end 
            end 
        end 
    end 
    levels(count2) = stages; 
    levelnum(count2) = count; 
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    count2 = count2 + 1;  
end  
  
levels = levels * 0.7872/60;  
maxlevelnum = round((max(levelnum)+10)); 
figure(numfig) 
bar(levels, levelnum);  
title('Number maximums throughout time');  
xlabel('Time (min)'); 
ylabel('Number of Peaks');  
axis([0,max(levels),0,maxlevelnum]) 
maxtime = [levels.', levelnum.']; 
header5 = {'Time', 'Number of Maximums'}; 
xlswrite(name,header5,'MaxVSTime','A1'); 
xlswrite(name,maxtime,'MaxVSTime','A2'); 
  
end 
 
Number of clusters figure 
function [] = clusternumfig(name, clustercat, time, numfig) 
%% Number of clusters/time 
% calculate the number of clusters within each frame and plot vs time  
% cluster number is equal to the size of each structure within clustercat 
% can be plotted as raw data or smoothed slightly to view trends.  
for clustersize = 1:size(clustercat,1) 
    clussize(clustersize,1) = size(clustercat(clustersize).cluster,1); 
end 
  
figure(numfig) 
plot(time, clussize) 
title('Cluster Number vs Time');  
clustertime = [time clussize]; 
header6 = {'Time', 'Cluster Number'}; 
xlswrite(name,header6,'clustime', 'A1'); 
xlswrite(name, clustertime, 'clustime', 'A2');  
  
end 
 
Average cells per cluster per time 
function [meancluscellavg] = avgcluscellfig(name, time, clustercat, numfig) 
  
%% Average number of cells/cluster/time 
% Average the number of clustered cells over time. Cluster cell number for 
% each cluster is recorded by frame.  These values are averaged. If no 
% clusters exist a 0 is recorded.  Zeros are changed to NaN and an average 
% is created for each from without the NaNs.  The NaNs are converted back 
% to zeros and the mean of each is plotted versus time.  It is possible to 
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% add in a smoothing function if desired.  
clustersize3 = 1;  
for clustersize = 1:size(clustercat,1) 
    if (size(clustercat(clustersize).cluster,1) > 0);  
        for clustersize2 = 1:size(clustercat(clustersize).cluster,1) 
           cluscellavg(clustersize3,clustersize) = 
size(clustercat(clustersize).cluster(clustersize2).centroid(:,1),1); 
           clustersize3 = clustersize3 + 1;  
        end 
    else 
          cluscellavg(clustersize3,clustersize) = 0; 
          clustersize3 = clustersize3 + 1;  
    end 
end 
  
cluscellavg(cluscellavg ==0) = NaN;  
meancluscellavg = nanmean(cluscellavg); 
meancluscellavg(isnan(meancluscellavg)) = 0;  
  
figure(numfig) 
plot(time, meancluscellavg') 
title('Average Cluster Cell Number vs Time'); 
cellnum = [time meancluscellavg']; 
header7 = {'Time', 'Average Cluster Cell Number'}; 
xlswrite(name, header7, 'cellnumcluster', 'A1'); 
xlswrite(name, cellnum, 'cellnumcluster', 'A2'); 
  
%end 
 
Percentage of cells in a cluster over time 
function [] = percellclusterfig(meancluscellavg, numObj, time, name, numfig) 
%% Average percent cells in cluster vs time 
percellclus = meancluscellavg/(numObj-1)*100; 
figure(numfig) 
plot(time, percellclus) 
title('Average percent cells in cluster vs Time'); 
percellnum = [time percellclus']; 
header8 = {'Time', 'Average Percent Cells in Cluster'}; 
xlswrite(name, header8, 'percellsclusters', 'A1');  
xlswrite(name, percellnum, 'percellsclusters', 'A2');  
  
end 
 
A.2 Consolidate data from runs together 
%% New script to average all runs 
clearvars -global 
clc; 
close all; 
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clearvars; 
clear workspace; 
figcount = 1;  
% Input the number of conditions and determine the directories of the files 
[allconditions, conditionnum, conditionname, dname, averagefilename] = conditioninport; 
% load the excel sheets into individual structures within a labeled cell array 
[allconditions, numfiles, fileNamescat] = readexcel(conditionnum, allconditions, dname); 
  
%% 
%Determine the conditions that should be used from each sheet 
for namenum = 1:conditionnum 
    [fnames, axisindex] = findnames(allconditions, namenum);   
end 
% Determine bounds for outputs and absolute maximums over different runs 
[altxmax, normindex, ymaxes] = findbounds(numfiles, allconditions, conditionnum, fnames, 
axisindex); 
  
%% 
%Preallocates a matrix for all the average data - uses the maximums found 
%in find bounds - ie normindex.  
  
    for outputnum = 1:size(axisindex, 2) 
        totalmatrix = 
allconditions{2,normindex(outputnum,2)}.exceldoc(normindex(outputnum,3),1).(fnames{axisindex
(outputnum)})(:,1); 
        averageouts.(fnames{axisindex(outputnum)}(1,:)) = totalmatrix; 
    end 
%% 
% For each condition the code produces individual outputs and saves data 
% for average graphs of combinded data 
for namenum = 1:conditionnum 
%for namenum = 3:3 
    % moves to the directory of the condition so that all outputs are saved 
    % there 
    cd(dname{namenum}); 
    % determines the maximum for tht individual condition for output 
    % purposes 
    [maxcond] = maxforcondition(allconditions, numfiles, axisindex, fnames, namenum); 
    % Outputs the data to figures, saves to combined excel files for the 
    % condition and compiles data into one file for average outputs 
    [averageouts, figcount] = averageoutputnew(altxmax, averageouts, figcount, fnames, 
axisindex, allconditions, numfiles, namenum, conditionname, fileNamescat, normindex, ymaxes);  
end 
  
%% Output combind averages of each condition 
averagegraph(averagefilename, conditionname, conditionnum, fnames, namenum, figcount, 
averageouts, ymaxes, axisindex); 
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Get data on the number of files to be consolidated 
%% Prompt the user for file information adn number of conditions 
  
function [allconditions, conditionnum, conditionname, dname, averagefilename] = conditioninport 
conditionnum = input('Please provide the number of various conditions you want analyzed: ');  
averagefilename = input('Please provide the name for your average file: ', 's'); 
for namenum = 1:conditionnum 
    conditionname{namenum} = input('Please provide the name of your various conditions: ', 's'); 
    display('Please select the directory with your excel documents for that condition'); 
    dname{namenum} = uigetdir; 
    allconditions = conditionname; 
end  
end 
Read in excel documents created during segementation 
%% Function to read in the excel documents.  It organizes the sheets from each document  
% into a composite structure with names.  
function [allconditions, numfiles, fileNamescat] = readexcel(conditionnum, allconditions, dname) 
% for each condition, the code  
for namenum = 1:conditionnum 
    % goes to the curent directory 
    cd(dname{namenum}); 
    % pulls in all the xls files in the directory 
    dirlist = dir('*xls') ; 
    % records the names of these files 
    fileNames = {dirlist.name}'; 
    % places the names of these files,  by condition into a structure 
    fileNamescat(:,namenum).log = fileNames; 
    % also determines the size of each file 
    sizefiles = size(fileNamescat(:,namenum).log,1); 
    fileNamescat(:,namenum).log{sizefiles +1, 1} = 'average'; 
    % computes the number of files for each condition 
    numfiles(namenum) = length(fileNames); 
    % reads in the various xls documents into a structure 
    for exceldocnum = 1:numfiles(namenum) 
        [~,sheets] = xlsfinfo(fileNames{exceldocnum}); 
        % sheet names are made into a structure 
        xlsstructdata(exceldocnum).sheets = sheets; 
        for sheetnum = 1:size(xlsstructdata(exceldocnum).sheets,2) 
           % each sheet is read in under the data for that sheet 
           sheetname = char(xlsstructdata(exceldocnum).sheets(sheetnum));  
           sheetdata = xlsread(fileNames{exceldocnum}, sheetname); 
           if size(sheetdata,1) >0; 
             % if the sheets have data in them they are copied to a 
             % composite structure 
             compositfile.exceldoc(exceldocnum, 1).(sheets{sheetnum}) = sheetdata; 
           end   
        end 
    end 
       % the structure for that condition is copied into a master structure 
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       % containing all conditions 
        allconditions{2,namenum} = compositfile;  
        clear compositfile; 
end  
  
%end 
%%which arrays have data in them for outputting.  If the matrix is a 1 or 
%%2D array then its index is saved for use later.  
 
Find names of each condition to consolidate 
function [fnames, axisindex] = findnames(allconditions, namenum) 
    count =1;  
    % finds the names for the various outputs 
    fnames = fieldnames(allconditions{2,namenum}.exceldoc(1,1)); 
    % determines which outputs are actual final output data - ie 1 
    % column(histogram) or 2 columns (time and an output).  It does this by 
    % calculating the size of the array and determining if it is size 1 or 
    % 2, if it is larger it is one of the origial matrices.  
    for findarrays = 1:size(fnames,1) 
        testcondition = size(allconditions{2,namenum}.exceldoc(1,1).(fnames{findarrays}),2); 
        if  (testcondition == 1) || (testcondition ==2); 
            axisindex(count) = findarrays; 
            count = count + 1;  
        end     
    end  
  
end 
 
Determine size and length of files for analysis 
%Function calculates the maximum bounds in the X and Y  
%for samples w/ no y it just calculates X (those for histograms)  
% sets 0 for the y.   
  
function [altxmax, normindex, ymaxes] = findbounds(numfiles, allconditions, conditionnum, 
fnames, axisindex) 
  
 for outputnum = 1:size(axisindex,2) % cycles each output 
     count = 1;  
   for namenum = 1:conditionnum % goes through each condition 
        for exceldocnum = 1:numfiles(namenum) % Goes through each set of files for the condition 
            testsize = allconditions{2,namenum}.exceldoc.(fnames{axisindex(outputnum)}); 
            if size(testsize,2) == 1; % If the sample only has one column, there will be no xmax 
                normalizedy(count, 1) = 0; 
                xmatrix(exceldocnum, namenum) = 
size(allconditions{2,namenum}.exceldoc(exceldocnum,1).(fnames{axisindex(outputnum)})(:,1),1); 
                normalizedx(count, 1) = 
max(allconditions{2,namenum}.exceldoc(exceldocnum,1).(fnames{axisindex(outputnum)})(:,1)); 
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            else   %% if it has more than one sample - get the maximums for both x and y 
                normalizedy(count, 1) = 
max(allconditions{2,namenum}.exceldoc(exceldocnum,1).(fnames{axisindex(outputnum)})(:,2));    
                normalizedx(count, 1) = 
max(allconditions{2,namenum}.exceldoc(exceldocnum,1).(fnames{axisindex(outputnum)})(:,1)); 
                xmatrix = 0;  
            end 
            % this is all the data on the current run, count #, the number 
            % of the condition, and the number of the excel sheet with the 
            % highest value 
            matrixpointinput = [count namenum exceldocnum]; 
            matrixpoints(count,:) = matrixpointinput; 
            count = count + 1; 
        end 
   end 
   % calculates the maximum of the x direction for that condition 
   [~, normedxi] = max(normalizedx);  
   % from this, using its index and the created matrixpoints matrix to 
   % pinpoint which file had the maximum so that its maximum can be used at 
   % later points.  We find the index and then save the value of it in the 
   % normindex.   
   p = find(normedxi == matrixpoints(:,1)); 
   % altmax is for the histogram conditions - it determines maximum of the  sum of the 
   % various outputs (ie the maximum total cell num for the conditions) 
   altxmax(outputnum,:) = max(sum(xmatrix));  
   normindex(outputnum,:) = matrixpoints(p,:); 
   % y maxes is the maximum y value for all conditions 
   ymaxes(outputnum, :) = max(normalizedy);  
   clear normalizedy normalizedx matrixinput matrixpoints 
    
end  
 
Determine the maximums in each condition 
function [maxcond] = maxforcondition(allconditions, numfiles, axisindex, fnames, namenum) 
% The function goes through each active sheet (from axisindex) and computes 
% the size for each excel sheet 
for outputnum = 1: size(axisindex,2) 
        for exceldocnum = 1:numfiles(namenum) 
            sizemaxcond(exceldocnum, 1) = 
size(allconditions{2,namenum}.exceldoc(exceldocnum,1).(fnames{axisindex(outputnum)}),1); 
        end 
        % a final matrix with the maximums of the max is created 
        maxcond(outputnum, 1) = max(max(sizemaxcond));  
end  
end 
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Create new matrix with all data included 
function [averageouts, figcount] = averageoutputnew(altxmax, averageouts, figcount, fnames, 
axisindex, allconditions, numfiles, namenum, conditionname, fileNamescat, normindex, ymaxes) 
  
              
%% Create matrix with all values 
for outputnum = 1:size(axisindex, 2) 
%for outputnum = 6:6 
    % determine the type of output - one column of data (for histogrm) or multiple  
        TF1 = strcmp((fnames{axisindex(outputnum)}), 'MaxVSINT'); 
        TF2 = strcmp((fnames{axisindex(outputnum)}), 'Maxpercell'); 
        TF3 = strcmp((fnames{axisindex(outputnum)}), 'MaxVSTime'); 
    % if TF1 or TF2 > 0 then it is 1 column data and runs that function otherwise 
    % it is run through twocolumn function 
        if (TF1 || TF2) > 0; 
        [averageouts, figcount] = onecolumn(outputnum, TF1, altxmax, averageouts, 
figcount,fnames, axisindex, allconditions, numfiles, namenum, conditionname); 
        else 
        [averageouts, figcount] = twocolumn(outputnum, TF3, averageouts, figcount, fnames, 
axisindex, allconditions, numfiles, namenum, conditionname, fileNamescat, normindex, ymaxes);     
        end 
  
end 
 
Consolidate histograms 
function [averageouts, figcount] = twocolumn(outputnum, TF3, averageouts, figcount, fnames, 
axisindex, allconditions, numfiles, namenum, conditionname, fileNamescat, normindex, ymaxes) 
%Analyzes and graphs data with 2 columns 
%% 
% sets the maximum for all conditions and preallocates arrays/counts 
maxval = 
size(allconditions{2,normindex(outputnum,2)}.exceldoc(normindex(outputnum,3),1).(fnames{axisi
ndex(outputnum)})(:,1),1); 
count = 1;  
totalmatrix = []; 
%% runs through all the excel documents for a single condition 
for exceldocnum = 1:numfiles(namenum) 
    % if the size of the data array in the excel document is not as long as 
    % the maximum, additional 0s are added at the end 
    sizearray = size(allconditions{2, namenum}.exceldoc(exceldocnum, 
1).(fnames{axisindex(outputnum)}), 1);  
    if sizearray < maxval; 
       
allconditions{2,namenum}.exceldoc(exceldocnum,1).(fnames{axisindex(outputnum)})((maxval),1) 
= 0; 
    end 
     
    % the new array is added to the total matrix - the first row is the 
	  	  
160 
    % maximum time array, the second columns are the outputs for each excel 
    % document 
    totalmatrix(:,1) = 
allconditions{2,normindex(outputnum,2)}.exceldoc(normindex(outputnum,3),1).(fnames{axisindex
(outputnum)})(:,1); 
    totalmatrix(:,count+1) = 
allconditions{2,namenum}.exceldoc(exceldocnum,1).(fnames{axisindex(outputnum)})(:, 2); 
    count = count + 1; 
     
    % if there had been a difference in the maximum vs the size of the 
    % array, this difference is calculated and the added 0s are turned to 
    % NaNs 
    sizediff = maxval - sizearray; 
    if sizearray < maxval;  
       for nandata = 1:(sizediff) 
%           totalmatrix((nandata + sizearray),(count-2)) = NaN; 
           totalmatrix((nandata + sizearray),count) = NaN;        
       end 
    end            
end   
  
%% The next set of code analyzes the data into combined averages 
totalsize = size(totalmatrix,2); 
    if TF3  >0; 
        % If TF3 > 0 - this means this is the number of maximums over 
        % various time intervals. To create a histogram we want to add up 
        % the number over each time interval which is what the first 
        % function does - adding each column's values all into the second 
        % column (1st is the various time intervals).  This set is then 
        % augmented onto the averageouts (average for each condition) sheet 
        additup = nansum(totalmatrix(:, 2:1:end),2);  
        newmatrix = averageouts.(fnames{axisindex(outputnum)}); 
        newmatrix(:, namenum + 1) = additup;  
        averageouts.(fnames{axisindex(outputnum)}) = newmatrix;     
    else  
        % If TF3 is not >0, then the values are just straight arrays that 
        % can be averaged for their various intensities.  The average, not 
        % including NaNs is computed for each time point and augmented onto 
        % the time array for each condition.  
        meanmatrix = nanmean(totalmatrix(:, 2:1:end),2);  
        totalmatrix(:,totalsize + 1) = meanmatrix; 
        newmatrix = averageouts.(fnames{axisindex(outputnum)}); 
        newmatrix(:, namenum + 1) = meanmatrix;  
        averageouts.(fnames{axisindex(outputnum)}) = newmatrix;  
    end 
%% Creates figure outputs     
count2 = 2;  
h1= figure(figcount); 
figcount = figcount + 1;  
    % if this is the number of maximums over various time intervals (TF3) 
  if TF3 >0; 
    % create the histogram output with a bar graph - graph the first column 
    % (the time vector) as the bins and the sum of the number of maximums 
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    % for all the runs in the additup column 
     bar(totalmatrix(:,1), additup);  
     ylabel('Number of cells') 
     xlabel(fnames{axisindex(outputnum)}); 
     legendentry = fileNamescat(1,namenum).log;  
     legendentry = ['Time'; legendentry]'; 
  else 
      % if the output is a normal average over time plot each line looping 
      % through each excel document.  At the end plot the average with a 
      % wider line to differentiate it. Label all data and save to file 
     hold all 
  for exceldocnum = 1:numfiles(namenum) 
     plot(totalmatrix(:, 1), totalmatrix(:, count2)); 
     count2 = count2 + 1;  
  end 
     plot(totalmatrix(:, 1), totalmatrix(:, count2), 'Linewidth', 4); 
     hold off  
     axis([0, max(totalmatrix(:,1)), 0, ymaxes(outputnum)]) 
     ylabel(fnames{axisindex(outputnum)}); 
     xlabel('Time (min)'); 
     legendentry = fileNamescat(1,namenum).log; 
     legend(legendentry) 
     legendentry = ['Time'; legendentry]'; 
  end     
     titlelabel = strcat(conditionname{namenum}, fnames{axisindex(outputnum)}); 
     title(titlelabel); 
     newfilename = strcat(conditionname{namenum},fnames{axisindex(outputnum)}); 
     saveas(h1,newfilename,'jpg');         
     xlswrite(conditionname{namenum},legendentry, fnames{axisindex(outputnum)},'A1'); 
     xlswrite(conditionname{namenum},totalmatrix, fnames{axisindex(outputnum)},'A2'); 
     clear totalmatrix newmatrix;  
 
Function to graph all figure averages 
 
function [  ] = averagegraph(averagefilename, conditionname, conditionnum, fnames, namenum, 
figcount, averageouts, ymaxes, axisindex  ) 
%% this function takes all the data combined from averagouts and saves it to file and also 
% makes figures displaying the data 
for outputnum = 1:size(axisindex, 2) 
%for outputnum = 6:6 
% continues augmenting the figurecount.  
    count2 = 2;  
        h1= figure(figcount); 
        figcount = figcount + 1;  
        TF1 = strcmp((fnames{axisindex(outputnum)}), 'MaxVSINT'); 
        TF2 = strcmp((fnames{axisindex(outputnum)}), 'Maxpercell'); 
        TF3 = strcmp((fnames{axisindex(outputnum)}), 'MaxVSTime'); 
  % If the output is a histogram.... TF1, 2 or 3 > 0 
      if TF1 || TF2 || TF3 >0; 
         if TF1 || TF2 >0; 
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             % TF1 and TF2 are traditional histograms so each output can be 
             % graphed together 
         hist(averageouts.(fnames{axisindex(outputnum)})); 
         %axis([0, max(totalmatrix(:,1)), 0, ymaxes(outputnum)]) 
         ylabel('Number of cells'); 
         xlabel(fnames{axisindex(outputnum)});  
         legendentry = conditionname; 
         legend(legendentry) 
         else 
             % TF3 is not a traditional output as we already have our bins 
             % (the timing intervals).  This takes each into xvals(the 
             % bins) and yvals(the frequencies).  Which is then plotted as 
             % a bar graph 
             xvals = averageouts.(fnames{axisindex(outputnum)})(:,1); 
             yvals = averageouts.(fnames{axisindex(outputnum)})(:, 2:1:end); 
             bar(xvals, yvals); 
             ylabel('Number of cells') 
             xlabel(fnames{axisindex(outputnum)}); 
             legendentry = conditionname; 
             legend(legendentry) 
             legendentry = ['Time'; legendentry']'; 
         end 
         % for non histogram outputs plot each row individaully against the 
         % time vector 
        else 
            hold all 
         for exceldocnum = 1:conditionnum 
            plot(averageouts.(fnames{axisindex(outputnum)})(:, 1), 
averageouts.(fnames{axisindex(outputnum)})(:, count2)); 
            count2 = count2 + 1;  
         end 
            hold off  
            % alter the axis data to the maximums 
            axis([0, max(averageouts.(fnames{axisindex(outputnum)})(:,1)), 0, ymaxes(outputnum)]) 
            ylabel(fnames{axisindex(outputnum)}); 
            xlabel('Time (min)'); 
            legendentry = conditionname; 
            legend(legendentry) 
            legendentry = ['Time'; legendentry']'; 
      end     
       % save data to file after changing the legends, etc.  
        titlelabel = strcat('average ', fnames{axisindex(outputnum)}); 
        title(titlelabel); 
        saveas(h1,titlelabel,'jpg'); 
        xlswrite(averagefilename,legendentry, titlelabel,'A1'); 
        xlswrite(averagefilename,averageouts.(fnames{axisindex(outputnum)}),titlelabel, 'A2'); 
 end 
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A.3 Hierarchical Clustering Scripts 
Find best clustering scheme 
%% Ths script will run through a variety of different scenarios to calculate the one 
% with the highest cophenetic correlation coefficient. This will be 
% deteremined by calculating initial and pseudo distances differently 
  
% Read in files for analysis 
numconditions = input('How many files do you want to analyze?: '); 
display('Please select the directory containing your files'); 
    %fname = uigetfile; 
dirname = uigetdir; 
cd(dirname); 
dirlist = dir('*xlsx'); 
  
% cycle through the various number of files with different conditions read 
% in the files, segement them into different time scales and analyze each 
% one for varous different distance measurement permutations  
for numindex = 1:numconditions 
    fname = dirlist(numindex).name;  
    filein = xlsread(fname);  
    filein = filein';  
    filein(1,:) = []; 
    tic 
    % segement the various runs into different parts - which part results 
    % in the best cluster anlaysis 
    fileseg.filein = filein(:,1:800); 
    fileseg.nostart = filein(:,50:800); 
    fileseg.peaktime = filein(:,150:800); 
    fileseg.justpeak = filein(:,150:450); 
    fileseg.endgame = filein(:, 450:800); 
    toc 
    names = fieldnames(fileseg);  
    docname = char(fname); 
    docsize = size(docname,2); 
    lowerbound = docsize - 4;  
    docname(lowerbound:docsize) = []; 
   pdistnames = {'euclidean', 'seuclidean', 'cityblock', 'minkowski', 'chebychev', 'cosine', 
'correlation','spearman'};     
   clusdis = {'average', 'complete', 'single'};  
   count = 1;  
   % cycle through the various distance measurements 
   for numcond = 1:size(names,1); 
      namechar = char(names(numcond)); 
      % determine the error or cophenet coefficient and write it to a 
      % structure for analsys 
      for clusdisnum = 1:size(clusdis,2) 
           for pdistnum = 1:size(pdistnames,2) 
            dismeas = pdist(fileseg.(names{numcond}),pdistnames{pdistnum}); 
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            clustTree = linkage(dismeas, clusdis{clusdisnum}); 
            errorread = cophenet(clustTree,dismeas); 
            mystruct.(docname).(namechar)(count) = errorread; 
            count = count + 1;  
            clear dismeas;  
            clear clustTree; 
            clear errorread; 
           end 
       end 
       count = 1;  
   end 
   clear filein; 
    
Hierarchical cluster analysis and heatmap creation 
%% this script reads in data, segments it and displays the figures of the various 
%% plots - distance measures were determined by a prior script 
%% Commented out the displays and clustered based on values picked visually 
  
% read in the number of files to analyze 
numconditions = input('How many files do you want to analyze?: '); 
display('Please select the directory containing your files'); 
    %fname = uigetfile; 
dirname = uigetdir; 
cd(dirname); 
dirlist = dir('*xlsx'); 
count =1;  
% cycle through each file breaking it into the portions that had the 
% greatest cluster efficiencies through prior analysis 
for numindex = 1:numconditions 
    fname = dirlist(numindex).name;  
    filein = xlsread(fname);  
    filein = filein';  
    filein(1,:) = []; 
     
    tic 
    fileseg.justpeak = filein(:,150:450); 
    fileseg.endgame = filein(:, 450:800); 
    toc 
     
    names = fieldnames(fileseg);  
    docname = char(fname); 
    docsize = size(docname,2); 
    lowerbound = docsize - 4;  
    docname(lowerbound:docsize) = []; 
   pdistnames = {'seuclidean', 'cosine'};     
   clusdis = {'average'}; 
   for numcond = 1:size(names,1); 
      namechar = char(names(numcond)); 
      if numcond == 1;  
          pdistance = pdistnames(186); 
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          cutval = 10; 
      else  
          pdistance = pdistnames(186); 
          cutval = 1;  
      end  
      % Create cluster dendrograms and heatmaps of the various outputs. 
      % Save these figures for display later and the data for further 
      % analysis 
           dismeas = pdist(fileseg.(names{numcond}),pdistance); 
            clustTree = linkage(dismeas, clusdis); 
            clusterout = cluster(clustTree, 'criterion', 'distance', 'cutoff', cutval);  
            mystruct.(docname).(namechar) = clusterout;  
           figure(count) 
            leafOrder = optimalleaforder(clustTree, dismeas); 
            [h, nodes] = dendrogram(clustTree, 'reorder', leafOrder); 
            titlename = [namechar, docname]; 
            set(gca, 'TickDir', 'out', 'TickLength', [.002 0], 'XTickLabel', []); 
            title(titlename); 
            p = figure(count); 
            savetitle = [titlename, '.tif']; 
            %saveas(p, savetitle) 
            count = count + 1; 
             flipedmatrix = flipud(fileseg.(names{numcond})'); 
            clusfig = clustergram(flipedmatrix, 'Standardize', 3, 'Cluster', 2, 'OptimalLeafOrder', 'false',  
'RowPDist', 'seuclidean', 'Colormap', 'jet', 'DisplayRange', 4, 'ShowDendrogram', 'off'); 
            clustitle = [namechar, docname, 'clustergram']; 
            savetitle = [clustitle, '.tif']; 
            hFig = plot(clusfig); 
            %saveas(hFig, savetitle); 
            savetitle = [clustitle, '.eps']; 
            %saveas(hFig, savetitle, 'epsc'); 
%              htmap = HeatMap(flipedmatrix, 'Colormap', 'jet', 'DisplayRange' ,4); 
%              htmapfig = plot(htmap); 
%              httitle = [namechar, docname, 'heatmap']; 
%              savetitle = [httitle, '.tif']; 
%              saveas(htmapfig, savetitle); 
             
            clear p; 
            clear clusfig; 
            clear clustitle; 
            clear titlename; 
            clear dismeas;  
            clear clustTree; 
    
    end 
   clear filein; 
end;  
 
Show all cell traces for each average 
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%% Clusters were broken up in the pickinconsistant script.  Take those clusters and 
% match them to the cells in the original files.  Average those together 
% and display in a graph.Show all individual cell traces along with a thick 
% line denoting the cluster average and the population based average 
  
numconditions = input('How many files do you want to analyze?: '); 
display('Please select the directory containing your files'); 
    %fname = uigetfile; 
dirname = uigetdir; 
cd(dirname); 
dirlist = dir('*xlsx'); 
count =1;  
count2 = 1;  
  
% read in all cell traces 
for numindex = 1:numconditions 
    fname = dirlist(numindex).name;  
    filein = xlsread(fname);  
  
    avgfiles.justpeak = mean(filein, 2); 
   avgfiles.endgame = mean(filein,2); 
    timestruct.justpeak = filein(:,1); 
   timestruct.endgame = filein(:, 1);  
     
    numcells = size(filein,2); 
     
    fileseg.justpeak = filein(:,2:numcells); 
    fileseg.endgame = filein(:,2:numcells); 
     
    namefileseg = fieldnames(fileseg);  
     
    % Get information on individual file 
    docname = char(fname); 
    docsize = size(docname,2); 
    lowerbound = docsize - 4;  
    docname(lowerbound:docsize) = []; 
     
    numstruct.numclusjustpeak = max(mystruct.(docname).justpeak); 
    numstruct.numclusendgame = max(mystruct.(docname).endgame); 
    namestruct = fieldnames(numstruct); 
     
    % Run through each structure plot the average for population analysis,  
    %then plot 
    % each individual cell trace.  finish the run by plotting the average 
    % of just those cell traces 
for structname = 1:size(namestruct,1) 
    sizestruct = numstruct.(namestruct{structname}); 
    structfield = namefileseg{structname};  
  
    for clusnum = 1:sizestruct 
        currentcluster = mystruct.(docname).(structfield); 
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        clusind = find(currentcluster == clusnum);  
        count = 1;  
        str = num2str(clusnum); 
        clusname = ['clus', str]; 
           count3 = 1;  
           %cc=Lines(256); 
            
          
            timex = timestruct.(structfield); 
            avgy = avgfiles.(structfield); 
            if size(clusind, 1) > 3; 
            hold on 
            figure(count2) 
            plot(timex, avgy*100, 'LineWidth', 5, 'color', 'y') %, 'color', cc(count3,:)) 
            end 
              
        for clussize = 1:size(clusind,1) 
        % plot each individual cell trace for clusters size above 3 
        alloneclus = fileseg.(structfield)(:,clusind(clussize,:)); 
        clusterstruct.(docname).(structfield).(clusname)(:,count) = alloneclus; 
        if size(clusind,1) > 3; 
            hold on 
        plot(timex, alloneclus*100) %, 'color', cc(count3,:)) 
        end 
         
        count = count + 1; 
        % plot the average of the clusters 
        if clussize == size(clusind,1); 
            avgrow = mean(clusterstruct.(docname).(structfield).(clusname),2); 
            clusterstruct.(docname).(structfield).(clusname)(:,count) = avgrow;  
            if size(clusind,1) > 3;  
                hold on 
            plot(timex, avgrow*100, 'LineWidth', 5, 'color', 'g') % cc(count3,:)) 
             titlename = [docname, structfield clusname]; 
            title(titlename) 
            hold off 
            savetitle = [titlename, '.tif']; 
            p = figure(count2); 
            saveas(p, savetitle) 
            count2 = count2+1; 
            end 
        end    
         
         
        clear alloneclus;  
        end 
         
         
     clear str; 
     clear clusname; 
    end 
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            hold off 
end    
     
    clear filein; 
end 
 
Match cells to clusters and display averages 
%% Clusters were broken up in the pickinconsistant script.  Take those clusters and 
% match them to the cells in the original files.  Average those together 
% and display in a graph. Show just the averages of clusters greater than 3 
% cells and the average of the population average.  
  
%Get user input on the number of individual runs 
numconditions = input('How many files do you want to analyze?: '); 
display('Please select the directory containing your files'); 
    %fname = uigetfile; 
dirname = uigetdir; 
cd(dirname); 
dirlist = dir('*xlsx'); 
count =1;  
count2 = 1;  
  
% cycle through each run collecting data on the run and then parsing out 
% individual information on the clusters within 
for numindex = 1:numconditions 
    fname = dirlist(numindex).name;  
    filein = xlsread(fname);  
    % Read in the individual data and information for each run 
    avgfiles.justpeak = mean(filein, 2); 
    avgfiles.endgame = mean(filein,2); 
    timestruct.justpeak = filein(:,1); 
    timestruct.endgame = filein(:, 1);  
  
     
    numcells = size(filein,2); 
  
    fileseg.justpeak = filein(:,2:numcells); 
    fileseg.endgame = filein(:,2:numcells); 
     
    namefileseg = fieldnames(fileseg);  
    % get information on each file 
    docname = char(fname); 
    docsize = size(docname,2); 
    lowerbound = docsize - 4;  
    docname(lowerbound:docsize) = []; 
     
    numstruct.numclusjustpeak = max(mystruct.(docname).justpeak); 
    numstruct.numclusendgame = max(mystruct.(docname).endgame); 
    namestruct = fieldnames(numstruct); 
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    % cycle through each set and each cluster within the set 
for structname = 1:size(namestruct,1) 
    sizestruct = numstruct.(namestruct{structname}); 
    structfield = namefileseg{structname};  
    count3 = 1;  
    cc= colormap('Lines'); 
    figure(count2) 
    hold on 
    timex = timestruct.(structfield); 
    avgy = avgfiles.(structfield); 
    %plot the average of each run (population average 
    plot(timex, avgy*100, 'LineWidth', 5, 'color', cc(count3,:)) 
    legendentries{count3} = 'Average';  
    avgstruct.average.(docname) = avgy; 
    % for each cluster identify the cells within the cluster and average 
    % their individual cell traces.  Document the percentage of total cells 
    % within that cluster to print in the legend 
    for clusnum = 1:sizestruct 
        currentcluster = mystruct.(docname).(structfield); 
        clusind = find(currentcluster == clusnum);  
        count = 1;  
        str = num2str(clusnum); 
        clusname = ['clus', str]; 
        for clussize = 1:size(clusind,1) 
        alloneclus = fileseg.(structfield)(:,clusind(clussize,:)); 
        clusterstruct.(docname).(structfield).(clusname)(:,count) = alloneclus; 
        count = count + 1; 
        if clussize == size(clusind,1); 
            avgrow = mean(clusterstruct.(docname).(structfield).(clusname),2); 
            clusterstruct.(docname).(structfield).(clusname)(:,count) = avgrow;        
            if clussize > 3; 
                count3 = count3 + 1;  
                plot(timex, avgrow*100, 'color', cc(count3,:)) 
                titlename = [docname, structfield]; 
                %title(titlename) 
                axis([0 10 -10   600]) 
                percentclus = (clussize/numcells*100); 
                percentclus = round(percentclus*100)/100; 
                percentstring = num2str(percentclus); 
                clussizestring = num2str(clussize); 
                numcellstring = num2str(numcells); 
                newstring = [percentstring]; 
                %newstring = [percentstring, '%', ' ', clussizestring, ' ', numcellstring]; 
                legendentries{count3} = newstring;  
                savetitle = [titlename, '.tif']; 
                 
            end     
        end 
         
        clear alloneclus;  
        end 
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     clear str; 
     clear clusname; 
    end 
    % After completing the analysis of all clusters against the average 
    % identify which cluster is the biggest (minimally activated mostly) 
    % and the average of the remaiing cells (high responders 
            baseline = 1; 
            cellcount = 1; 
            smallmatrix = []; 
            clusternames = fieldnames(clusterstruct.(docname).justpeak); 
            for clustercount = 1:size(clusternames,1); 
                tempsize = size(clusterstruct.(docname).justpeak.(clusternames{clustercount}),2); 
                if tempsize > baseline 
                    baseline = tempsize; 
                    bigcluster = clustercount; 
                end 
            end 
            for clustercount =  1:size(clusternames,1) 
                if bigcluster == clustercount 
                   avgstruct.bigaverage.(docname) = 
mean(clusterstruct.(docname).justpeak.(clusternames{clustercount}),2); 
                else 
                   newmatrix = clusterstruct.(docname).justpeak.(clusternames{clustercount}); 
                   smallmatrix = [smallmatrix newmatrix]; 
                     
                end 
            end 
            avgstruct.remainingavg.(docname) = mean(smallmatrix,2); 
            % finish the figure with legend enties and saving 
            legend(legendentries, 'Location', 'northeastoutside') 
            p = figure(count2); 
            saveas(p, savetitle) 
            savetitle = [titlename, '.eps']; 
            saveas(p, savetitle, 'epsc') 
            count2 = count2+1;  
            hold off 
end     
 
Find the bulk responders and read in cell size data 
%% Identfiy the biggest cluster in each data set.  Set values to 1 for the biggest cluster 
% and 0 for the high responders 
  
numconditions = input('How many files do you want to analyze?: '); 
display('Please select the directory containing your files'); 
    %fname = uigetfile; 
dirname = uigetdir; 
cd(dirname); 
dirlist = dir('*xlsx'); 
count =1;  
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for numindex = 1:numconditions 
    fname = dirlist(numindex).name;  
    filein = xlsread(fname);  
    fnamesmall = fname(1:end-5); 
    filein = filein(1:800, 2:end); 
    allfiles.(fnamesmall).all = filein; 
    allfiles.(fnamesmall).maxes = max(filein); 
     
    findbigcluster = mystruct.(fnamesmall).justpeak; 
    mde = mode(findbigcluster); 
    findbigcluster = findbigcluster'; 
     
    identity = 0; 
     
    for location = 1:size(findbigcluster,2) 
        if findbigcluster(1, location) == mde; 
        identity(1, location) = 1; 
        else 
        identity(1,location) = 0; 
        end 
    end 
    identifycluster.(fnamesmall) = identity; 
end 
% read in mat file associated with run, collect the L file which contains 
% cell layouts for each run. Compile them together into one named structure 
  numconditions = input('How many conditions do you have?  '); 
    numtreat = input('How many treatments do you have for each conditions? '); 
for numindex = 1:numconditions 
    for numindex2 = 1:numtreat 
        newdirname = uigetdir; 
        cd(newdirname) 
        currentDirectory = pwd; 
        [~, treatname, ~] = fileparts(currentDirectory); 
        newdir = dir; 
        newdir(1:3) = []; 
        count3 = 1; 
  
        for foldernum = 1:size(newdir,1) 
        cd(newdirname) 
        [~, treatname, ~] = fileparts(currentDirectory); 
        cd(newdir(foldernum).name) 
        foldname = newdir(foldernum).name; 
        matstuff = dir('*mat'); 
        matname = matstuff.name; 
        numindexstr = num2str(numindex); 
        numindexstr2 = num2str(numindex2); 
        foldernumstr = num2str(foldernum); 
        %treatname = ['cond', numindexstr, 'treat', numindexstr2]; 
        Lfiles.(treatname).(foldname) = load(matname, '-mat','L','s'); 
        currentsize(count3,1) = size(Lfiles.(treatname).(foldname).s,1); 
        count3 = count3 + 1; 
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        end 
        sizestruct.(treatname) = currentsize; 
  
    end    
  
end 
 
Combine size characteristics of all runs 
%% condense all runs together 
% remove background slide from L data (largest area) 
% make a new matrix that has all the cell data in it (allcells) 
% contains a time matrix for that data and each sets information (high or 
% bulk response in binary) 
  
sizeL = size(fieldnames(Lfiles),1); 
Lnames = fieldnames(Lfiles); 
for filenum = 1:sizeL 
    currentrun = Lnames{filenum}; 
    runnum = size(fieldnames(Lfiles.(currentrun)),1); 
    runnames = fieldnames(Lfiles.(currentrun)); 
    for runnumber = 1:runnum 
        I = find(fieldorder.(currentrun) == runnumber); 
        current = runnames{I}; 
        L = Lfiles.(currentrun).(current).L; 
        allcellstats = regionprops(L, 'Area', 'MajorAxisLength', 'MinorAxisLength', 'Centroid'); 
        x = max([allcellstats.Area]); 
        backslide = find([allcellstats.Area] == x); 
        allcellstats(backslide) = []; 
        if runnumber ==1 
            allcells.(currentrun) = allcellstats; 
        else 
            newmatrix = allcells.(currentrun); 
            amendedmatrix = [newmatrix; allcellstats]; 
            allcells.(currentrun) = amendedmatrix; 
        end     
    end 
    maxrow = allfiles.(currentrun).maxes; 
    maxrow = maxrow'; 
    maxrow = maxrow*100; 
    identify = identifycluster.(currentrun)'; 
    [Maxval, maxind] = max((allfiles.(currentrun).all)); 
     
    for sizes = 1:size(maxrow,1); 
        allcells.(currentrun)(sizes).Maxes = maxrow(sizes); 
        allcells.(currentrun)(sizes).Identity = identify(sizes); 
        timemaxval = time(maxind(sizes)); 
        allcells.(currentrun)(sizes).Maxtime = timemaxval; 
    end 
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end     
 
Compute dynamic data on population cell traces 
%% Compute Start points, end points, acceleration and deactivation rates for averages of all 
data, 
% bulk data or high responders 
% take in data from the avgstruct created when all figures were created 
  
%determine characteristics of the avgstruct structure 
sizeF = size(fieldnames(avgstruct.totalavg),1); 
Fnames = fieldnames(avgstruct.totalavg); 
cellpopnames = fieldnames(avgstruct); 
% for the number of individual runs, and for each run calculate a variety 
% of outputs 
for filenum = 1:sizeF 
    currentrun = Fnames{filenum}; 
    for popnum = 1:size(cellpopnames,1) 
    cellpop = cellpopnames{popnum}; 
    % calculate max value 
    [Maxval, maxind] = max(avgstruct.(cellpop).(currentrun)(50:800,:)); 
    averagedata.(cellpop).(currentrun)(1).Max = Maxval*100; 
    maxind = maxind + 49; 
    maxtimeval = time(maxind); 
    % calculate max time 
    averagedata.(cellpop).(currentrun)(1).MaxTime = maxtimeval; 
    averagedata.(cellpop).(currentrun)(1).Maxtimeind = maxind; 
    % calculate start time - must be over 3% of background 
       for framenum = 50:size(time,1) 
           if avgstruct.(cellpop).(currentrun)(framenum,1) >= .03; 
                averagedata.(cellpop).(currentrun)(1).starttime = time(framenum); 
                averagedata.(cellpop).(currentrun)(1).startind = framenum; 
                break; 
           end 
      % if the run doesn't ever get over that the end is the beginning 
           if framenum == size(time,1); 
                averagedata.(cellpop).(currentrun)(1).starttime = time(framenum); 
                averagedata.(cellpop).(currentrun)(1).startind = framenum; 
           end 
       end 
        startpoint = averagedata.(cellpop).(currentrun)(1).startind; 
        maxpoint = averagedata.(cellpop).(currentrun)(1).Maxtimeind; 
        % calculate the acceleration rate and deacceleration rate using a 
        % linear approximation (start point to max point and max point to 
        % end) 
        yup = 100* avgstruct.(cellpop).(currentrun)(startpoint:maxpoint,1); 
        xup = time(startpoint:maxpoint,1); 
        ptup = polyfit(xup, yup, 1); 
        averagedata.(cellpop).(currentrun)(1).upslope = ptup(1); 
        % if the maximum occurs at >795 frames (5 frames from end) and thus 
        % there is minimal time to decrese set downslope or deacceleration 
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        % to 0 
        if maxpoint >= 795; 
            averagedata.(cellpop).(currentrun)(1).downslope = 0; 
        else 
            ydown = 100*avgstruct.(cellpop).(currentrun)(maxpoint:800,1); 
            xdown = time(maxpoint:800,1); 
            ptdown = polyfit(xdown, ydown, 1); 
            averagedata.(cellpop).(currentrun)(1).downslope = ptdown(1); 
        end 
    end 
end     
 
Compute dynamic data on individual cell traces 
%% compute average, stdev, SEM, and P values for each individual run 
%% For P values compare first The All cells to Bulk then Bulk to High and finally 3rd column high 
to all 
% much of the data is gathered as it was in computedtapoint averages, but 
% now it is on an individual cell basis 
clear combinedallcellstats; 
clear indivcellinfo; 
  
sizeL = size(fieldnames(Lfiles),1); 
Lnames = fieldnames(Lfiles); 
  
% calculate the size data and run data on each individual cell 
for filenum = 1:sizeL 
    % read in L files that have all the cell stat information 
    currentrun = Lnames{filenum}; 
    runnum = size(fieldnames(Lfiles.(currentrun)),1); 
    runnames = fieldnames(Lfiles.(currentrun)); 
    identify = identifycluster.(currentrun)'; 
    sizecount = 0;  
    % for each run calculate the resulting statistical information 
    for runnumber = 1:runnum 
        % find the L file that corresponds to the current file 
        I = find(fieldorder.(currentrun) == runnumber); 
        current = runnames{I}; 
        L = Lfiles.(currentrun).(current).L; 
        % compute new stats on the data 
        combinedallcellstats = regionprops(L, 'Area', 'MajorAxisLength', 'MinorAxisLength', 
'Centroid'); 
        % remove the background slide (largest area) from the data set 
        x = max([combinedallcellstats.Area]); 
        backslide = find([combinedallcellstats.Area] == x); 
        combinedallcellstats(backslide) = []; 
        %write data to a new structure (all the cell characteristics) 
        indivcellinfo.all.(currentrun).(current) = combinedallcellstats; 
        sizerun = size(combinedallcellstats,1); 
        sizeend = sizecount + sizerun; 
        % find run that cooresponds to cell data (make sure they are in 
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        % correct order). Once the run is identified, find the maximum 
        % value in each run and also resave the matrix in a temporary 
        % matrix to make it easy to access later 
        if runnumber == 1;    
        identifyrun = identify(1:sizerun,1); 
        [Maxval, maxind] = max((allfiles.(currentrun).all(50:800,1:sizerun))); 
        currentmatrix = allfiles.(currentrun).all(1:800,1:sizerun); 
        sizecount = sizeend + 1; 
        else 
        identifyrun = identify(sizecount:sizeend-1,1); 
        [Maxval, maxind] = max((allfiles.(currentrun).all(50:800,sizecount:sizeend-1))); 
        currentmatrix = allfiles.(currentrun).all(1:800,sizecount:sizeend-1); 
        sizecount = sizeend; 
        end 
        maxind = maxind + 49; 
        Maxval = 100*Maxval; 
        count = 1; 
        count2 = 1; 
        % for each cell identify if it is a high responder or not, what its 
        % individual maximum value is, and what time that max value occurs 
    for sizes = 1:sizerun 
        indivcellinfo.all.(currentrun).(current)(sizes).Identity = identifyrun(sizes); 
        indivcellinfo.all.(currentrun).(current)(sizes).Maxes = Maxval(sizes); 
        indivcellinfo.all.(currentrun).(current)(sizes).Maxindex = maxind(sizes); 
        timemaxval = time(maxind(sizes)); 
        indivcellinfo.all.(currentrun).(current)(sizes).MaxTime = timemaxval; 
        % Find the start time (once it is over 3% of background) and start 
        % value (index) 
        for framenum = 50:size(time,1) 
           if currentmatrix(framenum,sizes) >= 0.03; 
                indivcellinfo.all.(currentrun).(current)(sizes).starttime = time(framenum); 
                indivcellinfo.all.(currentrun).(current)(sizes).startind = framenum; 
                break; 
           end 
           % if it never makes it over 3% then set it to the last time 
           % point 800 
           if framenum == size(time,1); 
                indivcellinfo.all.(currentrun).(current)(sizes).starttime = time(framenum); 
                indivcellinfo.all.(currentrun).(current)(sizes).startind = 800; 
           end 
        end 
        % Identify the acceleration rate and deacceleration rate for each cell  
        startpoint = indivcellinfo.all.(currentrun).(current)(sizes).startind; 
        maxpoint = indivcellinfo.all.(currentrun).(current)(sizes).Maxindex; 
        yup = 100* currentmatrix(startpoint:maxpoint,1); 
        xup = time(startpoint:maxpoint,1); 
        ptup = polyfit(xup, yup, 1); 
        indivcellinfo.all.(currentrun).(current)(sizes).upslope = ptup(1); 
        % if the max value is near the end of the run, set the 
        % deacceleration rate to 0 
        if maxpoint >= 795; 
            indivcellinfo.all.(currentrun).(current)(sizes).downslope = 0; 
        else 
	  	  
176 
            ydown = 100*currentmatrix(maxpoint:800,1); 
            xdown = time(maxpoint:800,1); 
            ptdown = polyfit(xdown, ydown, 1); 
            indivcellinfo.all.(currentrun).(current)(sizes).downslope = ptdown(1); 
        end 
       % parse information into bulk and high response (and all response we 
       % already have) 
        if indivcellinfo.all.(currentrun).(current)(sizes).Identity == 1; 
            indivcellinfo.bulk.(currentrun).(current)(count) = 
indivcellinfo.all.(currentrun).(current)(sizes); 
            count = count + 1;  
        else 
            indivcellinfo.high.(currentrun).(current)(count2) = 
indivcellinfo.all.(currentrun).(current)(sizes); 
            count2 = count2 +1; 
        end   
    end 
    cellcatname = fieldnames(indivcellinfo); 
    cellcatsize = size(cellcatname,1); 
    % calculate states on all the information gathered 
   fnames = fieldnames(indivcellinfo.(currentcat).(currentrun).(current)); 
   sfnames = size(fnames,1);  
   for fsize = 1:sfnames 
        currentfield = fnames{fsize}; 
        fieldinfo = indivcellinfo.all.(currentrun).(current).(currentfield); 
        for catsize = 1:cellcatsize 
        currentcat = cellcatname{catsize}; 
        if size(fieldinfo,2) ==1 
            if catsize ==1 
                finalsize = size(indivcellinfo.(currentcat).(currentrun).(current),1); 
            else 
                finalsize = size(indivcellinfo.(currentcat).(currentrun).(current),2); 
            end     
            % identify current cell list (average, bulk, high) and the 
            % cells in that list 
            for sizes = 1:finalsize 
            celllist(sizes,1) = indivcellinfo.(currentcat).(currentrun).(current)(sizes).(currentfield); 
            end 
            count = 1; 
            % compute an array of statistics on those cells including mean, 
            % standard deviation, SEM, and coefficient of variability 
            indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = mean(celllist); 
            count = count + 1; 
            indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = std(celllist); 
            count = count + 1;             
            indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = 
std(celllist)/sqrt(size(celllist,1)); 
            count = count + 1;             
            indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = 
std(celllist)/mean(celllist); 
            count = count + 1; 
            if catsize == 1 
                allcelllist = celllist; 
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            end 
            if catsize ==2 
                bulkcelllist = celllist; 
            end 
            if catsize == 3 
                highcelllist = celllist; 
                %once all cells are determined compare the bulk response to 
                %the high cell response, high to bulk, and bulk to average 
                %and compute p values for each statistical measure do  
                %permutations 
                [h,p] = ttest2(allcelllist,bulkcelllist);  
                indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = p; 
                count = count + 1; 
                indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = h; 
                count = count + 1; 
                 
                [h,p] = ttest2(allcelllist,highcelllist);  
                indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = p; 
                count = count + 1; 
                indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = h; 
                count = count + 1; 
  
                [h,p] = ttest2(bulkcelllist,highcelllist);  
                indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = p; 
                count = count + 1; 
                indivstatlist.(currentcat).(currentrun).(current)(count).(currentfield) = h; 
                count = count + 1; 
                
                 
            end 
            clear celllist 
                 
        end 
           
        end 
             
   end 
     
    end  
end 
 
Combine all statistics together 
 
%%combine all stats data together into an individual structure for easier 
% analysis 
treatnames = fieldnames(indivstatlist.high); 
sizetreat = size(treatnames,1); 
for streat = 1:sizetreat 
    currenttreat = treatnames{streat}; 
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    runnames = fieldnames(indivstatlist.high.(currenttreat)); 
    sizerun = size(runnames,1); 
    for runnum = 1:sizerun 
        currentrun = runnames{runnum}; 
        fnames = fieldnames(indivstatlist.high.(currenttreat).(currentrun)); 
        sfnames = size(fnames,1);  
        for cfield = 1:sfnames 
            currentfield = fnames{cfield}; 
            %create matrices combinig all the average stats together into 
            %one place 
            for sizeset2 = 1:size(indivstatlist.all.(currenttreat).(currentrun),2) 
                newmatrix(sizeset2,1) = 
indivstatlist.all.(currenttreat).(currentrun)(sizeset2).(currentfield); 
                finalsize1 = sizeset2; 
            end  
            for sizeset3 = 1:size(indivstatlist.bulk.(currenttreat).(currentrun),2) 
                newsize = sizeset3 + finalsize1; 
                newmatrix(newsize,1) = 
indivstatlist.bulk.(currenttreat).(currentrun)(sizeset3).(currentfield); 
                finalsize2 = newsize; 
            end      
            for sizeset = 1:size(indivstatlist.high.(currenttreat).(currentrun),2) 
            newsize = sizeset + finalsize2;  
            newmatrix(newsize,1) = indivstatlist.high.(currenttreat).(currentrun)(sizeset).(currentfield); 
            end 
            % use binary to show if the various outputs are greater than or 
            % less than each other (ie high response and bulk response) 
            if newmatrix(9,1) < newmatrix(5,1) 
                newmatrix(19,1) = 1; 
            else 
                newmatrix(19,1) = 0; 
            end 
            %create a big stats matrix with all the data together for each 
            %run type 
            if runnum == 1; 
            statsmatrix.(currenttreat).(currentfield) = newmatrix; 
            else 
            oldmatrix = statsmatrix.(currenttreat).(currentfield); 
            amendedmatrix = [oldmatrix newmatrix]; 
            statsmatrix.(currenttreat).(currentfield) = amendedmatrix; 
            end 
            clear newmatrix; 
            clear oldmatrix 
        end 
    end 
    count1 = 1; 
    count2 = 1; 
    for cfield = 1:sfnames 
        % compute data on all areas with cells split up in the bulk list 
        % and high list.  Ie evaluate all cells regardless of 
        % treatment/stiffness 
        currentfield = fnames{cfield}; 
        currentset = statsmatrix.(currenttreat).(currentfield)(19,:); 
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        positivelist = find(currentset); 
        perpos = size(positivelist,2)*100/size(currentset,2); 
        statsmatrix.(currenttreat).(currentfield)(20,1) = perpos; 
        bulklist = statsmatrix.(currenttreat).(currentfield)(5,:); 
        highlist = statsmatrix.(currenttreat).(currentfield)(9,:); 
        statsmatrix.(currenttreat).(currentfield)(21,1) = mean(bulklist); 
        statsmatrix.(currenttreat).(currentfield)(21,2) = std(bulklist); 
        statsmatrix.(currenttreat).(currentfield)(21,3) = std(bulklist)/sqrt(size(bulklist,2)); 
        statsmatrix.(currenttreat).(currentfield)(22,1) = mean(highlist); 
        statsmatrix.(currenttreat).(currentfield)(22,2) = std(highlist); 
        statsmatrix.(currenttreat).(currentfield)(22,3) = std(highlist)/sqrt(size(highlist,2)); 
        [h,p] = ttest(bulklist, highlist, 'tail', 'right'); 
        statsmatrix.(currenttreat).(currentfield)(23,1) = h; 
        statsmatrix.(currenttreat).(currentfield)(23,2) = p; 
    end     
end 
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